

2016 ANNUAL REPORT



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS



TABLE OF CONTENTS

Transmittal Letter	1
Introduction	3
CPRIT Oversight Committee	4
Report from the Chief Executive Officer	5
The Impact of Cancer in Texas and the State's Response	8
CPRIT Grant Programs: Academic Research	10
CPRIT Grant Programs: Prevention	16
CPRIT Grant Programs: Product Development Research	23
CPRIT Peer Review	29
CPRIT Compliance Program	37
Financials	40
Planning	42
Appendix: Conflict of Interest Documentation	46
Prevention	47
Academic Research	58
Product Development	226
FY 2016 Conflict of Interest Waivers	250



TRANSMITTAL LETTER

The Honorable Greg Abbott, Governor

The Honorable Dan Patrick, Lieutenant Governor

The Honorable Joe Straus, Speaker of the House of Representatives

Pursuant to V.T.C.A., Health and Safety Code Section 102.052, please accept this annual report from the Cancer Prevention and Research Institute of Texas (CPRIT). This document summarizes CPRIT's activities in state fiscal year 2016 and how CPRIT is fulfilling its mission of reducing the burden of cancer in Texas.

Despite advances, cancer is the second leading cause of death in Texas behind heart disease. On average, 100 Texans die from cancer every day. The tragic emotional and physical toll of cancer is incalculable, but in purely economic terms, Texas cancer deaths in 2016 translated into an annual cost to the state of about \$34.9 billion in direct medical costs and mortality losses. This amount is up from 2015's \$31.3 billion. These costs are unlikely to decline in light of the emerging demographic patterns in the population of Texas.

But Texas is not ignoring these tragic losses. Through August 2016, CPRIT has announced 1,056 awards for prevention, academic research and product development research grants totaling more than \$1.63 billion.

In 2016 CPRIT marked the halfway point in its constitutional funding authorization. Texas' 2007 decision to provide \$3 billion for cancer research and prevention remains the only such commitment in the United States. Many of CPRIT's grantees' tangible results at this juncture are highlighted in this report.

It has been said that nations that lead on the frontier, lead in the world. The same can be said for states – states that lead on the frontier, lead in the nation. CPRIT's programs are at the frontier of scientific knowledge.

In lay terms, cancer is a disease in which normal cells misbehave by multiplying uncontrollably, ignoring signals to stop, and often clumping into masses called tumors. However, cancer is not as simple as that description implies. There are at least 200 different types of cancer, each named for the organ or type of cell from which it begins. It is a complex disease.

The projects and programs supported by CPRIT, as with all biomedical undertakings, are part of an iterative cycle with observations emerging from the laboratory making their way to the patient's bedside and back again to the laboratory. Essential players in this cycle are basic scientists, physician-scientists, clinical researchers, product development entrepreneurs, public health professionals, patients and health care providers. The Institute arms all of these soldiers in the battle against cancer.

The year covered here sustains the momentum established in 2015. CPRIT investments now connect universities, researchers, physicians, companies, hospitals and clinics across our state forming a critical mass of distinguished cancer-fighting talent. In 2016, 17 talented recruits were added to the stable of prestigious CPRIT scholars. This activity has brought 113 premier cancer researchers to Texas since 2009, making this program the envy of research institutions around the nation.



During fiscal year 2016, a total of 12 companies had CPRIT projects in clinical trials. Cell Medica entered into a partnership with Baylor College of Medicine to engineer immune cells with enhanced functions in treating solid tumors, and ESSA successfully completed their Phase 1 clinical study and advanced their compound into the next stage of clinical research. Since 2010, CPRIT has made 29 product development research awards totaling over \$296.4 million. Private sector follow-on funding to these awards is nearly \$1.28 billion. This strongly indicates angel and venture capital confidence in the CPRIT peer-review and due diligence processes.

CPRIT produces measurable results. Its projects have created high quality jobs, critical lab infrastructure assets and along the way, helped thousands of cancer patients extend their lives. Promised benefits are being delivered today. Through CPRIT and in thousands of personal ways, Texans Conquer Cancer.

CPRIT can never fully express its gratitude to the teams of advocates from numerous cancer-related organizations. Their dedication and support inspires us daily in our efforts to serve all Texans.

On behalf of the CPRIT Oversight Committee and the agency's staff, we thank you and all members of the Texas Legislature for allowing us to make 2016 another great year. We look forward to new opportunities to fulfill our mission to improve the health and lives of our fellow Texans.

Sincerely,

Wayne R. Roberts
Chief Executive Officer

Pete Geren
Presiding Officer



INTRODUCTION

The Cancer Prevention and Research Institute of Texas, or CPRIT, is charged by the Texas Legislature to:

- Create and expedite innovation in the area of cancer research, and enhance the potential for a medical or scientific breakthrough in the prevention of cancer and cures for cancer;
- Attract, create, or expand research capabilities of public or private institutions of higher education and other public or private entities that will promote a substantial increase in cancer research and in the creation of high-quality new jobs in this state; and
- Develop and implement the Texas Cancer Plan.

Created by the Texas Legislature and authorized by Texas voters in 2007, CPRIT began in 2009 to award grants to Texas-based organizations and institutions for cancer-related academic research and product development research, and for the delivery of cancer prevention programs and services.

State statutes codifying CPRIT are V.T.C.A., Health and Safety Code, Chapter 102. In 2013 the regular session of the 83rd Texas Legislature substantially amended this legislation through the passage of Senate Bill 149. Changes related to that legislation effective in fiscal year 2013 were addressed in previous reports. No changes to Chapter 102 have occurred subsequent to 2013.



CPRIT OVERSIGHT COMMITTEE

The CPRIT Oversight Committee is the governing body of the Institute. The committee may adopt such policies and practices, consistent with applicable law, as it deems proper for the conduct of its meetings and the management of the agency.

According to V.T.C.A., Health and Safety Code, Section 102.107, the core responsibilities of the Oversight Committee include:

- Annually setting priorities for each grant program funded by the Institute (academic research, product development research and prevention)
- Considering these priorities in awarding grants
- Hiring a chief executive officer for the Institute
- Adopting rules governing conflicts of interest and grant awards process

In 2013, legislation required that three members (one appointed by each of the state's elected leadership officers) be "physicians or scientists with extensive experience in the field of oncology or public health."

Members (as of August 31, 2016):

Appointed by the Governor

Angelos Angelou Austin

Donald "Dee" Margo El Paso

William Rice, M.D. Austin

Appointed by the Lieutenant Governor

Ned Holmes Houston

Secretary Amy Mitchell Austin

Craig Rosenfeld, M.D. Dallas

Appointed by the Speaker of the Texas House of Representatives

Presiding Officer Preston, "Pete" Geren Fort Worth

Assistant Presiding Officer, Will Montgomery Dallas

Cynthia Mulrow, M.D. San Antonio



REPORT FROM THE CHIEF EXECUTIVE OFFICER

In 2016 CPRIT marked the halfway point in its constitutional funding authorization. Texas' 2007 decision to provide \$3 billion for cancer research and prevention remains the only such commitment in the United States.

It has been said that nations that lead on the frontier, lead in the world. The same can be said for states – states that lead on the frontier, lead in the nation. CPRIT's programs exist at the frontier of scientific knowledge.

At the halfway point, key metrics indicate that CPRIT is affecting Texas' national standing in both cancer research and the biomedical industry. In fact, CPRIT may well be transformational.

Historically, Texas lags nationally in both cancer research and venture capital life science company investment. Texas has 8.4 percent of the US population and 9.4 percent of the national gross domestic product. However, on a five-year rolling average Texas gets only 7.0 percent of National Cancer Institute (NCI) research awards and only 4.4 percent of National Institutes of Health awards.

On average, NCI provides more than \$200 million per year in cancer research to Texas-based institutions. CPRIT also doubles cancer research funding in Texas. Before CPRIT, Texas had one NCI-designated Comprehensive Cancer Center—The University of Texas MD Anderson Cancer Center in Houston. Now there are three. In addition to MD Anderson, in the last two years The University of Texas Southwestern Medical Center and Baylor College of Medicine have joined this prestigious group. In addition, The University of Texas Health Science Center at San Antonio is now an NCI-designated Cancer Center. Why are these listings important?

NCI centers anchor the national cancer research effort. There are currently 69 such centers in 35 states and the District of Columbia. These form the backbone of NCI's programs for studying and controlling cancer. A Designated Cancer Center has been recognized for its scientific leadership, resources, and depth and breadth of its research in basic, clinical and/or population science.

Comprehensive Cancer Centers demonstrate an additional depth and breadth of research, as well as substantial transdisciplinary research that bridges these scientific areas. CPRIT is demonstrably making Texas a national leader in cancer research.

On average, Texas gets \$216 million in life sciences venture capital. CPRIT averages \$51.0 million in translational research to early stage life science companies, thereby increasing such funding in Texas by nearly 25 percent. At the end of fiscal year 2016, CPRIT's \$296.6 million-plus in announced company awards have resulted in an additional \$1.28 billion in follow-on life science venture capital funding.

Without CPRIT, it is likely that this private sector follow-on investment would have gone to the East or West Coasts, the historical loci of the life science industry. CPRIT is demonstrably catalyzing the life sciences industry in Texas.

CPRIT also funds effective, evidence-based cancer prevention programs. Prevention focuses primarily on increasing the availability of screenings for colorectal, breast, and cervical cancers among medically underserved Texans and improving cancer education and awareness for both the general public and health



care providers. By the end of fiscal year 2016, \$169.1 million has gone to over 3.1 million prevention services in all 254 Texas counties. Over 7,000 cancers or cancer precursors have been identified. Can CPRIT claim to have saved lives? Some will say it did. However, CPRIT will claim that it gave them a fighting chance to beat what has been called the “Emperor of All Maladies”. CPRIT is improving the health of Texans today.

Below are a few of CPRIT’s 2016 milestones and key accomplishments. Each is discussed in greater detail starting on page 10 of this report.

- The academic research program awarded 112 grants, bringing CPRIT’s total since 2009 to \$1.21 billion.
- Ten percent of CPRIT’s research portfolio goes to childhood cancer research—more than twice the national rate.
- Another 17 CPRIT scholars were brought to Texas institutions, bringing the state’s total to 113 as of August 31, 2016.
- Seventeen grants provide \$23 million for research to improve prevention and early detection of cancer in Texas.
- Nine awards support \$24 million to fund applications of computational biology and analytical methods to investigate the complexity of cancer.
- CPRIT supported clinical trials provide Texans access to novel immunotherapies that harness the body’s immune systems to attack cancer.
- Two companies with product development awards received FDA Orphan Drug Designation status, and a third gained FDA fast track designation for its lead candidate. Orphan Drug status means that drugs have a longer period of government exclusivity, therefore attracting more investment.
- One CPRIT product development grantee was added to NASDAQ Biotech Index, and another raised \$47.3 million with its April 2016 IPO launch.
- Two companies with CPRIT product development awards gained Orphan medicine designations overseas (European Medicines Agency Priority Medicines (PRIME), EU Orphan Medicines, and Orphan UK).
- As of August 31, \$296.6 million in product development awards resulted in \$1.276 billion in follow-on funding, indicating private sector confidence in the high-quality merit-based peer review and due diligence required to receive a CPRIT award.
- The three millionth prevention service occurred. Since 2009, over 774,300 screenings and diagnostics for breast, cervical and colorectal cancer have been funded. From these, 4,833 cancer precursors were detected and 2,280 cancers found.
- Eighty-four new clinical trials are underway, treating nearly 5,600 patients.
- CPRIT’s highly acclaimed Innovations in Cancer Prevention and Research Conference was renewed in November 2015 with a record attendance. The meeting included 23 panels of oncology-related experts in academic research, prevention, and product development research and over 400 abstract poster sessions that provided significant networking opportunities for attendees from around the nation.



The question is often asked: “When are you going to cure cancer?” After all, CPRIT estimates that at least \$18.2 billion annually is pumped into fighting cancer nationally. CPRIT contributes \$300 million of this investment, or 1.6 percent.

But in asking this question, CPRIT encourages people to reflect upon how the scientific process works. Advances are generally made by building upon previous research and the work of others over considerable periods of time. In his book, *How We Got to Now*, author Steven Johnson points out that, much like the evolution of pollen that altered the design of the hummingbird’s wings, the most remarkable thing about innovations is the way they precipitate unanticipated changes that reverberate beyond the discipline or problem at the center of the particular innovation. The “Hummingbird Effect,” as Johnson calls it, can be seen in the Gutenberg printing press: it created the need for reading glasses, which led to experiments with lenses, followed by the invention of the microscope and the discovery of microscopic cells.

The science and technology that came together to make a microscope possible are similar to the science and technology CPRIT invests in today. Prevention and cures for cancer are made possible with every advancement. So the answer to the question—when will cancer be cured? — is now. Cancer is cured now, one discovery at a time. CPRIT is proud to be part of this connectivity.

Reflecting on 2016 and our halfway point as this report does, the Oversight Committee and staff of CPRIT are excited at the current momentum. Although proud of what’s been done to this point, we expect much, much more in the years ahead. At CPRIT the glass is only half full...the journey only half traversed. There is much good to do on the path ahead.

TEXANS CONQUER CANCER



THE IMPACT OF CANCER IN TEXAS AND THE STATE'S RESPONSE

Cancer is the second leading cause of death in Texas and the nation, behind heart disease. It is the leading cause of death for persons younger than 85 years, and is expected to surpass heart disease as the overall leading cause of death within this decade. It is estimated that one in two men and one in three women will be diagnosed with cancer in their lifetimes.

In 2016, it is estimated that there will be 116,690 Texans newly diagnosed with cancer and 39,450 who will die of the disease.

With improvements in treatment, and cancers being detected earlier, there are increasing numbers of cancer survivors. Additionally, the number of people diagnosed with and living with cancer will continue to increase as the population grows and ages.

Cost of Cancer to Texas

According to the report [*An Economic Assessment of the Cost of Cancer in Texas and the Benefits of the Cancer Prevention and Research Institute of Texas \(CPRIT\) and its Programs, The Perryman Group*](#), direct medical costs and morbidity and mortality losses in the state totaled \$34.9 billion in 2016, up from \$31.3 billion in 2015 and \$32.4 billion two years ago.

Cancer costs the Texas economy:

- \$169.9 billion in reduced annual spending
- \$83.3 billion in output losses annually
- 879,800 lost jobs from cancer treatment, morbidity and mortality and the associated spillover effects

Cancer also costs the government of the State of Texas nearly \$1 billion annually in health-related expenditures as shown below.

Initiative/Organization	Cancer-Related Expenditures*
Children's Health Insurance Program	\$8.2 million (FY 2015)
Texas Medicaid	\$308.9 million (FY 2015)
Teacher Retirement System of Texas	\$351.2 million (FY 2015)
Employees Retirement System of Texas	\$296 million (FY 2015)

*Most recent data available



National Cancer Funding

Despite the cost of cancer rising, between 2010 and 2014 the overall budget of the National Cancer Institute (NCI) has decreased \$100 million. This has affected NCI cancer funding, with a decrease of 3.3 percent over this time period. Despite this downward trend in federal cancer funding, NCI awards about \$204 million per year in grants to Texas institutions. CPRIT invests a similar amount in Texas. However, if the decline in federal funds continues, CPRIT's important role as the primary source of cancer research and prevention funding will be greater in years to come.

CPRIT's Economic Impact for Texas

Economic development, and specifically the creation of high-quality new jobs for Texas, is a part of CPRIT's statutory mission. Through the end of fiscal year 2016, according the Perryman Group's report, the following overall impact of CPRIT's activities and investments is:

- Nearly \$8 billion in Texas business activity
- Over 79,000 jobs created through direct and indirect economic activity
- \$361.4 million in state tax receipts and \$166.9 million in local government tax receipts

In addition to CPRIT's economic impact, CPRIT's efforts also enable Texans' prosperity by reducing the economic costs of cancer. Including initial outlays and secondary effects, every \$1 that CPRIT invests in screening programs results in \$21.89 savings in treatment costs, preserved productivity, and other economic benefits through earlier detection of cancers. It's also estimated that every \$1 spent on screening/prevention saves \$1.86 in direct health spending.

If CPRIT funds disappeared, presumably those state funds would be expended on another state activity. According to the Perryman Group, even after taking this alternative use into consideration, not extending CPRIT and its programs for another ten years would see a net cumulative economic loss of \$117.2 billion in lost gross product and 1,100,761 of lost person years of employment. The estimated fiscal losses to Texas state tax receipts are \$5.9 billion, and local governments are \$2.7 billion.



CPRIT GRANT PROGRAMS: ACADEMIC RESEARCH

The goal of CPRIT's Academic Research Program is to discover new information about cancer that can lead to prevention, early detection, and more effective treatments; translate new and existing discoveries into practical advances in cancer diagnosis, treatment, and survivorship; and increase the prominence and stature of Texas in the fight against cancer. CPRIT's strategy is to support the most creative ideas and the most meritorious projects brought forward by the cancer research community in Texas. The overarching principles for awarding CPRIT funds are scientific excellence and impact on reducing the burden of cancer.

In addition, it is critically important to enhance the life sciences infrastructure in Texas. This enables CPRIT's impact on cancer research to extend for years beyond the lifetime of the program. Most important to increasing infrastructure is the recruitment of preeminent researchers and the investment in core facilities. New researchers bring additional resources to the state, including research funding and new expertise, as well as help build the critical mass of science needed to attract investments in the development of products for cancer prevention, diagnosis, and treatment. Investments in core facilities assures that cancer researchers in Texas have access to the most up-to-date technologies needed for cutting-edge cancer research. Also important are the training programs that aim to produce the next generation of cancer researchers and increase the diversity of the cancer research workforce.

Finally, CPRIT's Academic Research Program seeks to fund projects in critical, but underfunded areas of cancer research. Areas of opportunity for strategic deployment of funds include prevention and early detection research; computational biology and analytic methods; childhood cancers; and intractable cancers with particular emphasis on population disparities and cancers of significance in Texas (e.g., lung, liver, and cervical cancers).

Principles

During fiscal year 2016, in advancing these principles the program continued to offer RFAs for investigator initiated grants that address a variety of cancer research topics, core facility support awards, High Impact/ High Risk, training awards and recruitment nominations. In addition, to stimulate research proposals that address Oversight Committee priorities that were considered underrepresented in past years, a more targeted approach to research proposal solicitations was taken. Additional RFAs were designed to stimulate applications that address childhood and adolescent cancers, prevention and early detection, and computational biology and analytic methods.

Priorities

The fiscal year 2016 program priorities for academic research adopted by the Oversight Committee include funding projects that address:

- A broad range of innovative, investigator-initiated academic research projects;
- Prevention and early detection;



- Computational biology and analytic methods;
- Rare and intractable cancers, including childhood cancers;
- Population disparities and cancers of importance in Texas (Lung, Cervix, Liver); and
- Recruit outstanding cancer researchers to Texas.

Table One illustrates targeted priorities as addressed by awards in fiscal year 2016.

TABLE ONE: FUNDING BY CPRIT ACADEMIC RESEARCH PROGRAM PRIORITIES*		
Priorities Addressed	Number of Grants	Award Amount
A broad range of innovative, investigator-initiated academic research projects	84	\$91,000,814
Recruit outstanding cancer researchers to Texas	25	\$76,520,000
Childhood cancers	20	\$26,984,209
Prevention and early detection	17	\$23,272,828
Computational biology and analytic methods	9	\$24,600,567
Rare and intractable cancers	31	\$42,255,865
Population disparities and cancers of importance in Texas (Lung, Cervix, Liver)	38	\$32,982,826

**Some grants address more than one priority*

Review Process and Grant Mechanisms

CPRIT academic research award applications undergo rigorous scientific reviews conducted by seven independent peer review panels. The peer review panels are composed of the most prominent cancer researchers in the country, and are selected from outside of Texas for their distinguished expertise. They are charged to assess academic research proposals on the basis of scientific merit and potential impact on cancer. Each of the seven panels is chaired by an eminent cancer researcher; together, these chairs make up the Scientific Review Council, chaired by a world-renowned scientist.

CPRIT utilizes a variety of grant award mechanisms to achieve the guiding principles and goals established for the academic research program:



- *Individual Investigator Research Awards (IIRA)* seek new fundamental knowledge about cancer and cancer development as well as the development of state-of-the-art technologies, and tools. This award provides the opportunity to explore new methods and approaches for investigating a question of importance that has not been inadequately addressed or for which there may be an absence of an established paradigm or technical framework. Targeted IIRAs solicit novel research in childhood and adolescent cancers, computational biology and prevention.
- *High-Impact/High Risk Research Awards* provide short-term funding to explore the feasibility of high-risk projects that if successful, would contribute major new insights into the etiology, diagnosis, treatment, or prevention of cancers.
- *Multi-Investigator Research Awards* stimulate collaboration and bring together researchers and clinicians to work on a common problem in cancer.
- *Core Facility Support Awards* facilitate the development or improvement of core facilities that will provide valuable services to support and enhance scientifically meritorious cancer research projects.
- Building a critical mass of cancer researchers in Texas is addressed by promoting recruitment of cancer scientists and clinicians at all levels to academic institutions in Texas and through training programs in which pre- and post-doctoral fellows are educated to become cancer researchers.

Academic Research Portfolio in Fiscal Year 2016

As shown in Table Two, in fiscal year 2016 CPRIT awarded \$135,082,887 in Academic Research grants. These awards fund a broad range of innovative, investigator-initiated projects through 51 Individual Investigator Research Awards, 21 High-Impact, High-Risk grants, and seven Multi-Investigator Research Awards. Six new Core Facilities Support Awards and four Research Training Awards renewals enhance Texas' cancer research capacity and life sciences infrastructure.

TABLE TWO: FISCAL YEAR 2016 ACADEMIC RESEARCH AWARDS BY RFA MECHANISM

Funding Mechanism	Applications Received	Applications Awarded	Total Funding	Success Rates
Individual Investigator Research Awards (IIRA)	351	39	\$34,740,000	11.1%
IIRA Cancer in Children and Adolescents	45	5	\$6,110,000	11.1%
IIRA Computational Biology	50	1	\$390,000	2.0%
IIRA Prevention and Early Detection	45	6	\$6,550,000	13.3%



Funding Mechanism	Applications Received	Applications Awarded	Total Funding	Success Rates
Multiple Investigator Research Awards	31	7	\$37,792,887	22.6%
Core Facilities Support Awards	18	6	\$30,340,000	33.3%
High Impact/High Risk	153	21	\$4,190,000	13.7%
Research Training Awards	13	4	\$14,970,000	30.8%
TOTAL	706	89	\$135,082,887	17.3%


Creating a world leading assemblage of cancer researchers in Texas is addressed by recruiting exceptional cancer scientists and clinicians, at all career levels, to academic institutions. As shown in Table Three below and Chart One on the following page, in fiscal year 2016 CPRIT supported the recruitment of 25 cancer researchers to Texas with awards totaling \$76,520,000.

TABLE THREE: FISCAL YEAR 2016 ACADEMIC RECRUITMENT RESEARCH AWARDS BY RFA MECHANISM				
Funding Mechanism	Applications Received	Applications Awarded	Total Funding	Success Rates
Established Investigators Award	18	5	\$30,000,000	28%
Rising Stars	13	4	\$15,700,000	31%
First-Time Tenure Track Faculty Members	46	16	\$30,820,000	35%
TOTAL	77	25*	\$76,520,000	32%

**Note: 17 executed contracts and eight pending contracts as of August 31, 2016.*



CHART ONE: FISCAL YEAR 2016 ACADEMIC RECRUITMENT RESEARCH AWARD
BY RFA MECHANISM



Representative Academic Research Program Grants

CPRIT uses a variety of funding mechanisms to support promising new areas of research that address CPRIT priorities as illustrated by the following grants.

Recruitment of Established Investigators

Gaudenz Danuser, Ph.D.

Gaudenz Danuser, Ph.D., was recruited from Harvard Medical School to The University of Texas Southwestern (UTSW) Medical Center as a CPRIT Established Investigator Scholar in 2012. The aim of the Established Investigator award mechanism is to bolster cancer research in Texas by providing financial support to attract world-class research scientists with distinguished professional careers to Texas institutions to establish research programs that add research talent to the state.

Dr. Danuser is an exceptional example of the impact this program is having on cancer research in Texas. As a distinguished computational biologist, his recruitment addresses a CPRIT priority to enhance Texas' expertise in computational biology and analytic methods. He develops innovative quantitative imaging methods to experimentally probe cancer and recently won a CPRIT investigator initiated research award (IIRA) to use artificial intelligence based on image contents inaccessible to a human observer to derive a tumor morphodynamic profile. This will predict the risk of stage III melanomas advancing to deadly stage IV metastases thereby allowing early targeted treatment.

As a CPRIT scholar Dr. Danuser's impact on computational biology in Texas extends well beyond his individual lab interests. He established a CPRIT-funded Bioinformatics Core Facility at UTSW to address the rapidly increasing challenges in information processing necessary for cancer research and provide special opportunities and a structured setting for the training and professional growth of computational biologists whose research is focused on cancer. Earlier this year, Dr. Danuser was appointed as the founding chair of the newly established Lyda Hill Department of Bioinformatics at UTSW to drive innovation in new information technology to help researchers and clinicians address scientific and medical challenges.



Multi-Investigator Research Award

Defining and Defeating Mechanistic Subtypes of KRAS-Mutant Lung Cancers

Principal Investigators: PI: Jonathan Kurie, MD; co-PI: John Heymach, MD, PhD;

co-PI: Pier-Paolo Scaglioni, MD; co-PI: Don Gibbons, MD, PhD

The University of Texas at MD Anderson, The University of Texas Southwestern Medical Center, Rice University

CPRIT offers Multi-Investigator Research Awards (MIRAs) to support creating integrated programs of collaborative and cross-disciplinary research among multiple investigators. MD Anderson, UTSW, and Rice University investigators have teamed up to develop a new targeted treatment for lung cancers containing the KRAS mutation. A normal KRAS gene performs an essential function in normal tissue signaling. A mutation of the KRAS gene is usually found in the development of many cancers. KRAS mutations are particularly common in colon cancer, lung cancer and pancreatic cancer.

Recent advancements developing targeted therapies for lung cancer have dramatically improved survival durations for some but not all patients. Lung cancers with the KRAS mutations have not benefited from these advances. This MIRA group organized to develop new solutions for KRAS-mutant lung malignancies based on a deep understanding of its genetic diversity. They will determine how co-mutations regulate tumor cell metabolomics and biological processes in the tumor microenvironment and validate targets discovered in experimental models using tissue specimens from a well-annotated human lung cancer tissue bank. The ultimate goal is to develop more effective personalized targeted therapeutics for patients with KRAS-mutant lung malignancies.

Core Facility Support Awards

The Adolescent and Childhood Cancer Epidemiology and Susceptibility Service for Texas

Michael Scheurer, Ph.D., Baylor College of Medicine

Core Facility Support Awards provide an institution substantial funding to establish or enhance core facilities to directly support cancer research programs by providing multiple cancer researchers access to appropriate research infrastructure, instrumentation, and technical expertise necessary for their research objectives.

The Adolescent and Childhood Cancer Epidemiology and Susceptibility Service for Texas (ACCESS-Texas) Core Facility is a CPRIT-funded resource that supports research to identify novel genetic risk factors and gene-environment interactions important in understanding cancer susceptibility among children and adolescents, particularly among the diverse patient population in Texas. ACCESS-Texas provides Texas cancer investigators access to highly annotated specimens for the discovery of novel biomarkers for cancer predisposition, early detection, diagnosis, treatment-related toxicity and response, survival, and late effects for childhood and adolescent cancers. ACCESS-Texas leverages existing Texas resources including the largest childhood cancer center in the US, Texas institutions with strong cancer genomics programs, and one of only a few centers in the US dedicated to the epidemiology of childhood cancers.

For a full list of projects in the CPRIT academic research portfolio visit: <http://www.cprit.texas.gov/funded-grants>



CPRIT GRANT PROGRAMS: PREVENTION

It is estimated that approximately half of all cancers can be prevented, however the ability to reduce cancer death rates depends, in part, on more broadly applying evidence-based prevention strategies currently available. Through its Prevention Program, CPRIT invests in building understanding of and the capacity to deliver effective community-based interventions so that new technologies and services are made available across the state, with priority given to areas and populations that are underserved.

CPRIT's prevention grant awards make it possible for prevention strategies and services to reach more Texans to decrease the burden of cancer. To date, CPRIT's Prevention Program has funded the delivery of close to 3.2 million services to Texans. These include 1.45 million education and training services and 1.74 million clinical services. The clinical services include screenings and diagnostic services for breast, cervix, colorectal and liver cancer as well as vaccinations, tobacco cessation, genetic testing and counseling, and survivor care services.

As a result of more prevention, early detection and better treatments, we are seeing steadily declining mortality rates. This is due to the efforts of everyone in the state who is addressing the incidence and mortality from cancer. Comparing 2008 to the latest data available in 2013, Texas has seen a drop in the death rates from cancer by 13 percent; this translates to approximately 3,306 averted deaths.

Preventing cancers or detecting them early provides economic benefits. According to the report "An Economic Assessment of the Cost of Cancer in Texas and the Benefits of the Cancer Prevention and Research Institute of Texas (CPRIT) and its Programs: 2016 Update" by The Perryman Group, every \$1 spent through CPRIT for screening/prevention leads to \$21.89 in treatment cost-savings, preserved productivity and other economic benefits through earlier detection of cancers.

Principles

The CPRIT Prevention Program is guided by the following principles:

- *Funding Evidence-Based Interventions.* CPRIT funds prevention programs and services, for any cancer type, that are culturally appropriate for the target population and validated by documented research or applied evidence.
- *Funding across the Prevention Continuum.* CPRIT funds quality proposals focused on:
 - Primary prevention: Reducing risk or preventing cancer from occurring (e.g., vaccine-conferred immunity, tobacco cessation)
 - Secondary prevention: Early detection of cancer to prevent it from spreading and treating diagnosed cases when the opportunity for greatest success exists (e.g., screening/early detection for breast, cervical, and/or colorectal cancer)
 - Tertiary prevention: Reducing risk of recurrence and improving quality of life for survivors and families (e.g. physical rehabilitation/therapy, psychosocial interventions, palliative care)



Priorities

The 2016 program priorities for prevention adopted by the Oversight Committee include funding projects that:

- Prioritize populations and geographic areas of greatest need, greatest potential for impact
- Focus on underserved populations
- Increase targeting of preventive efforts to areas where significant disparities in cancer incidence or mortality in the state exist

Table Four illustrates targeted priorities as addressed by awards in fiscal year 2016.

TABLE FOUR: FUNDING BY CPRIT PREVENTION PROGRAM PRIORITIES		
Priorities Addressed	Number of Grants	Award Amount
Prioritize populations and geographic area of greatest need, greatest potential for impact	60	\$91,000,814
Focus on underserved populations	76	\$101,305,994
Increase targeting of preventive efforts to areas where significant disparities in cancer incidence or mortality in the state exist	41	\$53,027,117

**Some grants address more than one priority*

Review Process and Grant Mechanisms

CPRIT prevention applications are first reviewed by two independent peer review panels. The peer reviewers are selected from outside of Texas and are prominent public health experts who assess the merit and potential impact on cancer. Each panel is chaired by a renowned public health expert. At the second stage of review, the Prevention Review Council (PRC) made up of the two panel Chairs and a Council Chair, conducts a programmatic review. Programmatic considerations may include, but are not limited to, geographic distribution, cancer type, population served, and type of program or service.

The Institute uses a variety of grant award mechanisms to achieve the goals of the Prevention Program. These include:

- *Evidence-Based Cancer Prevention Services* for projects that provide the delivery of evidence-based prevention services (e.g., primary prevention, screening, survivorship services). The maximum grant award is up to \$1.5 million for a maximum of three years.
- *Colorectal Cancer Prevention Coalition* for projects that will deliver comprehensive and integrated colorectal cancer screening that includes provision of screening, diagnostic, and navigation services



in conjunction with outreach and education of the target population through a coalition of partners with no funding cap for a maximum of three years.

- *Competitive Continuation/Expansion for Evidence-Based Cancer Prevention Services* for projects to continue or expand highly successful projects previously or currently funded by CPRIT. The award ranges from \$150,000 to \$1.5 million for up to three years, depending on the type of project proposed.
- *Cancer Prevention Promotion and Navigation to Clinical Services* for projects that deliver public education, outreach and navigation to cancer screening and preventive services with a maximum of \$400,000 and a maximum duration of 36 months.
- *Dissemination of CPRIT-Funded Cancer Control Interventions* for projects that facilitate the dissemination and implementation of successful CPRIT-funded, evidence-based cancer prevention and control interventions across Texas with a maximum of \$300,000 and a maximum duration of 24 months.
- *Evidence-Based Cancer Prevention Services – See, Test & Treat® Program* for projects that follow the CAP Foundation’s See, Test & Treat model to offer Pap tests and mammograms with same day results; provide information on prevention, risk reduction, and early detection; navigate participants to diagnostic testing and treatment as needed. The award maximum is \$25,000 for a maximum duration of 12 months.

Since 2009 CPRIT has funded 172 prevention grants, 79 of which were active during fiscal year 2016. The active evidence-based projects account for a total of \$104,892,274 in funding as seen in Table Five.

TABLE FIVE: PREVENTION AWARDS ACTIVE IN FISCAL YEAR 2016 BY RFA MECHANISM

Funding Mechanism	Award Maximum	Active Projects	Total Award Amount
Evidence-Based Cancer Prevention Services	• Up to \$1.5M • 3 years	41	\$62,165,988
Evidence-Based Cancer Prevention Services – Colorectal Cancer Prevention Coalition	• No funding cap • 3 years	4	\$11,788,527
Competitive Continuation/Expansion for Evidence- Based Cancer Prevention Services	• Up to \$1.5M • 3 years	21	\$27,060,641
Evidence-Based Cancer Prevention Services – See, Test & Treat® Program	• Up to \$25,000 • 1 year	2	\$48,124
Cancer Prevention Promotion and Navigation to Clinical Services	• Up to \$400,000 • 3 years	3	\$1,179,645



Funding Mechanism	Award Maximum	Active Projects	Total Award Amount
Dissemination of CPRIT-Funded Cancer Control Interventions	• Up to \$300,000 • 2 years	4	\$1,199,544
Behavior Change Through Public and Professional Education and Training	• Up to \$500,000 • 3 years	4	\$1,449,805
TOTAL		79	\$104,892,274

The following charts (Charts Two – Four) illustrate the distribution of these projects by type, cancer site and geographic location. Projects may address more than one focus area or cancer site.

CHART TWO: NUMBER OF ACTIVE PREVENTION PROJECTS BY PRIMARY FOCUS AREA




CHART THREE: NUMBER OF ACTIVE PREVENTION PROJECTS BY CANCER SITE







CHART FOUR: COUNTIES SERVED BY CPRIT PREVENTION PROJECTS
79 ACTIVE PROJECTS - FY 2016



Prevention grantees provide quarterly and annual progress reports. Based on these reports, since its inception, the Prevention Program has supported projects providing services to over 3.1 million Texans. Of these, 1,449,595 have been education and training services. In addition, 1,742,561 clinical services have been delivered. These projects have led to Texans receiving:

- 83,573 prevention vaccinations
- 201,425 tobacco cessation services
- 18,713 genetic testing and counseling services
- 15,143 survivor care services
- 726,264 screenings and diagnostics for breast, cervical, colorectal, and liver cancers:
 - 288,403 recipients had never before been screened
 - 5,281 cancer precursors detected
 - 2,450 cancers detected



Representative Prevention Program Grants

Dr. Katheleen Schmeler, cervical cancer screening and prevention

For an example on healthcare disparities between different parts of Texas, look no further than the counties of the Lower Rio Grande Valley (Cameron, Starr, Willacy, and Hidalgo) where cervical cancer mortality is approximately 30 percent higher than in non-border Texas counties. As a result of a CPRIT prevention grant of \$1.44 million in November 2014, Dr. Schmeler of The University of Texas MD Anderson Cancer Center created an educational outreach program designed for promotoras (community health workers) to teach low-income Hispanic women about cervical cancer screening.

Through the use of tele-mentoring technology, Project ECHO (Extension for Community Healthcare Outcomes) is used to train and support local providers in the appropriate evaluation and management of abnormal cervical cancer screening tests. To date, 2,585 women have been educated, 5,367 women underwent Pap/HPV testing and five providers from the RGV have been trained in performing colposcopy and LEEP and all are participating in a colposcopy mentoring program. These interventions have dramatically increased local rates of detection and treatment of pre-invasive cervical disease, ultimately decreasing cervical cancer incidence and mortality.

“The ease and confidence of practicing just got better. If it works here, it can work anywhere,” said Rose Gowen, MD OB-GYN of Su Clinica Familiar in Harlingen. Dr. Schmeler’s work has received national attention where legislation has been introduced in Congress to evaluate the impact of Project ECHO programs on rural and underserved populations.

Dr. David Poplack, childhood cancer survivors

An estimated 30,000 Texas childhood cancer survivors will experience late effects or health problems as they age. This is a result of exposure early in life to chemotherapeutic, radiation, surgery or other cancer treatments. Many survivors face uncertain futures well into adulthood due to inadequacies in tracking a cancer patient’s history between healthcare systems.

To address this deficiency, Dr. Poplack of Baylor College of Medicine used a CPRIT grant of \$1.5 million to support the development of a new system of care, the Survivor-Centered Service System. Dr. Poplack’s goal is to create an online data-based infrastructure to help care teams and clinicians monitor a patient’s late effects of treatment, and to help educate childhood cancer survivors on how to monitor their health. The Passport for Care survivor portal has enrolled 1,503 survivors, and the project has launched a collaboration with the Texas Cancer Registry to contact survivors to educate them about this resource.

“My son will go to college in a couple of years; this Passport is perfect for communicating his history and health needs with the college health services, and for teaching him what he himself needs to know for the future,” said PP, Mother (& Nurse) of JP, childhood cancer survivor. This project has the potential to serve as a national model for addressing the unmet need of providing follow-up screening services to survivors in adulthood.



Julie Laughlin, tobacco cessation and mental health

Tarrant County's lung cancer rates and tobacco use rates are significantly higher than the rest of the state. Julie Laughlin of Mental Health Mental Retardation of Tarrant Count (MHMR) also saw that individuals in drug and mental health treatment have significantly higher smoking rates (70-75 percent) than the national average of 21 percent. However, mental health clinicians often lack training to deliver tobacco interventions.

A CPRIT grant of \$2.2 million helped the organization start No Butts: No Opportunities, which serves high-risk smoking populations, including individuals with substance abuse disorders, serious mental illness, and youth who are cited for tobacco violations. Tobacco cessation is integrated into existing treatment for clients. So far, 772 clients have received individual tobacco cessation counseling in a total of 1,022 counseling sessions at various MHMR clinic locations. Nicotine replacement therapy products were provided to 626 clients, including a total of 54,334 nicotine replacement therapy items such as nicotine gum, lozenges and patches that were distributed during one year of the grant. Systems improvements were made such as the implementation of the Mental Health Services Smoking Cessation Treatment Plan into the mental health service array and MHMR's Mental Health and Addiction Services division was integrated into the behavioral health division.

"Although the journey has been a tough one, our patient Angela was able to go one week without smoking – this was enough to assure her that she could in fact beat this addiction," said Julie.

For a full list of projects in the CPRIT prevention portfolio visit: www.cprit.texas.gov/funded-grants



CPRIT GRANT PROGRAMS: PRODUCT DEVELOPMENT RESEARCH

The Product Development Research Program funds companies developing products that benefit cancer patients. Novel cancer treatments result from a series of research and development activities.

The process of product development converts a one-time phenomenon to a safe and reliable product usable in a clinical setting. Clinical research confirms the safety and efficacy on the target patient population. Regulatory approval is required prior to commercial use. Product development, clinical research and regulatory approval are historically conducted by startup companies funded by private investors and, in recent years, by the public sector to promote economic development.

As a product moves through this process, risks are reduced at each step. Earlier stage programs, e.g., basic research, have higher risk and are the least likely to attract private capital. CPRIT uses subject matter expert peer reviewers to identify the most promising projects and typically invests in early stage companies where private capital is hardest to obtain. CPRIT's investment in early stage companies increases the number of cancer therapies in development in Texas, thereby stimulating the Texas life sciences ecosystem.

Principles

CPRIT has limited resources to maximize clinical benefits, and more scientifically and commercially attractive product development opportunities exist than CPRIT can fund. Therefore, to invest strategically, Product Development Research is guided by the following principles:

- Supporting the commercial development of novel products to address unmet cancer diagnosis and treatment needs;
- Stimulating the Texas life sciences ecosystem by funding in spaces when private capital is most difficult to obtain, known as the “Valley of Death” between research and private funding;
- Invest in projects based on sound scientific research with strong management and sound business plans that will be attractive to private investment; and
- Providing an appropriate return on Texas taxpayer investment.

Priorities

The 2016 program priorities for product development research adopted by the Oversight Committee include funding projects that address:

- Funding projects at Texas companies and relocating companies that are most likely to bring important products to the market
- Providing funding that promotes the translation of research at Texas institutions into new companies able to compete in the marketplace
- Identifying and funding projects to develop tools and technologies of special relevance to cancer research, treatment, and prevention.



Table Six illustrates targeted priorities as addressed by awards in fiscal year 2016.

TABLE SIX: FUNDING BY CPRIT PRODUCT DEVELOPMENT RESEARCH PROGRAM PRIORITIES		
Priorities Addressed	Number of Grants	Award Amount
Funding projects at Texas companies and relocating companies that are most likely to bring important products to the market	3	\$53,913,939
Providing funding that promotes the translation of research at Texas institutions into new companies able to compete in the marketplace	1	\$18,668,717
Identifying and funding projects to develop tools and technologies of special relevance to cancer research, treatment, and prevention	N/A	N/A

Review Process and Grant Mechanisms

The Product Development Research Program funds companies developing novel products that benefit cancer patients including diagnostics, services and therapeutics. A merit-based selection process is used to select the most attractive applicants. Historically, CPRIT funds approximately 10 percent of applicant companies.

CPRIT product development awards are monitored by the Product Development Review Council comprised of five experts in the field of cancer research and cancer product development, in order to insure appropriate progress toward objectives. Funding occurs in tranches and can be discontinued if appropriate progress is not demonstrated. Award contracts require a royalty payment upon commercialization to insure appropriate return on Texas taxpayer investment.

CPRIT provides awards only to Texas-based companies or out-of-state firms willing to relocate to Texas through the relocation awards Request for Applications. Terms are similar for both programs.

Developing novel cancer drugs and diagnostics is expensive, with the latest studies showing the cost of new products can be up to \$3 billion. CPRIT provides only a portion of the funding required to complete development, and the bulk of the funding typically comes from private sources. As of August 31, 2016, CPRIT product development awardees have received more than \$1.28 billion in follow-on funding.

Portfolio Description

Overview

At the end of fiscal year 2016, CPRIT has active investment in 28 companies across multiple sectors of the cancer market including development services, diagnostics, devices and drugs. Most of the investments are to companies developing novel drug and biologic therapies for cancer patients.



CPRIT has 18 active investment drug development firms. These investments comprise 2/3 of CPRIT's investments and 90 percent of invested capital. The average investment is \$13.5 million. CPRIT has invested in companies developing cell therapies, drugs and biologic therapies. All 18 companies are in preclinical or clinical development.

While CPRIT mostly invests in cancer drug development, we also invest in other sectors including development services, diagnostics and devices. CPRIT has nine active investments in these sectors which comprise one third of CPRIT investments and 10 percent of invested capital. The average investment is \$3.8 million. CPRIT has investments in five of these companies that have already commercialized their service or product. Those five companies are FUJIFILM Diosynth Technologies Texas LLC, Rules-Based Medicine, Asuragen, Inc., Apollo, and Visualase.

Table Seven is CPRIT's current portfolio of product development research projects made to date with the potential for returns on CPRIT investment.

TABLE SEVEN: FISCAL YEAR 2016 CPRIT PRODUCT DEVELOPMENT PORTFOLIO				
Company	Sector	Cancer Indications	Project Focus	Total Award Amounts
FUJIFILM Diosynth Technologies Texas LLC (formerly Kalon Biotherapeutics)	Tools and Services	Multiple	Contract biologics manufacturing facility	\$7,901,420
Myriad RBM (formerly Rules-Based Medicine)	Tools and Services	Multiple	Biomarker test development	\$3,024,432
Asuragen, Inc.	Diagnostics	Multiple	Genetic and oncology diagnostics	\$6,837,265
InGeneron	Diagnostics	Multiple	System to isolate circulating cancer cells	\$198,111
OncoNano Medicine, Inc.	Devices	Multiple	Surgical device for margin detection	\$6,000,000
Apollo Endosurgery, Inc.	Devices	Colorectal, Gastric	Minimally invasive resection device	\$5,001,063
Visualase, Inc.	Devices	Multiple	MRI guided laser tumor ablation	\$2,151,776



Company	Sector	Cancer Indications	Project Focus	Total Award Amounts
Nuviant Medical, Inc. (formerly Rosellini Scientific)	Devices	Prostate, Cervical, Rectal	Neuro-stimulation device addressing overactive bladder complications from surgical resection	\$967,000
NanoTX Therapeutics, Inc.	Devices	Glioblastoma	Nanoparticle radiation therapy	\$2,000,000
Bellicum Pharmaceuticals, Inc.	Cell Therapeutics	Leukemia	De-activated T-cells for Leukemia	\$22,627,026
Cell Medica	Cell Therapeutics	Lymphoma	Activated T-cells	\$15,571,303
CerRx, Inc.	Molecular Therapy	Multiple	Small molecule affects tumor cell wall	\$6,000,000
Medicenna Therapeutics, Inc.	Molecular Therapy	Glioblastoma	Cytokines for IL4 receptor	\$14,140,090
AERase, Inc. (parent company Aeglea BioTherapeutics)	Molecular Therapy	Multiple	Enzyme for amino acid depletion	\$19,806,145
Beta Cat Pharmaceuticals, Inc.	Molecular Therapy	Colorectal	Betacatine pathway inhibitor	\$15,908,085
Pulmotect, Inc.	Molecular Therapy	Blood	Molecular anti-infective therapy	\$7,126,398
Curtana Pharmaceuticals, Inc.	Molecular Therapy	Glioblastoma	Targeted small molecule therapy	\$7,580,185
ESSA Pharma, Inc.	Molecular Therapy	Prostate	Androgen receptor blocker	\$12,000,000
Salarius Pharmaceuticals	Molecular Therapy	Multiple	LSD 1 Inhibitor	\$18,668,717
Peloton Therapeutics, Inc.	Molecular Therapy	Renal	Transcription factor agonist	\$11,044,931
Formation Biologics Corp. (formerly Armada Pharmaceuticals, Inc.)	Biologic Therapy	Multiple	Antibody drug conjugate	\$12,750,000



Company	Sector	Cancer Indications	Project Focus	Total Award Amounts
Mirna Therapeutics, Inc.	Biologic Therapy	Renal, skin	Tumor suppressor Micro RNA therapy	\$27,062,530 (2 grants)
DNAtrix, Inc.	Biologic Therapy	Glioblastoma	Adenovirus for glioblastoma	\$10,813,623
Molecular Templates, Inc.	Biologic Therapy	Blood Cancers	Antibody drug conjugate	\$25,800,000
Caliber Biotherapeutics, Inc.	Biologic Therapy	Blood Cancers	Biobetter cancer monoclonal antibody	\$12,808,151
Immatics US, Inc.	Biologic Therapy	Multiple	Targeted immunotherapy	\$19,652,175
Aravive Biologics, Inc. (formerly Ruga Corp.)	Biologic Therapy	Leukemia	Targeted immunotherapy	\$20,000,000
Pelican Therapeutics	Biologic Therapy	All Cancers	T-cell antibody	\$15,245,222

Representative Product Development Program Grants

Aravive Biologics

As a result of a \$20 million grant from CPRIT, Aravive Biologics (formerly known as Ruga Corp.) relocated its operations from San Francisco, California to Houston, Texas. The company is developing Aravive-S6, a therapeutic targeting certain aggressive, hard-to-treat cases of acute myeloid leukemia (AML). AML is a cancer that begins in bone marrow and affects cells intended to mature into different types of blood cells. The Aravive-S6 compound works as a decoy to bind to a cancer-causing protein. This prevents the protein from binding to cells and inducing cancer. The CPRIT grant funding supports late preclinical work (IND enabling studies) through early proof of concept studies (Phase 1/2) for AML and certain other aggressive solid tumors.

“We are very pleased to be selected to receive this significant funding from CPRIT and look forward to building our business in Houston’s Texas Medical Center,” said Ray Tabibiazar, president and CEO of Aravive Biologics.

“Houston’s vibrant biomedical community is home to many of the top cancer researchers in the United States, including noted experts on AML, our lead hematologic cancer indication. We look forward to accessing this outstanding expertise and growing our presence within the local biomedical community as we advance Aravive-S6 into clinical trials.”



Salarius Pharmaceuticals

Salarius specializes in developing novel drugs for rare pediatric cancers and other cancers by focusing on treatments that interrupt the final steps of the signaling cascade. Receiving a CPRIT grant of \$18.7 million to relocate from Connecticut to Houston, Texas, Salarius has developed a first-in-class highly specific LSD1 inhibitor for Ewing's Sarcoma and other undifferentiated sarcomas, in addition to late stage prostate cancer. Ewing's is a rare devastating pediatric, adolescent and young adult bone cancer with no approved treatment. Roughly 50 percent of Ewing's patients fail to respond to chemotherapy, radiation and surgical treatment and face 70 percent – 80 percent mortality.

"If you're in the oncology space, CPRIT has got to be number one on your list of organizations to talk to," said David Arthur, Salarius CEO. "The model they're using and the support they provide, as well as the life science infrastructure that is building in Texas and Houston, make it a really attractive venue financially and organizationally."

AERase/Aeglea Biotherapeutics

A recipient of a \$19.8 million CPRIT grant, Austin-based AERase is pioneering novel human enzyme therapies to treat cancer and metabolic diseases. These compounds selectively kill cancer cells, thus enhancing effectiveness and reducing side effects. AERase/Aeglea Biotherapeutics recently received FDA fast track designation for its lead candidate in cancer trials targeting skin melanoma, acute myeloid leukemia and myelodysplastic syndrome. Since the announcement of their CPRIT grant award in 2014, the company has garnered \$91.3 million in follow-on funding.

"The CPRIT grant allowed us to begin clinical trials to test what kinds of tumors respond to the human enzyme that is believed to degrade amino acids present in tumors." – David Lowe, CEO

For a full list of projects in the CPRIT product development research portfolio, visit: www.cprit.texas.gov/funded-grants.



CPRIT PEER REVIEW

Summary

Rigorous, independent merit-based peer review is the foundation of all of CPRIT's grant programs and the primary means for ensuring that the funds committed by the people of Texas to the academic research, product development research, and prevention programs are prudently invested with the greatest potential impact on cancer. From CPRIT's inception, the peer review process has included multiple safeguards to address potential conflicts of interest and ensure both fairness and accountability. Further enhancements were made to the process in fiscal year 2014 pursuant to the recommendations of the State Auditor and the provisions of Senate Bill 149 of the 83rd Texas Legislature.

CPRIT has followed the lead of organizations such as the National Cancer Institute (NCI), the American Cancer Society, and Susan G. Komen to establish a scientific peer review process through which all grant proposals are thoroughly vetted and scored. Scientific peer review provides an objective evaluation of the proposed hypothesis, and the methodology to prove the hypothesis and prospective findings. Since CPRIT makes awards only to organizations in Texas, it recruits scientific experts who live and work outside of Texas to participate on the peer review panels to reduce any potential conflict of interest between the reviewers and the proposals under review.

The National Cancer Institute has officially designated CPRIT as a NCI-approved funding entity. This certification involves a comprehensive assessment of CPRIT's peer review process to ensure it conforms to the standards set by the National Institutes of Health, including conflict of interest protections.

Any research proposals received from companies require an additional due diligence review to determine if a commercial path for the prospective discovery exists to make it available in health care practice to cancer patients for treatment or to the general population as a preventive measure, such as a vaccination. This review is unique to CPRIT among cancer grant-making organizations and ensures that CPRIT only invests in research on discoveries with the highest probability of reaching and benefiting Texans as soon as possible.

CPRIT Peer Review Processes

The following tables show the process in effect for prevention, academic research and product development research program grants as of the end of fiscal year 2016.



CPRIT PREVENTION PEER REVIEW PROCESS

STEP 1 Request for Application (RFA)	CPRIT releases a Request for Application (RFA) via the website, subscribers to CPRIT's email newsletter and the Texas Register.
STEP 2 Applying Online	Applicants submit proposals using CPRIT's online application receipt system (www.cpritgrants.org). Applicants must include information about all sources of funding, including private investors. Only applications submitted via the designated electronic portal are eligible for consideration of a grant award and only for the grant mechanism under which the grant application was submitted.
STEP 3 Administrative Review	Applications submitted by the deadline are checked for compliance against the application's administrative requirements and may be withdrawn at this step.
STEP 4 Reviewer Conflict of Interest (COI) Identification	Experts and advocates in cancer prevention are recruited by panel chairs, provisionally appointed by CPRIT's CEO and approved by the Oversight Committee (OC). The reviewers access a non-confidential summary, a list of key personnel and sources of funding for every application. Reviewers identify which applications match their area of expertise and flag potential COI. Some categories of COI may excuse a reviewer from reviewing any application submitted under the same grant mechanism.
STEP 5 Reviewer Assignment	Peer reviewers are assigned to panels in their area of expertise. At least one advocate reviewer is assigned to each panel. All reviewers live and work outside of the state. A list of members by panel can be found on CPRIT's website. A reviewer with a conflict does not participate in the discussion, presentation, or scoring of the application at any point in the process.
STEP 6 Initial Scoring	An eligible application undergoes a rigorous peer review; the proposal is evaluated by (usually three) primary reviewers who provide an individual overall score. Individual overall scores are averaged to produce a single initial overall score for the application.
STEP 7 Panel Discussion	The full peer review panel (12-15 reviewers) discusses the applications. If there is insufficient time to discuss all grant applications, the Review Panel chair determines applications to be discussed. After discussion, each panel member provides individual overall scores that are averaged to provide a final overall score. A reviewer with a conflict of interest for an application recuses themselves from the discussion and scoring of that application.
STEP 8 Final Scoring	Based upon the discussion and the scores, the peer review panel develops a rank ordered list of applications it recommends for grant awards. A final overall score and a summary statement of the reviewers' comments are provided to each applicant.



STEP 9 Review Council Recommendation	The Prevention Review Council, consisting of the Chair and panel chairs, considers the panels' recommendations and conducts a programmatic review. Criteria considered during programmatic review are spelled out in the RFA. The Council assigns a numerical ranking score to each application. The Council specifies and explains changes, if any, to the applications' goals, objectives, budget or timeline and these are provided to both the CEO and the OC. Once the review process is complete, all reviewers sign a statement that they have followed the CPRIT COI agreement terms.
STEP 10 Program Integration Committee (PIC) Review	The Program Integration Committee (PIC) considers the prioritized list of applications submitted by the Program Review Councils and approves by a majority vote a final list of applications to be recommended to the OC. The PIC includes an explanation for its recommendations.
STEP 11 Oversight Committee Action	The CPRIT CEO forwards the PIC's recommendations and provides an affidavit that each application complied with CPRIT's submission and review process. Two-thirds of the OC members present and voting must approve each grant award recommendation submitted by the PIC. The CPRIT Compliance Officer also certifies each recommended award.
STEP 12 Grant Award Contract	All CPRIT grants are awarded through a contract that specifies the responsibilities and obligations of the award recipient and reflects certain reporting and legal requirements.



CPRIT ACADEMIC RESEARCH PEER REVIEW PROCESS

STEP 1 Request for Application (RFA)	CPRIT releases a Request for Application (RFA) via the website, subscribers to CPRIT's email newsletter and the Texas Register.
STEP 2 Applying Online	Applicants submit proposals using CPRIT's online application receipt system (www.cpritgrants.org). Applicants must include information about all sources of funding, including private investors. Only applications submitted via the designated electronic portal are eligible for consideration of a grant award and applications are eligible only for the grant mechanism under which the grant application was submitted.
STEP 3 Administrative Review	Applications submitted by the deadline are checked for compliance against the application's administrative requirements and may be withdrawn at this step.
STEP 4 Reviewer Conflict of Interest (COI) Identification	Experts and advocates in cancer research are recruited by panel chairs, provisionally appointed by CPRIT's CEO and approved by the Oversight Committee (OC). The reviewers access a non-confidential summary, a list of key personnel and sources of funding for every application. Reviewers flag potential COI. Some categories of COI may excuse a reviewer from reviewing any application submitted under the same grant mechanism.
STEP 5 Reviewer Assignment	Peer reviewers are assigned to panels in their area of expertise. Panel chairs assign applications to primary reviewers (usually three per application). At least one advocate reviewer is assigned to each panel. All reviewers live and work outside of the state. A list of members by panel can be found on CPRIT's website. A reviewer with a conflict does not participate in the discussion, presentation, or scoring of the application at any point in the process. Due to volume, research applications may undergo a preliminary evaluation using the process and criteria specified in the RFA.
STEP 6 Initial Scoring	An eligible application undergoes a rigorous peer review; the proposal is evaluated by (usually three) primary reviewers who provide an individual overall score. Individual overall scores are averaged to produce a single initial overall score for the application.
STEP 7 Panel Discussion	The full peer review panel (12- 15 reviewers) discusses the applications. If there is insufficient time to discuss all grant applications, the Review Panel chair determines applications to be discussed, based on initial scores. After discussion, each panel member provides individual overall scores that are averaged to provide a final overall score.



STEP 8 Final Scoring	Based upon the discussion and the scores, the peer review panel develops a rank ordered list of applications it recommends for grant awards. A final overall score and a summary statement of the reviewers' comments are provided to each applicant.
STEP 9 Review Council Recommendation	The Scientific Review Council, consisting of the Chair and panel chairs, considers the panels' recommendations and conducts a programmatic review. Criteria considered during programmatic review are spelled out in the RFA. The Council assigns a numerical ranking score to each application. The Council specifies and explains changes, if any, to the applications' goals, objectives, budget or timeline and these are provided to both the CEO and the OC. Once the review process is complete, all reviewers sign a statement that they have followed the CPRIT COI agreement terms.
STEP 10 Program Integration Committee (PIC) Review	The Program Integration Committee (PIC) considers the prioritized list of applications submitted by the Program Review Councils and approves by a majority vote a final list of applications to be recommended to the OC. The PIC includes an explanation for its recommendations.
STEP 11 Oversight Committee Action	The CPRIT CEO forwards the PIC's recommendations and provides an affidavit that each application complied with CPRIT's submission and review process. Two-thirds of the OC members present and voting must approve each grant award recommendation submitted by the PIC. The CPRIT Compliance Officer also certifies each recommended award.
STEP 12 Grant Award Contract	All CPRIT grants are awarded through a contract that specifies the responsibilities and obligations of the award recipient and reflects certain reporting and legal requirements.



CPRIT PRODUCT DEVELOPMENT RESEARCH PEER REVIEW PROCESS

STEP 1 Request for Application (RFA)	CPRIT releases a Request for Application (RFA) via the website, subscribers to CPRIT's email newsletter and the Texas Register.
STEP 2 Applying Online	Applicants submit proposals using CPRIT's online application receipt system (www.cpritgrants.org). Applicants must include information about all sources of funding, including private investors. Only applications submitted via the designated electronic portal are eligible for consideration of a grant award and only for the grant mechanism under which the grant application was submitted.
STEP 3 Administrative Review	Applications submitted by the deadline are checked for compliance against the application's administrative requirements and may be withdrawn at this step.
STEP 4 Reviewer Conflict of Interest (COI) Identification	Experts and advocates in development of products related to cancer research are recruited by panel chairs, provisionally appointed by CPRIT's CEO and approved by the Oversight Committee (OC). The reviewers access a non-confidential summary, a list of key personnel and sources of funding for every application. Reviewers identify which applications match their area of expertise and flag potential COI. Some categories of COI may excuse a reviewer from reviewing any application submitted under the same grant mechanism.
STEP 5 Reviewer Assignment	Peer reviewers are assigned to panels in their area of expertise. At least one advocate reviewer is assigned to each panel. All reviewers live and work outside of the state. A list of members by panel can be found on CPRIT's website. A reviewer with a conflict does not participate in the discussion, presentation, or scoring of the application at any point in the process.
STEP 6 Individual Evaluation and Scoring	An eligible application undergoes a rigorous peer review; the proposal is evaluated by (usually three or four) primary reviewers who provide an individual overall score. Individual overall scores are averaged to produce a single initial overall score for the application.
STEP 7 Panel Discussion	The full peer review panel (12-15 reviewers) meets by teleconference and discusses the applications. After discussion, the primary reviewers may adjust their initial scores. The primary reviewers' individual overall scores are then averaged to provide an overall evaluation score for the application; the score and a summary statement of the reviewers' comments are generated for each application that does not move forward for further review. A reviewer with a conflict of interest for an application recuses themselves from the discussion and scoring of that application.



STEP 8 In Person Presentations	Applicants with sufficiently positive scores after the panel discussion are invited to present their proposal to the full review panel and answer reviewer questions. Following the presentation, the reviewers discuss the application and all reviewers individually submit an overall score for the application. The individual overall scores are then averaged to provide a final overall evaluation score for the application; the score and a summary statement of the reviewers' comments are provided to each applicant. A reviewer with a conflict of interest for an application recuses themselves from the discussion and scoring of that application.
STEP 9 Due Diligence Review	The applications that score sufficiently well after the in-person presentation undergo due diligence review conducted by outside contractors hired by CPRIT and overseen by the Chief Product Development Officer. Due diligence involves an in-depth evaluation of the proposal's underlying intellectual property, clinical trial design, regulatory affairs, manufacturability of product, marketing, etc. The due diligence reports are provided to the primary reviewers and the Product Development Review Council for their consideration.
STEP 10 Review Council Recommendation	Following a discussion of the due diligence reports, the Review Council conducts a programmatic review and decides which applications should be recommended for CPRIT grant funding. Criteria considered during programmatic review are spelled out in the RFA. All Product Development applications recommended for grant funding are numerically ranked by the Review Council and submitted to the Program Integration Committee (PIC). The Council specifies and explains changes, if any, to the applications' goals, objectives, budget or timeline and these are provided to both the CEO (as Chair of the PIC) and the OC. Once the review process is complete, all reviewers sign a statement that they have followed the CPRIT COI agreement terms.
STEP 11 Program Integration Committee (PIC) Review	The PIC considers the prioritized list of applications submitted by the Program Review Councils and approves by a majority vote a final list of applications to be recommended to the OC. The PIC includes an explanation for its recommendations.
STEP 12 Oversight Committee Action	The CPRIT CEO forwards the PIC's recommendations and provides an affidavit that each application complied with CPRIT's submission and review process. Two-thirds of the OC members present and voting must approve each grant award recommendation submitted by the PIC. The CPRIT Compliance Officer also certifies each recommended award.
STEP 13 Grant Award Contract	All CPRIT grants are awarded through a contract that specifies the responsibilities and obligations of the award recipient and reflects certain reporting and legal requirements, including revenue sharing terms and agreed upon milestones.



Review Councils

The Institute's three review councils – Scientific Review, Prevention Review, and Product Development Review – oversee the peer review of all applications submitted to CPRIT. Members of the review councils chair the peer review committees within each program area. The councils assess the evaluations completed by the peer review committees and create a final list of proposals recommended for CPRIT grant awards.

Pursuant to Texas Health and Safety Code § 102.251, the review councils submit their lists of recommendations simultaneously to the presiding officers of the CPRIT Program Integration Committee and the Oversight Committee. The Program Integration Committee then forwards its final recommendations to the Oversight Committee, which approves awards by a two-thirds vote at a quarterly public meeting.

Scientific Review Council members:

www.cprit.state.tx.us/grants-process/peer-review-committees/scientific-review-council-src/

Prevention Review Council members:

www.cprit.state.tx.us/grants-process/peer-review-committees/prevention-review-council-prc/

Product Development Review Council members:

www.cprit.state.tx.us/grants-process/peer-review-committees/productdevelopment-review-council-crc/



CPRIT COMPLIANCE PROGRAM

Summary

Established by the CPRIT Oversight Committee and later codified by Senate Bill 149, 83rd Texas Legislature, the compliance program is mandated “to assess and ensure compliance by the Institute’s committee members and employees with applicable laws, rules and policies.”

The compliance program is also statutorily required to provide fiscal and administrative oversight of all CPRIT grants through review of grantee processes to ensure compliance with rules, regulations, and laws, as well as internal codes of conduct, policies and procedures.

CPRIT Employee and Oversight Committee Compliance

One purpose of the compliance program is to ensure that each CPRIT employee and Oversight Committee member complies with reporting and training requirements as provided in state laws, agency rules and policies. All CPRIT employees verify that they have read the Standards of Conduct, completed annual ethics training, signed a non-disclosure agreement and attest that they have no outside employment that conflicts with their CPRIT employment. In addition to completing all conflict of interest and training requirements, CPRIT Oversight Committee members submit annual personal financial statements and disclose all political contributions over \$1,000.

Grant Award Compliance

The compliance program also works to oversee that all grants, from the time of application submission through project completion, comply with agency processes and procedures in place at the time of the award. Each step in the application process is documented in a grant pedigree developed for each grant award. The pedigree provides documentation and assurance to the Program Integration Committee (PIC) and the Oversight Committee that each grant award has met statutory requirements, administrative rules and Institute procedures. The pedigree begins with pre-receipt compliance activities, covering the approval of the Request For Applications (RFAs) by the respective program officer through the submission of grant applications in the CPRIT Application Receipt System (CARS). The pedigree then goes on to verify the procedural stages through administrative review of the application, assignment to a peer review panel, peer review meeting, review council, PIC, and up to and through the Oversight Committee’s final decision on the application.

Post Award Grant Monitoring

Pursuant to Texas Health and Safety Code, Chapter 102, CPRIT continuously monitors and ensures that each grant recipient complies with the terms and conditions of its grant contract. CPRIT is required to track the dates grant recipient reports are due and monitor the status of any required report that is not timely



submitted. To facilitate and monitor the submission of reports, CPRIT maintains an electronic grants reporting and monitoring system. As reports are received, they are reviewed by CPRIT programmatic and finance staff to ensure that they comply with all applicable laws and reporting rules.

CPRIT's compliance team consists of a grant compliance manager and three grant compliance specialists. Grant compliance specialists play a key role in the compliance process by focusing their efforts on assisting in the completion of risk assessments, performing second-level reviews of grant reimbursements, executing desk and on-site reviews, providing technical assistance to grant recipients and conducting on-site training of grant recipients as required.

In fiscal year 2016, the grant compliance specialists focused much of their efforts conducting reviews of grant reimbursements and providing verification that the initial reviews were thorough, consistent, and compliant with CPRIT's statutes, rules and procedures. In addition to these reviews, grant specialists assisted with grantee training and technical assistance, supported the development of a grantee onboarding and annual training process, and participated in the preventative desk and on-site review process for current grant recipients.

Risk Assessment Model

CPRIT's compliance plan calls for the completion of a comprehensive risk analysis of awarded grants with the goal of determining monitoring coverage, type, priority, recommended staffing, and monitoring schedules for adequate oversight of grant recipients and associated grants. The Risk Assessment was first implemented in fiscal year 2016 and has been modified to reflect monitoring findings from the current fiscal year and recommended changes from CPRIT's internal auditor.

The Risk Assessment Model considers several factors in determining grantee risk, including:

- Financial exposure
- Entity maturity
- Prior experience administering grants

Risk Assessments are performed on a quarterly and annual basis. Quarterly assessments are performed for new grant recipients that receive funding during the year. Annual assessments provide for ongoing reviews of grant recipients with multi-year awards and those who receive grants over multiple years. Each Risk Assessment assigns a priority ranking to grant recipients, which helps in determining training and monitoring needs.

Based on the results of the Risk Assessment, grantees receive a desk review or an onsite monitoring review completed by grant compliance staff. Compliance monitoring reviews evaluate a grantee's compliance with grant requirements included in the Texas Administrative Code, Texas Health and Safety Code, CPRIT Policies and Procedures, Uniform Grant Management Standards, and terms of the grant contract.



Fraud, Waste, and Abuse Hotline

Effective July 2015 CPRIT implemented a compliance and ethics hotline that allows individuals to report any concerns regarding fraudulent activity/theft, misconduct, safety violations, or unethical behavior. This service is not run by CPRIT employees and allows users to remain anonymous if they so choose.

The establishment of a hotline is consistent with amendments, passed in 2013, to the Texas Health & Safety Code, Chapter 102. This hotline is part of CPRIT's ongoing efforts to ensure that it has strong internal controls and to protect the integrity of CPRIT's grant process, and use of Texas taxpayer dollars. This reporting mechanism is available to Oversight Committee members, CPRIT employees, CPRIT grantees and the general public. Information regarding the hotline was communicated via CPRIT's Grant Management System (CGMS), CPRIT's website and listserv, and has been included in grantee training material.

Conflict of Interest Information for Fiscal Year 2016

The following conflict of interest information is applicable for grants awarded in fiscal year 2016:

- A list of conflicts of interest that require recusal: See Appendix, page 46
- Any unreported conflicts of interest confirmed by an investigation conducted by CPRIT: None
- Any waivers to CPRIT's conflict of interest rules: See Appendix, page 254



FINANCIALS

FINANCIAL SUMMARY (UNAUDITED) - FOR THE YEAR ENDED AUGUST 31, 2016	
Revenues	
Legislative Appropriations	\$297,085,446
License, Fees, and Permits	\$203,637
Interest Income	\$262
Other	\$76,000
Total Revenues	\$297,365,345
Expenses	
Salaries and Wages	\$3,439,330
Other Personnel Cost	\$729,984
Professional Fees and Services	\$11,045,056
Consumable Supplies	\$111,783
Utilities	\$68,307
Travel	\$84,364
Rent - Building	\$190,684
Rent - Machine and Other	\$59,563
Other Operating Expenses	\$169,979
Grants	\$229,707,447
Capital Expenditures	-
Total Expenses	\$245,606,497
Excess of Revenues Over Expenses	\$51,758,848



Financial Position

Executive management of CPRIT is responsible for establishing and maintaining adequate internal control over financial reporting and compliance with applicable laws, regulations, contracts, and grant agreements, as well as other matters.

McConnell & Jones LLP, a public accounting firm, audited CPRIT's financial statements for the year ended August 31, 2016, ascertaining that the statements "present fairly, in all material respects, the respective financial position of the governmental activities and governmental fund information of CPRIT as of August 31, 2016, and the respective changes in financial position for the year then ended in accordance with U.S. GAAP."

As part of the audit of the financial statements, McConnell & Jones LLP performed tests of CPRIT's compliance with certain provisions of laws, regulations, contracts, and grant agreements to ensure that the statements are free from material misstatements. McConnell & Jones LLP identified no instance of noncompliance or other matter required to be reported under *Government Auditing Standards*.



PLANNING

Creating and expediting innovation in cancer research and enhancing the potential for medical or scientific breakthroughs in the prevention of cancer and cures for cancer requires comprehensive planning for current operations as well as longer-term goals. CPRIT engages in continuous strategic planning and priority setting activities. Each year, the Oversight Committee establishes priorities for CPRIT's three programs. This year CPRIT staff and the Oversight Committee also embarked on an operational strategic planning exercise. As part of the operational strategic planning, CPRIT staff identified several issues to be resolved leading up to the agency's scheduled sunset review in 2021.

Program Priorities

CPRIT's statute instructs the Oversight Committee to set priorities annually for each grant program funded by CPRIT. The priority-setting process provides transparency for how the Oversight Committee orients the agency's funding portfolio between and within its three programs. The program priorities guide CPRIT staff and review councils on the development and issuance of program-specific Requests for Applications (RFAs) and the evaluation of applications submitted in response to those RFAs.

The Oversight Committee annually reviews and adjusts the priorities as circumstances change and new information becomes known concerning cancer-related advances in prevention, academic research, and product development research. The Oversight Committee adopted fiscal year 2016 program priorities in November 2015. Each program in its section of this report describes implementation of the individual program priorities for fiscal year 2016. Program priorities for fiscal year 2017 were adopted at the Oversight Committee's November 2016 meeting and are available on CPRIT's website.

Operational Strategic Planning

In 2016, CPRIT staff and the Oversight Committee developed an operational strategic plan over the course of several meetings and a specially called work session of the entire Oversight Committee. The operational plan is separate from but complementary to the strategic plan CPRIT submits to the Governor's Office and legislative oversight offices every two years that focuses primarily on state funding elements. A primary planning objective of CPRIT's operational plan is to identify performance measures to support and monitor program progress through 2021. As part of the development process, CPRIT identified three key operational strategic goals. The strategic goals and the key objectives associated with each goal are:

- **To expedite innovation in cancer research and prevention**

Key objectives connected to expediting innovation include supporting innovative cancer research and prevention interventions, focusing on the unique needs of Texans, fostering statewide collaboration in prevention and research, growing the cancer life science ecosystem in Texas, and effectively planning for the next five years.



- **To engage stakeholders**

Fulfilling CPRIT's strategic goal to engage stakeholders requires assuring that grant applicants and grantees are served effectively, that CPRIT employees are fully engaged, and that the advice, concerns and guidance of legislators, advocates, grantees and the public are solicited and incorporated as appropriate.

- **To demonstrate ethics and accountability**

Demonstrating ethical behavior and accountability includes a commitment to ensuring grant processes adhere to all rules and regulations, service recipients and grantees are served effectively, and all state administrative and ethics guidelines are followed.

CPRIT's performance measures are continuously under development, monitored and evaluated to document success at meeting strategic objectives including developing cures and treatments and preventing cancer when programmatically appropriate. In addition to fiscal accountability reviews by the compliance program, non-Texas professionals with substantive experience in their appropriate fields objectively evaluate grantee progress reports. These annual reviews of every project verify that the grantees are carrying out the qualitative work specified in the grant contract and are performing as intended. CPRIT staff reports at each quarterly Oversight Committee meeting on 45 accountability, mission, and transparency management metrics.

Looking Ahead

CPRIT used the operational planning process to categorize necessary steps leading up to CPRIT's scheduled sunset review in 2021. Defining these steps now allows the agency to consider modifications the Oversight Committee should make to the research and prevention portfolios over the next five years to prepare for possible reduction or cessation of state funding. Five major issues that came to the forefront during this process are described below. CPRIT will work with stakeholders to refine the issues and devise action plans leading up to sunset review.

- **Unexpended Balance of Constitutional Bond Authority**

CPRIT projects that approximately \$148 million in constitutional bond authority and unexpended grant award balances will remain and not be used by August 31, 2021. The balance exists because CPRIT was not appropriated or did not use the full appropriation authorized by the Legislature for the 2010-2011 and 2012-2013 biennium. In addition, not all grants approved by the Oversight Committee are fully expended. A potential grantee may decline the award or the grantee spends less than the original budget achieving the grant objectives. These awarded but unspent grant funds are added back to the total constitutional bond authority.

- **Monitoring On-going Projects**

CPRIT grant projects typically last two to five years. CPRIT's statute authorizes the Oversight Committee to award grants through August 31, 2020. Unless CPRIT severely truncates award periods, which will affect the grantee's ability to complete project work, many CPRIT grant projects will continue to be active beyond CPRIT's sunset date. These grant projects will require continued specialized monitoring



to assure that contractual requirements are met and the state's interests protected. Grant management and compliance will require some combination of state employees and/or contracted personnel.

- **Drawing Down Bond Proceeds**

CPRIT reimburses approved grant project costs incurred by the grantee for the previous fiscal quarter. This lengthy fiscal review and draw down process affects when the state issues debt to cover approved disbursements. Unless CPRIT changes course and advances the entire grant award amount at the initiation of the project, bonds must continue to be issued after August 31, 2021, to reimburse ongoing grant costs.

- **Ensuring the State Receives Contractually Required Revenue Sharing Payments**

Every CPRIT grant contract includes terms ensuring that the state benefits monetarily if a grant project generates revenue. Given the long drug development life cycle, grantees will pay the largest portion of revenue sharing obligations after August 31, 2021. Over the next several years we expect more intellectual property to be licensed and products to reach the market as CPRIT-funded projects move further through the regulatory and development process.

An ongoing monitoring system to track CPRIT's grant investments is necessary to ensure that grantees are fulfilling their contractual obligations and to protect potential state assets. The tracking system should monitor CPRIT-funded projects at both academic institutions and public/private companies. CPRIT staff has met with the Texas Treasury Safekeeping Trust Company to determine whether they can take on the managerial and disposition obligations related to potential assets resulting from CPRIT's revenue sharing agreements. If the Safekeeping Trust Company is unable to do so and no other state entity is available, a vendor must be secured to provide this service for the state's assets.

- **Protecting and Preserving Momentum in Texas after 2021**

Planning for the potential winding down of operations by August 31, 2021, raises the question of what the Texas cancer landscape will look like without CPRIT or a similar entity with sufficient resources to support the momentum Texas has gained in the fight against cancer. Some suggest that CPRIT fill this role as a financially self-sufficient entity. However, the nature of CPRIT's awards and the inconsistent timing and amount of potential revenue return make this option untenable. CPRIT or a successor entity must have a consistent level of income to be self-sufficient without state funding. Options for funding sources include fundraising and relying upon the state's share of license/royalty proceeds from CPRIT funded projects. Both alternatives are not viable solutions to CPRIT's long term funding needs.

Although CPRIT originally raised additional funds through donations to the CPRIT Foundation, Texas law now prohibits a person or entity that gives money to CPRIT from ever receiving a CPRIT grant. The Texas Legislature changed the statute to preserve the integrity of CPRIT's grant review process. The State Auditor determined that contributions to CPRIT made by grant applicants and grantees, or entities closely associated with grant applicants such as supporting foundations, risk influencing the grant recommendation process and create an obvious conflict of interest. Reversing course and restarting efforts to raise funds from individuals and organizations that also compete for grants jeopardizes CPRIT's conflict-free review process.



Relying exclusively upon revenues contractually shared with the state by grantees is not a workable solution either. Every grantee is obligated to pay the state if the CPRIT-funded project generates profit. The statute requires the state to use this income to pay the debt service on CPRIT bonds. To the extent that the legislature redirects the state's portion of revenues in support CPRIT's future operations and activities, there is no mechanism to appropriate these proceeds to CPRIT if the Institute is no longer a state agency.

Even if CPRIT remains as a quasi-state entity, the state's portion of the grantee profits is not consistent to serve as a sustainable, predictable funding source. The timing of CPRIT's operational and grant-making needs does not coincide with the bulk of the potential payments. It may take up to 15 years for a laboratory discovery to navigate successfully through preclinical and animal testing, clinical trials, and regulatory approval. The successful project must traverse the entire drug development pathway and generate profit before CPRIT begins receiving income.

APPENDIX: CONFLICT OF INTEREST DOCUMENTATION

CONFLICT OF INTEREST LISTING

For each peer review panel (Prevention, Scientific Research, and Product Development) during fiscal year 2016, a list of peer reviewers with a conflict of interest is provided. Conflicts of interest reported by Oversight Committee members are also listed. This document includes the CPRIT program type, grant application number, principal investigator, institution, and the name of the peer reviewer with a conflict of interest. There were no unreported conflicts of interest or investigations in fiscal year 2016.

PEER REVIEW CERTIFICATION OF NON-PARTICIPATION IN EVALUATION OF INDIVIDUAL APPLICATIONS BECAUSE OF REAL OR APPARENT CONFLICT OF INTEREST

The third party grant review administrator's representative certifies that the reviewer identified as having a conflict of interest has signed this form and left the panel room or the teleconference call during the discussion of the application. This document includes the CPRIT program and name of panel, the meeting type (on-site or teleconference), the date, application number, principal investigator, institution, reviewer name and signature, and the grant review administrator's name.

Information related to steps taken by the Oversight Committee members with conflicts of interest are reflected in the publicly available meeting minutes.

FY 2016 CONFLICT OF INTEREST WAIVERS

Conflict of interest waivers are granted through a process established under Section 102.1062. For FY 2016, waivers were approved by the Oversight Committee on August 19, 2015, for Dr. Margaret Kripke, Kirk Cole, Will Montgomery, Donald Brandy, Amy Mitchell; February 17, 2015, for Dr. John Hellerstedt; and May 18, 2016, for Dr. Becky Garcia. Individual post review statements signed by each committee member are not included in this appendix due to the large number of pages, but they are available for public viewing on the Compliance page of the CPRIT website at www.cprit.texas.gov.

APPENDIX: CONFLICT OF INTEREST DOCUMENTATION

PREVENTION



Conflicts of Interest for Prevention Cycle 16.1 Applications
(Prevention Cycle 16.1 Awards Announced at November 19, 2015, Oversight Committee Meeting)

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Prevention Cycle 16.1 include *Cancer Prevention Promotion and Navigation to Clinical Services*, *Competitive Continuation/Expansion–Evidence-Based Cancer Prevention Services*, *Evidence-Based Cancer Prevention Services*, *Evidence-Based Cancer Prevention Services - Colorectal Cancer Prevention Coalition*, and *Dissemination of CPRIT-Funded Cancer Prevention and Control Interventions*. All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC. COI information used for this table was collected by SRA International, CPRIT’s third party grant administrator, and by CPRIT.

Application ID	Applicant	Institution	Conflict Noted
Applications considered by the PIC and Oversight Committee			
PP160023	Sauter, Edward	The University of Texas Health Center at Tyler	Schwartz, Randy; Cole, Kirk
PP160027	Foxhall, Lewis	The University of Texas M.D. Anderson Cancer Center	Vanderpool, Robin; Cole, Kirk
PP160042	Parra-Medinca, Deborah	The University of Texas Health Science Center at San Antonio	Vanderpool, Robin
PP160046	Cuccaro, Paula	The University of Texas Health Science Center at Houston	Vanderpool, Robin
PP160047	Savas, Lara	The University of Texas Health Science Center at Houston	Brownson, Ross
PP160048	Bolin, Jane	Texas A&M University System Health Science Center	Escabedo, Luis; Cole, Kirk
PP160051	Fernandez, Maria	Texas A&M University System	Cole, Kirk

Application ID	Applicant	Institution	Conflict Noted
		Health Science Center	
Applications Not Recommended for PIC or Oversight Committee Consideration			
PP160026	Handal, Gilbert	Texas Tech University Health Sciences Center at El Paso	Escobedo, Luis
PP160043	Gonzalez, Hector	City of Laredo Health Department	Escobedo, Luis

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Prevention Programs
Panel: Prevention Review Council FY16.1 Programmatic Review Meeting
Meeting Type: Teleconference

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
10/23/15	PP160046	Savas, Lara	The University of Texas Health Science Center at Houston	Brownson, Ross	Verified telephonically by SRA	Kellie Reese/ KR

SRA Approval:

Name (PRINT):	Kellie Reese
Signature:	Kellie Reese
Date:	10/23/15

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document



Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Prevention Programs

Panel: 16.1 Prevention Panel - 1

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
9/22/15	PP160023	Sauter, Edward	The University of Texas Health Center at Tyler	Schwartz, Randy		Morgan Majchrzak mm
9/22/15	PP160026	Handal, Gilbert	Texas Tech University Health Sciences Center at El Paso	Escobedo, Luis	Not Discussed	Morgan Majchrzak mm
9/22/15	PP160027	Foxhall, Lewis	The University of Texas M. D. Anderson Cancer Center	Vanderpool, Robin	Not Present	Morgan Majchrzak mm
9/21/15	PP160042	Parra-Medina, Deborah	The University of Texas Health Science Center at San Antonio	Vanderpool, Robin	Not Present	Morgan Majchrzak mm
9/21/15	PP160043	Gonzalez, Hector	City of Laredo Health Department	Escobedo, Luis		Morgan Majchrzak mm

SRA Approval:

Name (PRINT):	Morgan Majchrzak
Signature:	
Date:	9/22/15

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Prevention Programs

Panel: 16.1 Prevention Panel - 1

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
9/21/15	PP160046	Cuccaro, Paula	The University of Texas Health Science Center at Houston	Vanderpool, Robin	Not Present	Morgan Majchrzak mm
9/21/15	PP160047	Savas, Lara	The University of Texas Health Science Center at Houston	Brownson, Ross	R Brown	Morgan Majchrzak mm
9/22/15	PP160048	Bolin, Jane	Texas A&M University System Health Science Center	Escobedo, Luis	Lu B	Morgan Majchrzak mm

SRA Approval:

Name (PRINT):	Morgan Majchrzak
Signature:	Morgan Majchrzak
Date:	9/22/15

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Conflict of Interest Disclosure
Prevention Cycle 16.2 Applications
(Prevention Cycle 16.2 Awards Announced at August 17, 2016, Oversight Committee Meeting)

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Prevention Cycle 16.2 include *Cancer Prevention Promotion and Navigation to Clinical Services*, *Competitive Continuation/Expansion - Evidence-Based Cancer Prevention Services*, *Dissemination of CPRIT-Funded Cancer Control Interventions*, *Evidence-Based Cancer Prevention Services*, *Evidence-Based Cancer Prevention Services - See, Test & Treat® Program*, and *Evidence-Based Cancer Prevention Services - Colorectal Cancer Prevention Coalition*. All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC. COI information used for this table was collected by SRA International, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant	Institution	Conflict Noted
Applications considered by the PIC and Oversight Committee			
PP160075	Singal, Amit	The University of Texas Southwestern Medical Center	Nguyen, Mindie; Willson, Jim
PP160079	Jibaja-Weiss, Maria	Baylor College of Medicine	Nguyen, Mindie
PP160097	Rodriguez, Ana	The University of Texas Medical Branch at Galveston	Nguyen, Mindie
PP160103	Ross, Theodora S.	The University of Texas Southwestern Medical Center	Nguyen, Mindie; Willson, Jim
PP160110	Ross, Theodora S.	The University of Texas Southwestern Medical Center	Nguyen, Mindie; Willson, Jim
PP160121	Trivedi, Madhukar H.	The University of Texas Southwestern Medical Center	Willson, Jim
PP160122	Rustveld, Luis	Baylor College of Medicine	Nguyen, Mindie
Applications not considered by the PIC or Oversight Committee			
PP160060	Gardner, Julie	Texas AgriLife Extension Service	Nguyen, Mindie

Application ID	Applicant	Institution	Conflict Noted
PP160076	Lucci, Joseph	The University of Texas Health Science Center at Houston	Nguyen, Mindie
PP160092	Poplack, David	Baylor College of Medicine	Nguyen, Mindie
PP160094	McNeill, Lorna	The University of Texas M.D. Anderson Cancer Center	Nguyen, Mindie
PP160096	McGaha, Paul	The University of Texas Health Center at Tyler	Nguyen, Mindie
PP160098	Tomlinson, Gail	The University of Texas Health Science Center at San Antonio	Nguyen, Mindie
PP160099	Crocker, Andrew	Texas AgriLife Extension Service	Nguyen, Mindie
PP160102	Argenbright, Keith	The University of Texas Southwestern Medical Center	Nguyen, Mindie
PP160109	Villarreal, Roberto	University Health System	Nguyen, Mindie
PP160112	Felini, Martha	University of North Texas Health Science Center at Fort Worth	Nguyen, Mindie
PP160117	Misra, Subhasis	Texas Tech University Health Sciences Center	Nguyen, Mindie
PP160124	Handal, Gilbert	Texas Tech University Health Sciences Center at El Paso	Bright, Frank
PP160126	Singh, Hitesh	Scott & White Healthcare	Nguyen, Mindie
PP160133	Garcia, Fernandina	Mercy Ministries of Laredo	Nguyen, Mindie
PP160135	Benedict, Deb	Rio Grande Cancer Foundation	Nguyen, Mindie


Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Prevention Programs


Panel: 16.2 Prevention Panel-1

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
5/23/16	PP160124	Handal, Gilbert	Texas Tech University Health Sciences Center at El Paso	Bright, Frank		Morgan Majchrzak/MA

SRA Approval:

Name (PRINT):	Morgan Majchrzak
Signature:	
Date:	5/24/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Prevention Programs

Panel: 16.2 Prevention Panel-2

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*

SRA Approval:

Name (PRINT):	Morgan Maychozak
Signature:	Morgan Maychozak
Date:	5/25/16

Comments:

No COIs

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Prevention Programs
Panel: Prevention Review Council FY 16.2 Programmatic Review Meeting
Meeting Type: Teleconference

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*

SRA Approval:

Name (PRINT):	Morgan Majchrzak
Signature:	Morgan Majchrzak
Date:	7/1/16

Comments:

No COIs noted

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

APPENDIX:
CONFLICT OF INTEREST DOCUMENTATION

ACADEMIC RESEARCH



Conflicts of Interest for Academic Research Cycles 15.2 and 16.1 Recruitment Applications

Academic Research Cycle 15.2 and 16.1 Recruitment Awards Announced at September 10, 2015, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Cycles 15.2 and 16.1 include *Recruitment of First-Time, Tenure-Track Faculty Members*; *Recruitment of Established Investigators*; and *Recruitment of Rising Stars*. All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC. COI information used for this table was collected by SRA International, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant	Institution	Conflict Noted
Applications considered by the PIC and Oversight Committee			
RR150106	Kuspa, Adam	Baylor College of Medicine	Tempero, Margaret
Applications not considered by the PIC or Oversight Committee			
RR150099	Fitz, John	The University of Texas Southwestern Medical Center	Sellers, Thomas

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2015 Cancer Prevention and Research Institute of Texas Research Programs

Panel: Recruitment FY15 Cycle 2-RRP-10

Meeting Type: Teleconference Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
7/16/2015	RR150099	Fitz, John	The University of Texas Southwestern Medical Center	Sellers, Thomas	verified telephonically by SRA	Brahm Gicheru/BG
7/16/2015	RR150106	Kuspa, Adam	Baylor College of Medicine	Tempero, Margaret	verified telephonically by SRA	Brahm Gicheru/BG

SRA Approval:

Name (PRINT):	Brahm Gicheru
Signature:	Brahm Gicheru
Date:	7/16/2015

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Recruitment Programs

Panel: Recruitment FY16 Cycle 1

Meeting Type: Teleconference Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*

SRA Approval:

Name (PRINT):	BRENDAN MORALES
Signature:	<i>Brendan Morales</i>
Date:	8/14/15

Comments:

No COI's

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Conflicts of Interest for Academic Research Cycle 16.1 Applications
(Academic Research Cycle 16.1 Awards Announced at November 19, 2015 Oversight Committee Meeting)

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, SRA staff, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Cycle 16.1 include *Individual Investigator Research Awards*, *Individual Investigator Research Awards for Prevention and Early Detection*, *Individual Investigator Research Awards for Cancer in Children and Adolescents*, *Individual Investigator Research Awards for Computational Biology*, and *Research Training Awards*. All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC. COI information used for this table was collected by SRA International, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant	Institution	Conflict Noted
Applications considered by the PIC and Oversight Committee			
RP160183pe/ RP160183	Davies, Michael	The University of Texas M. D. Anderson Cancer Center	McMahon, Martin
RP160471pe/ RP160471	Draetta, Giulio	The University of Texas M. D. Anderson Cancer Center	Courtneidge, Sara
RP160013pe/ RP160013	Kundra, Vikas	The University of Texas M. D. Anderson Cancer Center	Riddell, Stanley; Engelhard, Victor
RP160188pe/ RP160188	Schluns, Kimberly	The University of Texas M. D. Anderson Cancer Center	Engelhard, Victor
RP160482pe/ RP160482	Heimberger, Amy	The University of Texas M. D. Anderson Cancer Center	Engelhard, Victor
RP160577pe/ RP160577	Poojary, Venuprasad	Baylor Research Institute	Cooney, Kathleen
RP160497pe/ RP160497	Krishnan, Sunil	The University of Texas M. D. Anderson Cancer Center	Berbeco, Ross
RP160589	Chapkin, Robert	Texas AgriLife Research	Fearon, Eric; Greene, Geoffrey

Application ID	Applicant	Institution	Conflict Noted
RP160015	Ness, Roberta	The University of Texas Health Science Center at Houston	Haiman, Christopher; Kushi, Lawrence
RP160030	Gerber, David	The University of Texas Southwestern Medical Center	Barlow, William
RP160097	Spitz, Margaret	Baylor College of Medicine	Martinez, Maria
RP160145	Bast, Robert	The University of Texas MD Anderson Cancer Center	Kushi, Lawrence; Li, Christopher
RP160023	Arur, Swathi	The University of Texas MD Anderson Cancer Center	Atwal, Gurinder; Garcia-Crespo, Katia
RP160054	Marchetti, Dario	Baylor College of Medicine	Atwal, Gurinder
RP160211	Castrillon, Diego	The University of Texas Southwestern Medical Center	Atwal, Gurinder
RP160268	Liu, Yi	The University of Texas Southwestern Medical Center	Atwal, Gurinder
RP160318	Kraus, W. Lee	The University of Texas Southwestern Medical Center	Atwal, Gurinder
RP160319	Kraus, W. Lee	The University of Texas Southwestern Medical Center	Atwal, Gurinder
RP160440	Brugarolas, James	The University of Texas Southwestern Medical Center	Atwal, Gurinder
RP160451	Donehower, Lawrence	Baylor College of Medicine	Atwal, Gurinder
RP160462	Songyang, Zhou	Baylor College of Medicine	Atwal, Gurinder
Applications Not Recommended for PIC or Oversight Committee Consideration			
RP160117pe/ RP160117*	Chen, Benjamin	The University of Texas Southwestern Medical Center	Bart Williams
RP160472pe	Cox, Marc	The University of Texas at El Paso	McMahon, Martin
RP160079pe	Saikumar, Pothana	The University of Texas Health Science Center at San Antonio	Sonenberg, Nahum

* = Not discussed

Application ID	Applicant	Institution	Conflict Noted
RP160113pe	Davis, Anthony	The University of Texas Southwestern Medical Center	Tomkinson, Alan; Chazin, Walter
RP160304pe	Denicourt, Catherine	The University of Texas Health Science Center at Houston	Petrini, John
RP160335pe/ RP160335*	Wang, Bin	The University of Texas M. D. Anderson Cancer Center	Weitzman, Matthew; Gurinder, Atwal
RP160374pe	Boothman, David	The University of Texas Southwestern Medical Center	Tomkinson, Alan
RP160611pe	Schiff, Rachel	Baylor College of Medicine	Petrini, John
RP160621pe	Latham, Michael	Texas Tech University	Petrini, John
RP160506pe	Aiden, Erez	Baylor College of Medicine	Bernstein, Bradley; Hahn, William
RP160537pe	Kim, Min	The Methodist Hospital Research Institute	Wahl, Geoffrey
RP160477pe	Hassan, Manal	The University of Texas M. D. Anderson Cancer Center	Petersen, Gloria; Martinez, Maria
RP160076pe	Jha, Mithilesh	The University of Texas Health Science Center at San Antonio	Hochster, Howard
RP160143pe/ RP160143	Nurieva, Roza	The University of Texas M. D. Anderson Cancer Center	Stadler, Walter; Engelhard, Victor
RP160176pe/ RP160176*	Sharma, Padmanee	The University of Texas M. D. Anderson Cancer Center	Riddell, Stanley
RP160230pe	Trippier, Paul	Texas Tech University Health Sciences Center	Balk, Steven
RP160336pe/ RP160336*	Diab, Adi	The University of Texas M. D. Anderson Cancer Center	Engelhard, Victor
RP160359pe	Bhattacharya, Pratip	The University of Texas M. D. Anderson Cancer Center	Haas-Kogan, Daphne
RP160580pe	Biros, George	The University of Texas at Austin	Mitchell, Duane
RP160645pe/ RP160645*	Jo, Javier	Texas Engineering Experiment Station	Liu, Jonathan; Sutcliffe, Julie
RP160648pe/ RP160648*	Chen, Wei	The University of Texas at Arlington	Zinn, Kurt

* = Not discussed

Application ID	Applicant	Institution	Conflict Noted
RP160222	Rao, Hai	The University of Texas Helath Science Center at San Antonio	Carol Prives; Atwal, Gurinder
RP160373	Naora, Honami	The University of Texas MD Anderson Cancer Center	Greene, Geoffrey
RP160395*	Lee, Min Gyu	The University of Texas MD Anderson Cancer Center	Belinsky, Steven
RP160535	Kang, Min	Texas Tech University Health Sciences Center	DeClerck, Yves
RP160567*	Zhang, Michael	The University of Texas at Dallas	Lowlor, Elizabeth
RP160168	Felini, Martha	University of North Texas Health Science Center at Fort Worth	Olshan, Andrew
RP160224	Schick, Vanessa	The University of Texas Health Science Center at Houston	Brandon, Thomas
RP160354*	Stingo, Francesco	The University of Texas MD Anderson Cancer Center	Barlow, William; Li, Christopher; Peterson, Gloria
RP160408*	Shen, Qiang	The University of Texas MD Anderson Cancer Center	Kumar, Nagi
RP160470	Valerio, Melissa	The University of Texas Health Science Center at Houston	Kushi, Lawrence
RP160499*	Minnix, Jennifer	The University of Texas MD Anderson Cancer Center	Brandon, Thomas; Schnoll, Robert
RP160527	Hanash, Samir	The University of Texas MD Anderson Cancer Center	Barlow, William; Li, Christopher; Mucci, Lorelei
RP160554	Bondy, Melissa	Baylor College of Medicine	Haiman, Christopher; Martinez, Maria
RP160587	Wetter, David	Rice University	Brandon, Thomas
RP160525*	Jiang, Ning	The University of Texas at Austin	Press, Oliver; Riddell, Stanley
RP160540	Reynolds, Charles	Texas Tech University Health Sciences Center	Grupp, Stephen; Kast, W. Martin;
RP160466	Yuan, Baohong	University of Texas at Arlington	Zinn, Kurt

* = Not discussed

Application ID	Applicant	Institution	Conflict Noted
RP160072	Bai, Yidong	The University of Texas Health Science Center at San Antonio	Atwal, Gurinder
RP160163	Lin, Shiaw-Yih	The University of Texas MD Anderson Cancer Center	Atwal, Gurinder
RP160175	Vasquez, Karen	The University of Texas at Austin	Atwal, Gurinder
RP160196	Man, Tsz-Kwong	Baylor College of Medicine	Atwal, Gurinder
RP160221	Ram, Prahlad	The University of Texas MD Anderson Cancer Center	Atwal, Gurinder
RP160255	Luo, Xuelian	The University of Texas Southwestern Medical Center	Atwal, Gurinder
RP160281	Fakhouri, Walid	The University of Texas Health Science Center at Houston	Atwal, Gurinder
RP160301	Otwinowski, Zbyszek	The University of Texas Southwestern Medical Center	Atwal, Gurinder
RP160349	Liu, Xin	The University of Texas Southwestern Medical Center	Atwal, Gurinder
RP160356	Qin, Lidong	The Methodist Hospital Research Institute	Atwal, Gurinder
RP160362	Li, Bing	The University of Texas Southwestern Medical Center	Atwal, Gurinder
RP160428	Chang, Eric	Baylor College of Medicine	Atwal, Gurinder
RP160505	Calin, George	The University of Texas M. D. Anderson Cancer Center	Atwal, Gurinder
RP160529	Brown, Powel	The University of Texas M. D. Anderson Cancer Center	Atwal, Gurinder
RP160551	Claret, Francois	The University of Texas M. D. Anderson Cancer Center	Atwal, Gurinder
RP160559	Fofanov, Yuriy	The University of Texas Medical Branch at Galveston	Atwal, Gurinder

Application ID	Applicant	Institution	Conflict Noted
RP160560	Chen, Yidong	The University of Texas Health Science Center at San Antonio	Atwal, Gurinder
RP160588	Li, Fuhai	The Methodist Hospital System	Atwal, Gurinder
RP160597	Wong, Stephen	The Methodist Hospital Research Institute	Atwal, Gurinder
RP160606	Grishin, Nick	The University of Texas Southwestern Medical Center	Atwal, Gurinder
RP160610	Skouta, Rachid	The University of Texas at El Paso	Atwal, Gurinder
RP160616	Zoltowski, Brian	Southern Methodist University	Atwal, Gurinder
RP160632	Tao, Peng	Southern Methodist University	Atwal, Gurinder
RP160650	Liu, Jin	University of North Texas Health Science Center at Fort Worth	Atwal, Gurinder

2016 Cancer Prevention and Research Institute of Texas Research Programs

Order of Review

Panel: Basic Cancer Research-1 - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict	Assignments	Part Type
	RP160037pe	Dent, Sharon		1-K. Haigis (SR)	SR
	IIRA-PreE	The University of Texas M. D. Anderson Cancer Center		2-H. Schatten (SR)	SR
		Defining the Role of Gcn5 in Myc Driven Oncogenesis		3-S. Sukumar (SR)	SR
	RP160069pe	Rao, Ganesh		1-S. Fiering (SR)	SR
	IIRA-PreE	The University of Texas M. D. Anderson Cancer Center		2-J. Schiffman (SR)	SR
		The role of immunosuppression in the malignant progression of glioma		3-R. Wechsler-Reya (SR)	SR
	RP160089pe	DeBerardinis, Ralph		1-A. Balmain (SR)	SR
	IIRA-PreE	The University of Texas Southwestern Medical Center		2-B. Williams (SR)	SR
		Carbamoyl Phosphate Synthase-I: A new metabolic liability in non-small cell lung cancers		3-A. Raz (SR)	SR
	RP160092pe	Habib, Aryn		1-R. Wechsler-Reya (SR)	SR
	IIRA-PreE	The University of Texas Southwestern Medical Center		2-H. Schatten (SR)	SR
		Regulation of programmed necrosis in cancer		3-P. Hinds (SR)	SR
	RP160094pe	Heymach, John		1-A. Raz (SR)	SR
	IIRA-PreE	The University of Texas M. D. Anderson Cancer Center		2-S. Fiering (SR)	SR
		Adrenergic receptor-mediated therapeutic resistance in NSCLC		3-J. Wang (SR)	SR
	RP160104pe	Nguyen, Hoang		1-B. Williams (SR)	SR
	IIRA-PreE	Baylor College of Medicine		2-A. Balmain (SR)	SR
		Defining the tumor suppressive role of miR-204 in skin tumorigenesis		3-S. Sukumar (SR)	SR
	RP160117pe	Chen, Benjamin	B. Williams	1-S. Sukumar (SR)	SR
	IIRA-PreE	The University of Texas Southwestern Medical Center		2-F. Rauscher, III (SR)	SR
		Synthetic lethality of BAP1 deficient renal cell carcinoma with radiotherapy and a novel HIF-2alpha inhibitor		3-K. Hunter (SR)	SR
	RP160148pe	Heijnen, Cobi		1-H. Schatten (SR)	SR
	IIRA-PreE	The University of Texas M. D. Anderson Cancer Center		2-J. Wang (SR)	SR
		Mechanisms and Treatment of Chemobrain		3-X. Wang (SR)	SR

2016 Cancer Prevention and Research Institute of Texas Research Programs

Order of Review

Panel: Basic Cancer Research-1 - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict	Assignments	Part Type
	RP160156pe	Burma, Sandeep		1-K. Hunter (SR)	SR
	IIRA-PreE	The University of Texas Southwestern Medical Center		2-J. Wang (SR)	SR
		Role of EXO1 in maintaining genomic integrity: implications for cancer therapy		3-J. Schiffman (SR)	SR
	RP160159pe	Zhang, Wei		1-F. Rauscher, III (SR)	SR
	IIRA-PreE	The University of Texas M. D. Anderson Cancer Center		2-J. Wang (SR)	SR
		Nuclear and immunological reprogramming in CTNNB1 mutation-driven endometrial cancer		3-H. Schatten (SR)	SR
	RP160169pe	Zaki, Hasan		1-K. Haigis (SR)	SR
	IIRA-PreE	The University of Texas Southwestern Medical Center		2-B. Williams (SR)	SR
		Molecular Mechanism of NLRP12-mediated Regulation of Colorectal Cancer		3-A. Balmain (SR)	SR
	RP160173pe	Xin, Li		1-A. Raz (SR)	SR
	IIRA-PreE	Baylor College of Medicine		2-S. Fiering (SR)	SR
		IDENTIFICATION OF NOVEL THERAPEUTIC TARGETS FOR CASTRATION RESISTANT PROSTATE CANCER		3-H. Schatten (SR)	SR
	RP160183pe	Davies, Michael	M. McMahon	1-P. Hinds (SR)	SR
	IIRA-PreE	The University of Texas M. D. Anderson Cancer Center		2-B. Williams (SR)	SR
		Exploiting molecular and metabolic dependencies to optimize personalized therapeutic approaches for melanomas		3-S. Sukumar (SR)	SR
	RP160192pe	Deneen, Benjamin		1-H. Schatten (SR)	SR
	IIRA-PreE	Baylor College of Medicine		2-J. Schiffman (SR)	SR
		Decoding Cellular Heterogeneity of Malignant Glioma		3-S. Sukumar (SR)	SR
	RP160205pe	Penalva, Luiz		1-L. Maquat (SR)	SR
	IIRA-PreE	The University of Texas Health Science Center at San Antonio		2-J. Manley (SR)	SR
		Splicing factors and RNA processing alterations: exploring new players in glioblastoma development		3-F. Rauscher, III (SR)	SR
	RP160208pe	Ha, Chul		1-S. Fiering (SR)	SR
	IIRA-PreE	The University of Texas Health Science Center at San Antonio		2-J. Schiffman (SR)	SR
		Low-dose arsenic-induced normal tissue protection is mediated by deacetylase SIRT1		3-P. Hinds (SR)	SR

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Basic Cancer Research-1 - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160037pe IIRA-PreE	Dent, Sharon The University of Texas M. D. Anderson Cancer Center Defining the Role of Gcn5 in Myc Driven Oncogenesis	
	RP160069pe IIRA-PreE	Rao, Ganesh The University of Texas M. D. Anderson Cancer Center The role of immunosuppression in the malignant progression of glioma	
	RP160089pe IIRA-PreE	DeBerardinis, Ralph The University of Texas Southwestern Medical Center Carbamoyl Phosphate Synthase-1: A new metabolic liability in non-small cell lung cancers	
	RP160092pe IIRA-PreE	Habib, Aryn The University of Texas Southwestern Medical Center Regulation of programmed necrosis in cancer	
	RP160094pe IIRA-PreE	Heymach, John The University of Texas M. D. Anderson Cancer Center Adrenergic receptor-mediated therapeutic resistance in NSCLC	
	RP160104pe IIRA-PreE	Nguyen, Hoang Baylor College of Medicine Defining the tumor suppressive role of miR-204 in skin tumorigenesis	
	RP160117pe IIRA-PreE	Chen, Benjamin The University of Texas Southwestern Medical Center Synthetic lethality of BAP1 deficient renal cell carcinoma with radiotherapy and a novel HIF-2alpha inhibitor	B. Williams
	RP160148pe IIRA-PreE	Heijnen, Cobi The University of Texas M. D. Anderson Cancer Center Mechanisms and Treatment of Chemobrain	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Basic Cancer Research-1 - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160156pe IIRA-PreE	Burma, Sandeep The University of Texas Southwestern Medical Center Role of EXO1 in maintaining genomic integrity: implications for cancer therapy	
	RP160159pe IIRA-PreE	Zhang, Wei The University of Texas M. D. Anderson Cancer Center Nuclear and immunological reprogramming in CTNNB1 mutation-driven endometrial cancer	
	RP160169pe IIRA-PreE	Zaki, Hasan The University of Texas Southwestern Medical Center Molecular Mechanism of NLRP12-mediated Regulation of Colorectal Cancer	
	RP160173pe IIRA-PreE	Xin, Li Baylor College of Medicine IDENTIFICATION OF NOVEL THERAPEUTIC TARGETS FOR CASTRATION RESISTANT PROSTATE CANCER	
	RP160183pe IIRA-PreE	Davies, Michael The University of Texas M. D. Anderson Cancer Center Exploiting molecular and metabolic dependencies to optimize personalized therapeutic approaches for melanomas	M. McMahon
	RP160192pe IIRA-PreE	Deneen, Benjamin Baylor College of Medicine Decoding Cellular Heterogeneity of Malignant Glioma	
	RP160205pe IIRA-PreE	Penalva, Luiz The University of Texas Health Science Center at San Antonio Splicing factors and RNA processing alterations: exploring new players in glioblastoma development	
	RP160208pe IIRA-PreE	Ha, Chul The University of Texas Health Science Center at San Antonio Low-dose arsenic-induced normal tissue protection is mediated by deacetylase SIRT1	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Basic Cancer Research-1 - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160209pe	Mills, Gordon	
	IIRA-PreE	The University of Texas M. D. Anderson Cancer Center	
		Functional consequences of RNA editing in breast cancer	
	RP160218pe	Moghaddam, Seyed Javad	
	IIRA-PreE	The University of Texas M. D. Anderson Cancer Center	
		Dissecting the Role of IL-6/STAT3/Ubc13 Pathway as an Alternative Path for Treatment and Prevention of K-Ras Mutant Lung Cancer	
	RP160242pe	Shen, Xuetong	
	IIRA-PreE	The University of Texas M. D. Anderson Cancer Center	
		Mechanisms and targeting strategies for SWI/SNF mutations in cancer	
	RP160245pe	Aldaz, C. Marcelo	
	IIRA-PreE	The University of Texas M. D. Anderson Cancer Center	
		Role of WWOX, the FRA16D gene, in Multiple Myeloma	
	RP160250pe	Lozano, Guillermina	
	IIRA-PreE	The University of Texas M. D. Anderson Cancer Center	
		Identifying vulnerabilities in mutant p53 driven tumorigenesis	
	RP160253pe	Wang, Zhonghua	
	IIRA-PreE	The University of Texas Health Science Center at San Antonio	
		Targeting HuR-RNA Interaction for Cancer Therapy	
	RP160254pe	Zhou, Yong	
	IIRA-PreE	The University of Texas Health Science Center at Houston	
		Bile acids activate MAPK by altering EGFR spatiotemporal organization	
	RP160259pe	Lee, Mong-Hong	
	IIRA-PreE	The University of Texas M. D. Anderson Cancer Center	
		EGF signaling and COP9 signalosome activity in tumorigenesis	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Basic Cancer Research-1 - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160264pe IIRA-PreE	Hu, Ming Chang The University of Texas Southwestern Medical Center Dual beneficial action of Klotho on cisplatin chemotherapy	
	RP160265pe IIRA-PreE	Hung, Mien-Chie The University of Texas M. D. Anderson Cancer Center Rational Combination Therapy with PARP inhibitors in Triple Negative Breast Cancer	
	RP160269pe IIRA-PreE	Alto, Neal The University of Texas Southwestern Medical Center Probing the Molecular Etiology of Cancer with Novel Bacterial Effector Genes	
	RP160275pe IIRA-PreE	Chen, Junjie The University of Texas M. D. Anderson Cancer Center Targeting the Hippo Tumor Suppressor Pathway and Metabolism for Cancer Treatment	
	RP160284pe IIRA-PreE	Li, Wenliang The University of Texas Health Science Center at Houston A novel GRK3-EZH2 regulatory pathway in neuroendocrine prostate cancers	
	RP160306pe IIRA-PreE	Mani, Sendurai The University of Texas M. D. Anderson Cancer Center Target the p38MAPK-FOXC2-Zeb1-AR/PSA signaling axis to restore ADT-sensitivity & prevent progression of neuroendocrine, recurrent or metastatic prostate tumors	
	RP160317pe IIRA-PreE	Bratton, Shawn The University of Texas M. D. Anderson Cancer Center A Novel TRAIL Mutant for the Treatment of Prostate Cancer	
	RP160320pe IIRA-PreE	Nikonowicz, Edward Rice University Selective inhibition of miRs 155 and 181a function towards treatment of chronic lymphocytic leukemia and triple negative breast cancer	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Basic Cancer Research-1 - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160324pe IIRA-PreE	Chiao, Paul The University of Texas M. D. Anderson Cancer Center Novel Regulation and Function of TAK1 in Mutant Kras-driven Development of Pancreatic Ductal Adenocarcinoma	
	RP160328pe IIRA-PreE	LIN, CHUNRU The University of Texas M. D. Anderson Cancer Center Cross-talk Between LncRNA and Hippo-YAP Pathway Promotes Cancer Bone Metastasis	
	RP160329pe IIRA-PreE	Bartholomeusz, Chandra The University of Texas M. D. Anderson Cancer Center MELK: a novel therapeutic target for triple negative breast cancer metastasis	
	RP160340pe IIRA-PreE	Carroll, Thomas The University of Texas Southwestern Medical Center The role of the Lats kinases in sarcomatoid renal cell carcinoma	
	RP160358pe IIRA-PreE	Sen, Subrata The University of Texas M. D. Anderson Cancer Center Role of Aurora-A-PLK1 Signaling in ER Positive Hormone Independent Breast Cancer: Implications in Designing Novel Therapeutics	
	RP160364pe IIRA-PreE	Kim, James The University of Texas Southwestern Medical Center Embryonic Pathways in Epithelial-Stromal Interactions of Lung Cancer	
	RP160366pe IIRA-PreE	Bachoo, Robert The University of Texas Southwestern Medical Center Modeling pediatric glioma metabolism in the mouse	
	RP160376pe IIRA-PreE	Carter, Bing The University of Texas M. D. Anderson Cancer Center Improving cure rate in patients with FLT3-mutated AML by combined targeting of Wnt/ β -catenin and FLT3 signaling	

2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review

Panel: Basic Cancer Research-1 - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160379pe IIRA-PreE	Byrne, John The University of Texas Health Science Center at Houston Investigating the Molecular Mechanisms that Underlie ChemoBrain and Developing Pharmacological Methods that Restore Learning and Memory	
	RP160381pe IIRA-PreE	Lee, Ju-Seog The University of Texas M. D. Anderson Cancer Center Beta-catenin induced sensitivity to sorafenib in liver cancer	
	RP160389pe IIRA-PreE	Huang, Suyun The University of Texas M. D. Anderson Cancer Center Mechanistic Roles of Long Non-Coding RNA in Glioblastoma Development and Treatment	
	RP160398pe IIRA-PreE	Link, Richard Baylor College of Medicine Exploring the gene mutations underlying clear cell renal cell carcinoma using conditional reprogramming and genome editing in patient-derived tumor avatars	
	RP160407pe IIRA-PreE	Yang, Peiying The University of Texas M. D. Anderson Cancer Center The antitumor effect of mistletoe in hepatocellular carcinoma via downregulation of myc signaling and metabolism	
	RP160416pe IIRA-PreE	Potts, Patrick The University of Texas Southwestern Medical Center Germline Proteins as Oncogenic Drivers of Cancer	
	RP160422pe IIRA-PreE	Bishop, Alexander The University of Texas Health Science Center at San Antonio Estrogen-induced NRF2 and R-loops are balanced by BRCA1	
	RP160458pe IIRA-PreE	Zhang, Yan Jessie The University of Texas at Austin Study on the assembly and regulation of a master neural silencing complex to reduce neural tumor growth	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Basic Cancer Research-1 - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order	Log No.	PI / Institution / Title	Conflict
	RP160472pe IIRA-PreE	Cox, Marc The University of Texas at El Paso Characterization and therapeutic targeting of FKBP52/beta-catenin interactions in prostate cancer	M. McMahon
	RP160488pe IIRA-PreE	Janku, Filip The University of Texas M. D. Anderson Cancer Center Clinical Utility of Plasma and Urine-Based Liquid Biopsies in Cancer	
	RP160501pe IIRA-PreE	Webb, Paul The Methodist Hospital Research Institute De-Orphanizing TLX: Implications for Glioblastomas	
	RP160514pe IIRA-PreE	He, Bin Baylor College of Medicine Role of the Germ Cell Gene TDRD1 in Prostate Cancer	
	RP160543pe IIRA-PreE	PHUNG, THUY Baylor College of Medicine Growth Regulation in Vascular Tumors	
	RP160544pe IIRA-PreE	Liu, Yu University of Houston A novel role of Mesp1 in the pathogenesis of lung cancer	
	RP160545pe IIRA-PreE	Liu, Jinsong The University of Texas M. D. Anderson Cancer Center Polyploid Giant Cancer Cells, Embryonic-like Cancer Stem Cells, and Drug Resistance	
	RP160572pe IIRA-PreE	Iyer, Vishwanath The University of Texas at Austin Defining the epigenetic and regulatory heterogeneity in glioblastoma	
	RP160579pe IIRA-PreE	Li, Yi Baylor College of Medicine A novel LGR4 oncogenic signaling in breast cancer progression and metastasis	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Basic Cancer Research-1 - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order	Log No.	PI / Institution / Title	Conflict
	RP160609pe IIRA-PreE	Van Den Berg, Carla The University of Texas at Austin Targeting JNK2 in Luminal and basal-like breast cancers	
	RP160613pe IIRA-PreE	Sauter, Edward The University of Texas Health Center at Tyler Milk Exosomes Stimulate Breast Cancer Growth	
	RP160629pe IIRA-PreE	Yu, Yonghao The University of Texas Southwestern Medical Center Therapeutic Approaches against Adaptive Resistance of mTORC1 Inhibitors in Breast Cancer	
	RP160642pe IIRA-PreE	Kim, Moon The University of Texas at Dallas In vivo Intracellular Monitoring and Regulation of Aberrant Canonical Wnt Signaling Pathway in APC-Mutant Colon Cancer Cells by a Nanopore Probe	
	RP160646pe IIRA-PreE	Guillen Ahlers, Hector Texas Biomedical Research Institute A novel approach to study Wnt-mediated transcription in colorectal cancer	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Basic Cancer Research-2 - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160023pe	Arur, Swathi	
	IIRA-PreE	The University of Texas M. D. Anderson Cancer Center	
		Investigating the genetic and molecular mechanisms underlying RAS/ERK substrate network	
	RP160026pe	Yang, Jianchang	
	IIRA-PreE	Baylor College of Medicine	
		THE ROLE AND FUNCTIONAL MECHANISM OF SALL4 IN MLL-REARRANGED LEUKEMIA	
	RP160041pe	Thompson, Timothy	
	IIRA-PreE	The University of Texas M. D. Anderson Cancer Center	
		Biomarkers for DDR-Targeted Therapy for Aggressive Variant Prostate Cancer	
	RP160048pe	Hofmann, Sandra	
	IIRA-PreE	The University of Texas Southwestern Medical Center	
		Protein Palmitoylation Vulnerabilities in Lung Cancer	
	RP160052pe	Roth, Michael	
	IIRA-PreE	The University of Texas Southwestern Medical Center	
		Determining the Mechanism of Selective Toxicity for Non-small Cell Lung Cancer of a Novel Inhibitor of Topoisomerase I	
	RP160054pe	MARCHETTI, DARIO	
	IIRA-PreE	Baylor College of Medicine	
		The CTC Circulator Phenotype: Insights into Mechanisms of Breast Cancer Dormancy	
	RP160072pe	Bai, Yidong	
	IIRA-PreE	The University of Texas Health Science Center at San Antonio	
		The implication of mitochondrial DNA heteroplasmy and their shift in tumorigenesis	
	RP160079pe	Saikumar, Pothana	N. Sonenberg
	IIRA-PreE	The University of Texas Health Science Center at San Antonio	
		Targeting Interconnected Signaling Pathways of Tumor and Immune cells in Triple Negative Breast Cancer	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Basic Cancer Research-2 - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160081pe IIRA-PreE	Ganapathy, Vadivel Texas Tech University Health Sciences Center Carbidopa, an FDA-approved drug, as a dual chemotherapy and immunotherapy agent to treat breast cancer	
	RP160090pe IIRA-PreE	Lu, Xiongbiao The University of Texas M. D. Anderson Cancer Center Targeting Human Cancers with Hemizygous Loss of TP53	
	RP160103pe IIRA-PreE	Wong, Kwong Kwok The University of Texas M. D. Anderson Cancer Center Deciphering MEK inhibitor resistance in ovarian cancer	
	RP160106pe IIRA-PreE	Slinker, Jason The University of Texas at Dallas Delineating the Mechanism of Parp1 Hyperactivation as an Efficacious Death Agent in Pancreatic Cancer	
	RP160107pe IIRA-PreE	Rashid, M.Bazlur University of Houston - Clear Lake Characterization of novel perinuclear mTOR complex, mTOR/p, that regulates rapid colon cancer growth through ribosomal protein translation	
	RP160108pe IIRA-PreE	Lucci, Anthony The University of Texas M. D. Anderson Cancer Center Highly Adaptable Triple-Negative Breast Cancer Cells as a Functional Model for Testing Anticancer Agents	
	RP160113pe IIRA-PreE	Davis, Anthony The University of Texas Southwestern Medical Center Aberrant modulation of DNA-PKcs autophosphorylation drives breast cancer etiology	A. Tomkinson W. Chazin
	RP160135pe IIRA-PreE	DeMartino, George The University of Texas Southwestern Medical Center Chemical modulators of proteasome assembly: a novel strategy for cancer therapy	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Basic Cancer Research-2 - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160163pe	Lin, Shiaw-Yih	
	IIRA-PreE	The University of Texas M. D. Anderson Cancer Center	
		Signature-guided PARP inhibitor-based precision therapies for triple negative breast cancer	
	RP160175pe	Vasquez, Karen	
	IIRA-PreE	The University of Texas at Austin	
		Mechanisms of repair of chemotherapeutic and carcinogenic DNA crosslinking agents	
	RP160195pe	Song, Shumei	
	IIRA-PreE	The University of Texas M. D. Anderson Cancer Center	
		Identifying Novel Therapeutic Targets for Esophageal Adenocarcinoma by Targeting Cancer Stem Cells-Focus on TGF-beta and Hippo/YAP Signaling	
	RP160210pe	Kittler, Ralf	
	IIRA-PreE	The University of Texas Southwestern Medical Center	
		Therapeutic Targeting of ERG Turnover in Prostate Cancer	
	RP160211pe	Castrillon, Diego	
	IIRA-PreE	The University of Texas Southwestern Medical Center	
		Novel tumorigenic mechanisms of the LKB1 tumor suppressor in endometrial and cervical cancer	
	RP160215pe	Patel, Akash	
	IIRA-PreE	Baylor College of Medicine	
		Establishing the Genomic Landscape of Human Atypical Meningiomas	
	RP160222pe	Rao, Hai	
	IIRA-PreE	The University of Texas Health Science Center at San Antonio	
		The double life of the XPC protein	
	RP160233pe	Kuo, Macus	
	IIRA-PreE	The University of Texas M. D. Anderson Cancer Center	
		Molecular Mechanisms of Arginine Starvation Cancer Therapy	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Basic Cancer Research-2 - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160255pe IIRA-PreE	Luo, Xuelian The University of Texas Southwestern Medical Center Structural and Functional Analyses of the Spindle Checkpoint	
	RP160261pe IIRA-PreE	Grimm, Elizabeth The University of Texas M. D. Anderson Cancer Center Post-translational modifications induced by reactive nitric oxide support melanoma growth and survival	
	RP160268pe IIRA-PreE	Liu, Yi The University of Texas Southwestern Medical Center DNA damage-induced small non-coding RNAs: mechanism and their role in cancer development	
	RP160286pe IIRA-PreE	Frost, Jeffrey The University of Texas Health Science Center at Houston Regulation of genomic stability and tumorigenesis by Net1	
	RP160291pe IIRA-PreE	Li, Yue The University of Texas Health Science Center at Houston Molecular mechanism of SENP7 regulates Src and screening of SENP7 inhibitors to prostate cancer	
	RP160299pe IIRA-PreE	Fang, Bingliang The University of Texas M. D. Anderson Cancer Center A novel cFLIP and PI3K/AKT/mTOR inhibitor and its predictive biomarker for precision therapy against acute myeloid leukemia	
	RP160304pe IIRA-PreE	Denicourt, Catherine The University of Texas Health Science Center at Houston Mechanisms of increased ribosome synthesis in cancer	J. Petrini
	RP160311pe IIRA-PreE	Orlowski, Robert The University of Texas M. D. Anderson Cancer Center Proteasome Assembly Chaperones in Sensitivity and Resistance to Proteasome Inhibitors	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Basic Cancer Research-2 - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160319pe IIRA-PreE	Kraus, W. Lee The University of Texas Southwestern Medical Center Role of PARP-1 in Estrogen Receptor Enhancer Function and Gene Regulation Outcomes in Breast Cancers	
	RP160326pe IIRA-PreE	Sieglwart, Daniel The University of Texas Southwestern Medical Center Exploiting base excision repair for pancreatic cancer lethality via drug-loaded selective nanoparticles	
	RP160335pe IIRA-PreE	Wang, Bin The University of Texas M. D. Anderson Cancer Center Linking protection of stalled replication fork to cancer	M. Weitzman
	RP160342pe IIRA-PreE	Gan, Boyi The University of Texas M. D. Anderson Cancer Center Studying a novel long non-coding RNA which regulates AMPK activation and tumor suppression	
	RP160344pe IIRA-PreE	Fu, Siqing The University of Texas M. D. Anderson Cancer Center Mechanism Study of Pazopanib plus Vorinostat for Preferentially Targeting TP53 Mutations	
	RP160346pe IIRA-PreE	Tekmal, Rajeshwar The University of Texas Health Science Center at San Antonio Targeting breast cancer progression and recurrence using novel ER beta agonists	
	RP160349pe IIRA-PreE	Liu, Xin The University of Texas Southwestern Medical Center Molecular Mechanisms of Polycomb Repressive Complex 2-Independent Functions of Ezh2	
	RP160356pe IIRA-PreE	Qin, Lidong The Methodist Hospital Research Institute Cell-Assay-on-a-Chip for CRISPR-Cas9 Knockout Screening of Kinases Regulating Tumor Progression and Metastasis	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Basic Cancer Research-2 - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160361pe IIRA-PreE	LAKSHMANASWAMY, RAJKUMAR Texas Tech University Health Sciences Center at El Paso Prevention and Treatment of Breast Cancer with 6-desacetyl nimbinene	
	RP160362pe IIRA-PreE	Li, Bing The University of Texas Southwestern Medical Center Molecular Mechanisms of SETD2-mediated Tumor Suppression	
	RP160365pe IIRA-PreE	O'Donnell, Kathryn The University of Texas Southwestern Medical Center Deubiquitinating Enzymes as Novel Targets for Acute Leukemias - Discovery to Therapy	
	RP160374pe IIRA-PreE	Boothman, David The University of Texas Southwestern Medical Center Dual functions of K-H-p15RS homologs in RNA transcription and DNA repair	A. Tomkinson
	RP160403pe IIRA-PreE	Kidane Mulat, Dawit The University of Texas at Austin Cancer associated variant of DNA glycosylase (NEIL3) and genomic instability	
	RP160415pe IIRA-PreE	Ittmann, Michael Baylor College of Medicine A novel androgen regulated oncogene in African-American prostate cancer	
	RP160418pe IIRA-PreE	Udugamasooriya, Damith University of Houston Activity validation and target identification of cancer stem cell (CSC) binding peptidomimetics	
	RP160428pe IIRA-PreE	Chang, Eric Baylor College of Medicine Overcoming NF1 loss, a key driver for endocrine resistance and recurrence of ER-positive breast cancer	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Basic Cancer Research-2 - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160437pe IIRA-PreE	Jonasch, Eric The University of Texas M. D. Anderson Cancer Center Mechanisms of PD-L1 Regulation in Renal Cell Carcinoma	
	RP160440pe IIRA-PreE	Brugarolas, James The University of Texas Southwestern Medical Center Targeting the undruggable: a first-in-class inhibitor of the HIF-2 transcription factor	
	RP160451pe IIRA-PreE	Donehower, Lawrence Baylor College of Medicine Protein Truncation Mutations in WIP1: Effects on Cancer and Hematopoiesis	
	RP160459pe IIRA-PreE	Weihua, Zhang University of Houston Novel functions of EGFR in prostate cancer resistance to tyrosine kinase inhibition	
	RP160462pe IIRA-PreE	Songyang, Zhou Baylor College of Medicine Systematic identification of small molecule inhibitors that manipulate telomerase activities	
	RP160465pe IIRA-PreE	Post, Sean The University of Texas M. D. Anderson Cancer Center Individualizing AML treatment strategies with BET bromodomain inhibitors	
	RP160469pe IIRA-PreE	Siddik, Zahid The University of Texas M. D. Anderson Cancer Center Rewiring the MDM4 Circuitry to Activate p53 in Chemoresistant Tumor Cells	
	RP160479pe IIRA-PreE	Ozpolat, Bulent The University of Texas M. D. Anderson Cancer Center Novel Tumor Targeted SiRNA Therapeutics for Ovarian Cancer	
	RP160481pe IIRA-PreE	Burgess, Kevin Texas A&M University Fast-track Identification of Small Molecules That Disrupt PPIs Involving EGFR	

2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review

Panel: Basic Cancer Research-2 - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160485pe IIRA-PreE	Basu, Alakananda University of North Texas Health Science Center at Fort Worth S6 kinase 2 as a potential new target for breast cancer therapy	
	RP160486pe IIRA-PreE	Killary, Ann The University of Texas M. D. Anderson Cancer Center On the role of DEAR1 as a novel ubiquitin ligase for ER alpha and predictor of tamoxifen response in ER positive breast cancer	
	RP160490pe IIRA-PreE	Watowich, Stanley The University of Texas Medical Branch at Galveston NNMT inhibitors as novel multitargeted therapeutics for obesity-associated breast cancer and oral squamous cell carcinoma	
	RP160491pe IIRA-PreE	Zhang, Shuxing The University of Texas M. D. Anderson Cancer Center A ubiquitination pathway-based therapy for breast cancer metastasis and resistance	
	RP160505pe IIRA-PreE	Calin, George The University of Texas M. D. Anderson Cancer Center Anti-miR-155 therapy for overcoming chemoresistance in lung cancers	
	RP160508pe IIRA-PreE	Sahin, Ergun Baylor College of Medicine Cooperative effect of short telomeres and high fructose intake in causing intestinal cancer	
	RP160516pe IIRA-PreE	Yang, Feng Baylor College of Medicine Targeting GATA2 stability as a novel therapeutic for castration-resistant prostate cancer	
	RP160528pe IIRA-PreE	Zhang, Jun Texas Tech University Health Sciences Center The role of CSC complex in the reproductive tumorigenesis	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Basic Cancer Research-2 - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160529pe	Brown, Powel	
	IIRA-PreE	The University of Texas M. D. Anderson Cancer Center	
		DAPK-1, a Novel Target for the Treatment of p53 Mutant Cancers	
	RP160531pe	Li, Xiaotao	
	IIRA-PreE	Baylor College of Medicine	
		REGgamma Is a Driver of colitis Associated Cancer	
	RP160542pe	Raj, Ganesh	
	IIRA-PreE	The University of Texas Southwestern Medical Center	
		ANDROGEN RECEPTOR COREGULATOR BINDING INHIBITORS (ARCB1):A NOVEL THERAPEUTIC STRATEGY IN ADVANCED PROSTATE CANCER	
	RP160562pe	Gustafsson, Jan-Åke	
	IIRA-PreE	University of Houston	
		Spontaneous development of squamous cell cancer in the lungs of LRXalpha, beta knockout mice	
	RP160563pe	Jin, Jianping	
	IIRA-PreE	The University of Texas Health Science Center at Houston	
		The role of constitutive proteolysis of IkappaB-alpha in development of the basal-like breast cancer	
	RP160569pe	Tasciotti, Ennio	
	IIRA-PreE	The Methodist Hospital Research Institute	
		Etiological relationship between chemoresistance and DNA repair	
	RP160571pe	Lin, Weei-Chin	
	IIRA-PreE	Baylor College of Medicine	
		New mechanisms of checkpoint perturbation and cancer therapeutics	
	RP160575pe	Lee, Ryang Hwa	
	IIRA-PreE	Texas A&M University System Health Science Center	
		SorLA as a novel target for breast cancer treatment	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Basic Cancer Research-2 - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160599pe IIRA-PreE	Chen, Changyi (Johnny) Baylor College of Medicine Tumor suppression mechanisms of Jade-2 and its small molecule mimics for the treatment of pancreatic cancer	
	RP160608pe IIRA-PreE	Wu, Hongli (Catherine) University of North Texas Health Science Center at Fort Worth Novel Drug Discovery of Natural Product Glutaredoxin Inhibitors: the Future of Anti-Liver Cancer Treatment	
	RP160611pe IIRA-PreE	Schiff, Rachel Baylor College of Medicine HER2+ breast cancer PDX models for individualized targeting of drivers of anti-HER2 drug resistance	J. Petrini
	RP160616pe IIRA-PreE	Zoltowski, Brian Southern Methodist University Role of Metabolism and Circadian Clock Function in Cancer Development	
	RP160621pe IIRA-PreE	Latham, Michael Texas Tech University NMR Structural Studies of DNA Double Strand Break Repair Complexes	J. Petrini
	RP160639pe IIRA-PreE	Shulaev, Vladimir University of North Texas Role of antioxidants in modulating persistent oxidative stress response networks in cancer cells	
	RP160649pe IIRA-PreE	Li, Wei Texas Tech University A high throughput study on multilayered nanocoating to co-deliver siRNA and chemo-drugs for triple negative breast cancer (TNBC) treatment	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Cancer Biology - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order	Log No.	PI / Institution / Title	Conflict
	RP160011pe IIRA-PreE	Bar-Eli, Menashe The University of Texas M. D. Anderson Cancer Center Control of the Melanoma Metastatic Phenotype by RNA Editing	
	RP160016pe IIRA-PreE	Chattopadhyay, Chandrani The University of Texas M. D. Anderson Cancer Center Targeting IGF-1R pathway in uveal melanoma: single and combination therapy approaches	
	RP160024pe IIRA-PreE	Estecio, Marcos The University of Texas M. D. Anderson Cancer Center Elucidating the Functional Role of the Chromatin Remodeler Enzyme CHD7 in Colorectal Cancers	
	RP160035pe IIRA-PreE	Nakada, Daisuke Baylor College of Medicine The role of Prdm16 and histone H3 lysine 9 methyltransferase complex in MDS	
	RP160038pe IIRA-PreE	Mok, Samuel The University of Texas M. D. Anderson Cancer Center Role of heterogenous stromal microenvironment in ovarian cancer progression	
	RP160049pe IIRA-PreE	Hamill, Owen The University of Texas Medical Branch at Galveston Targeting Piezo1 Ca2+ channels to kill tumor cells	
	RP160061pe IIRA-PreE	Efstathiou, Eleni The University of Texas M. D. Anderson Cancer Center Therapy-driven evolution in prostate cancer informs the application of androgen signaling therapy in a progression dependent manner	
	RP160078pe IIRA-PreE	Bacich, Dean The University of Texas Health Science Center at San Antonio PSMA and folate interact to regulate androgen receptor splicing and promote castrate resistant prostate cancer progression	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Cancer Biology - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160080pe IIRA-PreE	McNiece, Ian The University of Texas M. D. Anderson Cancer Center CLL CANCER STEM CELLS	
	RP160137pe IIRA-PreE	Jiang, Jean The University of Texas Health Science Center at San Antonio Osteocytic Hemichannels in Suppression of Breast Cancer Bone Metastasis	
	RP160142pe IIRA-PreE	Zhang, Xiang Baylor College of Medicine Modeling and targeting bone micrometastases	
	RP160153pe IIRA-PreE	Dalby, Kevin The University of Texas at Austin Targeting the Mechanosensing Machinery in TNBC to Reduce Metastatic Potential	
	RP160160pe IIRA-PreE	Xie, Keping The University of Texas M. D. Anderson Cancer Center Epigenetic mechanisms for FOXM1-beta-catenin signaling in pancreatic cancer progression	
	RP160166pe IIRA-PreE	Pan, Zhizhong The University of Texas M. D. Anderson Cancer Center Targeting specific HDACs for better pain relief	
	RP160189pe IIRA-PreE	SUN, LUZHE The University of Texas Health Science Center at San Antonio Role of Gli3 in the development of castration resistant prostate cancer	
	RP160193pe IIRA-PreE	Hsieh, Jer-Tsong The University of Texas Southwestern Medical Center Targeting androgen receptor variants and chemo-resistance in metastatic prostate cancer	
	RP160197pe IIRA-PreE	Sood, Anil The University of Texas M. D. Anderson Cancer Center Targeting ovarian cancer microenvironment using Exosomal Therapeutics	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Cancer Biology - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160203pe IIRA-PreE	Clark, Allan The University of Texas at Arlington Uncoupling differentiation and proliferation in leukemia cells through caspase conformational control	
	RP160204pe IIRA-PreE	Martinez-Zaguilan, Raul Texas Tech University Health Sciences Center Low carbohydrate diet and proton pump inhibitors increase chemotherapeutic efficacy to inhibit tumor growth and metastasis: studies in vitro and in vivo	
	RP160207pe IIRA-PreE	Ekmekcioglu, Suhendan The University of Texas M. D. Anderson Cancer Center Parainflammation in melanoma microenvironment defines the protumorigenic functions of IFN-gamma	
	RP160212pe IIRA-PreE	Galko, Michael The University of Texas M. D. Anderson Cancer Center Genetic and Epigenetic Dissection of a Metastasis-Like Cell Behavior Switch	
	RP160226pe IIRA-PreE	McCarty, Joseph The University of Texas M. D. Anderson Cancer Center Deconstructing the Perivascular Niche in Glioblastoma	
	RP160231pe IIRA-PreE	Ghosh, Rita The University of Texas Health Science Center at San Antonio Metastatic melanoma prevention mediated by NexrutineR	
	RP160235pe IIRA-PreE	Liu, Qingyun The University of Texas Health Science Center at Houston Regulation of tumor aggressiveness and immune suppression in lung adenocarcinoma	
	RP160238pe IIRA-PreE	Lin, Chin-Yo University of Houston Targeting liver X receptors in pancreatic cancer	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Cancer Biology - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160247pe IIRA-PreE	Gladden, Andrew The University of Texas M. D. Anderson Cancer Center Role of Apicobasal Polarity in Epithelial Tumor Progression	
	RP160256pe IIRA-PreE	Fontoura, Beatriz The University of Texas Southwestern Medical Center Uncovering Nuclear Speckles in Oncogenesis	
	RP160258pe IIRA-PreE	Su, Dong-Ming University of North Texas Health Science Center at Fort Worth A potential pre-metastatic niche (thymus) in tumor dormancy & eradication	
	RP160263pe IIRA-PreE	Wen, Hong The University of Texas M. D. Anderson Cancer Center Targeting epigenetic regulators in human cancer	
	RP160271pe IIRA-PreE	Li, Yi-Ping The University of Texas Health Science Center at Houston Targeting muscle wasting in Cancer Cachexia	
	RP160273pe IIRA-PreE	Beretta, Laura The University of Texas M. D. Anderson Cancer Center Differentiation-targeted Therapy for the Prevention and Treatment of Hepatocellular Carcinoma	
	RP160288pe IIRA-PreE	Zhong, Qing The University of Texas Southwestern Medical Center Targeting Autophagy Regulated Ciliogenesis in Breast Cancer Treatment	
	RP160295pe IIRA-PreE	McCarty, Nami The University of Texas Health Science Center at Houston Mechanisms of quiescence and growth control in multiple myeloma	
	RP160307pe IIRA-PreE	Terada, Lance The University of Texas Southwestern Medical Center Targeting Metastatic Pathways	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Cancer Biology - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order	Log No.	PI / Institution / Title	Conflict
	RP160321pe IIRA-PreE	Elmquist, Joel The University of Texas Southwestern Medical Center The Role of TLR4 in Obesity-Induced Development and Progression of Hepatocellular Carcinomas	
	RP160325pe IIRA-PreE	Lu, Xin The University of Texas M. D. Anderson Cancer Center Single Cell Oncogenesis	
	RP160331pe IIRA-PreE	Suh, Junghae Rice University Modular and tunable bioresponsive viruses for treatment of ovarian cancer	
	RP160337pe IIRA-PreE	Markiewski, Maciej Texas Tech University Health Sciences Center The tissue resident macrophages-complement C5a receptor cross-talk in regulating the premetastatic niche	
	RP160338pe IIRA-PreE	Pappas, Dimitri Texas Tech University Mechanistic Effects of Hypoxia on Prostate Cancer Cell Drug Resistance	
	RP160347pe IIRA-PreE	Wang, Fen Texas A&M University System Health Science Center Restraint of Prostate Tumor Progression by Endocrine FibroblastGrowth Factors Through Control of Adipocyte Function	
	RP160350pe IIRA-PreE	Bedford, Mark The University of Texas M. D. Anderson Cancer Center Developing Small Molecule Inhibitors to Block Methyl-binding Epigenetic Effectors	
	RP160360pe IIRA-PreE	Yeung, Tsz-Lun The University of Texas M. D. Anderson Cancer Center Targeting stromal-cancer cell crosstalk networks in ovarian cancer treatment	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Cancer Biology - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order	Log No.	PI / Institution / Title	Conflict
	RP160367pe IIRA-PreE	Mahalingam, Devalingam The University of Texas Health Science Center at San Antonio Modulation of sorafenib induced autophagy using hydroxychloroquine in hepatocellular cancer	
	RP160372pe IIRA-PreE	Tang, Dean The University of Texas M. D. Anderson Cancer Center Xenograft modeling uncovers novel mechanisms of CRPC and provides preclinical rationale for personalized treatment	
	RP160392pe IIRA-PreE	Yeung, Sai-Ching The University of Texas M. D. Anderson Cancer Center Defining and targeting metabolic vulnerabilities of adrenal cortical carcinoma to enhance therapeutic effectiveness	
	RP160396pe IIRA-PreE	Scheet, Paul The University of Texas M. D. Anderson Cancer Center Genome-wide Mutation Profiles in Progression of Primary Lung Tumors to Lymph Node Metastasis	
	RP160401pe IIRA-PreE	Wen, Yunfei The University of Texas M. D. Anderson Cancer Center Promoting a non-canonical autophagic cell death in high-grade serous ovarian cancer by prolactin antagonism	
	RP160404pe IIRA-PreE	Wood, Christopher The University of Texas M. D. Anderson Cancer Center Targeting Autotaxin-LPA signaling to block RCC growth and Sunitinib resistance	
	RP160405pe IIRA-PreE	Sarbassov, Dos The University of Texas M. D. Anderson Cancer Center "Regulation of RhoGDI2 and its role in cell migration and metastasis"	
	RP160412pe IIRA-PreE	Barton, Michelle The University of Texas M. D. Anderson Cancer Center TRIM24: an epigenetic regulator of metabolism and its role in cancers	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Cancer Biology - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160431pe IIRA-PreE	Zhu, Chengming The University of Texas M. D. Anderson Cancer Center Understanding the mechanism of chronic inflammation and tumorigenesis in the colon	
	RP160442pe IIRA-PreE	Thevananther, Sundararajah Baylor College of Medicine Targeting P2Y2 purinergic receptors to prevent and treat hepatocellular carcinoma in fatty liver disease	
	RP160445pe IIRA-PreE	DASGUPTA, SANTANU The University of Texas Health Center at Tyler The role of mitophagy and mitochondrial fusion in breast cancer progression	
	RP160447pe IIRA-PreE	Agyin, Joseph The University of Texas Health Science Center at San Antonio Novel bone-targeted therapeutics for cancer	
	RP160452pe IIRA-PreE	Park, Dongsu Baylor College of Medicine Defining in vivo mechanisms of the bone microenvironment in breast cancer metastasis development	
	RP160454pe IIRA-PreE	Moustaid-Moussa, Naima Texas Tech University Adipocyte-derived exosomes increase breast cancer cell inflammation, metabolism and invasion: Preventive effects of omega 3 fatty acids	
	RP160468pe IIRA-PreE	Liu, Leyuan Texas A&M University System Health Science Center Interrupting the Interaction between HDAC4 and MAP1S to Prolong Survival of Prostate Cancer Patients	
	RP160471pe IIRA-PreE	Draetta, Giulio The University of Texas M. D. Anderson Cancer Center Identifying new epigenetic vulnerabilities in pancreatic cancer	S. Courtneidge

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Cancer Biology - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160492pe IIRA-PreE	Pinney, Kevin Baylor University Therapeutic Targeting of Cathepsin L in Combination Drug Treatment as a Strategy to Inhibit Tumor Growth and Metastasis	
	RP160493pe IIRA-PreE	Martinez, Elisabeth The University of Texas Southwestern Medical Center Characterization and pharmacological targeting of the oncogenic activity of Jumonji enzymes	
	RP160502pe IIRA-PreE	Zhu, Lin Texas A&M University System Health Science Center IMPROVING OVARIAN CANCER TARGETABILITY AND OVERCOMING DRUG RESISTANCE BY MULTIFUNCTIONAL POLYMERIC MICELLES	
	RP160506pe IIRA-PreE	Aiden, Erez Baylor College of Medicine Mapping chromatin loops and hubs in Acute Myeloid Leukemia oncogenesis	B. Bernstein W. Hahn
	RP160509pe IIRA-PreE	Pandita, Tej The Methodist Hospital Research Institute Chromatin modulates inhibition of DNA repair by hyperthermia	
	RP160518pe IIRA-PreE	Lee, Brendan Baylor College of Medicine The role of Jag1 in bone niche and breast cancer bone metastasis	
	RP160534pe IIRA-PreE	Porter, Weston Texas AgriLife Research Metabolic Adaptation in DCIS Progression	
	RP160537pe IIRA-PreE	Kim, Min The Methodist Hospital Research Institute Lung Fibroblast Factor Inhibits Non-Small-Cell Lung Cancer Metastasis	G. Wahl

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Cancer Biology - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160539pe IIRA-PreE	Rahman, Md The University of Texas Health Science Center at San Antonio DHA, a natural remedy for breast cancer bone metastasis	
	RP160555pe IIRA-PreE	Lu, Zhimin The University of Texas M. D. Anderson Cancer Center Determining unique metabolic features of hepatocellular carcinoma	
	RP160557pe IIRA-PreE	Ayala, Gustavo The University of Texas Health Science Center at Houston Semaphorin 4F Regulation of Interactions between Nerves and Cancer	
	RP160574pe IIRA-PreE	Wang, Guliang The University of Texas at Austin Mechanisms of Cytosine Methylation-induced Genetic Instability at Mutation Hotspots in Cancer	
	RP160593pe IIRA-PreE	Roy Sarkar, Tapasree Texas AgriLife Research Exosome mediated induction of EMT in breast cancer cells	
	RP160604pe IIRA-PreE	Cobb, Melanie The University of Texas Southwestern Medical Center Defining WNK1 as a therapeutic target in cancer	
	RP160612pe IIRA-PreE	Rylander, Marissa Nichole The University of Texas at Austin Elucidating the Influence of the Stem Cell Niche and the Tumor Microenvironment on Inflammatory Breast Cancer Progression Using 3D Novel Microfluidic Platforms	
	RP160614pe IIRA-PreE	Baker, Aaron The University of Texas at Austin Mechanisms of Organ Specific Endothelial Cell Adhesion in Breast Cancer Metastasis	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Cancer Biology - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160615pe	Tang, Liping	
	IIRA-PreE	The University of Texas at Arlington	
		Novel device for trapping and eliminating metastatic cancer	
	RP160626pe	Prockop, Darwin	
	IIRA-PreE	Texas A&M University System Health Science Center	
		An expandable standardized platform based on iPSC-derived MSCs for targeted cancer therapy	
	RP160647pe	Ogbureke, Kalu	
	IIRA-PreE	The University of Texas Health Science Center at Houston	
		Matrix Metalloproteinases 20-Dentin Sialophosphoprotein Interaction in Oral Cancer	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Cancer Prevention Research - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160065pe IIRA-PreE	Guadagnolo, B. Ashleigh The University of Texas M. D. Anderson Cancer Center Comparing managed care versus fee-for-service Medicaid in cancer care	
	RP160105pe IIRA-PreE	Blalock, Janice The University of Texas M. D. Anderson Cancer Center Treatment development of a cognitive-behavioral smoking cessation intervention for smokers with elevated worry	
	RP160228pe IIRA-PreE	Daniel-MacDougall, Carrie The University of Texas M. D. Anderson Cancer Center BE GONE trial: beans to enrich the gut of obese colorectal cancer survivors	
	RP160274pe IIRA-PreE	Yennu, Sriram The University of Texas M. D. Anderson Cancer Center Multimodal Therapy for the Treatment of Sleep Disturbances in Patients with Cancer	
	RP160277pe IIRA-PreE	Gorenstein, David The University of Texas Health Science Center at Houston Identification of Biomarkers for Ovarian Cancer using Morph-X-Select	
	RP160371pe IIRA-PreE	El-Zein, Randa The Methodist Hospital Research Institute GENOMIC INSTABILITY PATTERNS AS MARKERS FOR EARLY DETECTION OF BREAST CANCER AMONG ETHNIC GROUPS	
	RP160438pe IIRA-PreE	Lee, Cheng Chi The University of Texas Health Science Center at Houston Re-establishing Disrupted Sleep-Wake Rhythm Using Small Molecule Compounds	
	RP160477pe IIRA-PreE	Hassan, Manal The University of Texas M. D. Anderson Cancer Center N-Nitroso Compounds and Risk of Hepatocellular Carcinoma in USA	G. Petersen M. Martinez

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Cancer Prevention Research - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160523pe	Fu, Loning	
	IIRA-PreE	Baylor College of Medicine	
		Prevention of Circadian Disruption-Induced Hepatocarcinogenesis	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Clinical / Translational Cancer Research - Preliminary Evalu

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160012pe IIRA-PreE	Li, Shulin The University of Texas M. D. Anderson Cancer Center Induction of NKG2D Ligand for Treating Metastatic Tumors	
	RP160013pe IIRA-PreE	Kundra, Vikas The University of Texas M. D. Anderson Cancer Center Visualizing T-cell trafficking	S. Riddell V. Engelhard
	RP160019pe IIRA-PreE	Wang, Michael The University of Texas M. D. Anderson Cancer Center An Adaptive Personalized Clinical Trial using a Patient-Derived Xenograft Strategy to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma	
	RP160025pe IIRA-PreE	Lichtenberger, Lenard The University of Texas Health Science Center at Houston Radiation induced oral mucositis in head and neck cancer: Role of salivary surfactant lipids and proteins	
	RP160027pe IIRA-PreE	Ober, Raimund Texas A&M University System Health Science Center Targeting PSMA for the treatment of prostate cancer	
	RP160034pe IIRA-PreE	Kim, Jeri The University of Texas M. D. Anderson Cancer Center A Randomized Placebo-Controlled Trial of Testosterone Therapy in Hypogonadal Men with Clinically Localized Prostate Cancer Undergoing Active Surveillance	
	RP160036pe IIRA-PreE	Sawakuchi, Gabriel The University of Texas M. D. Anderson Cancer Center Triggering homologous recombination repair pathway in tumors using proton therapy: A preclinical study to combine proton and molecularly targeted therapies	

2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review

Panel: Clinical / Translational Cancer Research - Preliminary Evalu

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160044pe IIRA-PreE	Sun, Xiaoping The University of Texas M. D. Anderson Cancer Center Pre-clinical therapeutic evaluation of targeting IL-7/IL-7R in BCR-ABL+ acute lymphoblastic leukemia	
	RP160045pe IIRA-PreE	Letra, Ariadne The University of Texas Health Science Center at Houston Finding Novel Gene Loci for Familial Adenomatous Polyposis with Dental Anomalies	
	RP160076pe IIRA-PreE	Jha, Mithilesh The University of Texas Health Science Center at San Antonio Mechanism of anti-tumor immunity in bladder cancer	H. Hochster
	RP160098pe IIRA-PreE	Beckingham, Kathleen Rice University Enhanced cancer detection through development of novel immunoprobes	
	RP160100pe IIRA-PreE	Du, Xianglin The University of Texas Health Science Center at Houston Statewide Post-Marketing Surveillance of Adverse Events Associated with Cancer Drug Therapies in Texas	
	RP160110pe IIRA-PreE	Story, Michael The University of Texas Southwestern Medical Center Determining the anti-tumor mechanisms of the normal tissue radioprotector GC4419	
	RP160112pe IIRA-PreE	Iyengar, Puneeth The University of Texas Southwestern Medical Center Tumor GM-CSF enhances cachexia through increase of macrophage regulated lipolysis	
	RP160115pe IIRA-PreE	Aroumougame, Asaithamby The University of Texas Southwestern Medical Center Hypofractionated Proton therapy for Lung and Brain Cancers: A Pre-clinical study	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Clinical / Translational Cancer Research - Preliminary Evalu

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160116pe IIRA-PreE	Saha, Debabrata The University of Texas Southwestern Medical Center Localized lung cancer therapy via novel nanoparticles and radiation	
	RP160121pe IIRA-PreE	Parmar, Simrit The University of Texas M. D. Anderson Cancer Center Clinical Safety and Efficacy of Third party, fucosylated, cord blood derived regulatory T cells to prevent graft versus host disease	
	RP160128pe IIRA-PreE	Hannan, Raquibul The University of Texas Southwestern Medical Center Preclinical Evaluation of Radiation-Induced Anti-Tumor Neutrophils and its Potentiation by G-CSF	
	RP160130pe IIRA-PreE	Abe, Jun-ichi The University of Texas M. D. Anderson Cancer Center Cancer Therapy-Induced Vasculopathy and Multiple Organ Dysfunction Syndrome in Sepsis	
	RP160141pe IIRA-PreE	Ullrich, Stephen The University of Texas M. D. Anderson Cancer Center Will blocking mast cell function improve checkpoint control antibody therapy in pancreatic cancer?	
	RP160143pe IIRA-PreE	Nurieva, Roza The University of Texas M. D. Anderson Cancer Center Role of T follicular helper cell in ant-tumor immunity	W. Stadler V. Engelhard
	RP160154pe IIRA-PreE	Qin, Zhenpeng The University of Texas at Dallas Intravascular regulation of magnetoliposomes to improve anti-cancer drug delivery	
	RP160165pe IIRA-PreE	Wheeler, David Baylor College of Medicine Translational genomics for aggressive cutaneous T-cell lymphoma	

2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review

Panel: Clinical / Translational Cancer Research - Preliminary Evalu

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160176pe IIRA-PreE	Sharma, Padmanee The University of Texas M. D. Anderson Cancer Center Investigating Immunotherapy Strategies in Patients with Metastatic RCC	S. Riddell
	RP160181pe IIRA-PreE	Ajani, Jaffer The University of Texas M. D. Anderson Cancer Center Dual pathway inhibition in a biomarker based enriched patient population with advanced gastroesophageal cancer	
	RP160184pe IIRA-PreE	Majeti, Ravikumar Texas A&M University System Health Science Center Precision polymer nanosystems (P2Ns) for oral metronomic dosing in ovarian cancer	
	RP160188pe IIRA-PreE	Schluns, Kimberly The University of Texas M. D. Anderson Cancer Center Regulation of infiltration and function of tumor-resident CD8 T cells by IL-15	V. Engelhard
	RP160194pe IIRA-PreE	Yang, Qing The University of Texas Health Science Center at Houston A novel mechanism of paclitaxel-induced peripheral neuropathy and potential treatment	
	RP160198pe IIRA-PreE	Wistuba, Ignacio The University of Texas M. D. Anderson Cancer Center Development and Validation of Clinical Assays for Predicting Patient Outcomes in Lung Cancer	
	RP160219pe IIRA-PreE	Harvey, Barrett The University of Texas Health Science Center at Houston Intraoperative Detection of Prostate Cancer Positive Lymph Nodes	
	RP160230pe IIRA-PreE	Trippier, Paul Texas Tech University Health Sciences Center Small Molecule Adjuvants for the Treatment of AML	S. Balk

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Clinical / Translational Cancer Research - Preliminary Evalu

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160232pe IIRA-PreE	Mirkovic, Dragan The University of Texas M. D. Anderson Cancer Center Understanding Biological and Physical Factors Affecting Response to Proton Therapy to Improve its Clinical Effectiveness	
	RP160234pe IIRA-PreE	Jia, Xun The University of Texas Southwestern Medical Center A level-set approach for optimizing rotational cancer radiotherapy	
	RP160241pe IIRA-PreE	Fang, Shenyang The University of Texas M. D. Anderson Cancer Center The role of systematic inflammation factor in melanoma development and progression	
	RP160248pe IIRA-PreE	Dou, Huanyu Texas Tech University Health Sciences Center at El Paso Tumor Associated Macrophages Targeted Anti-Glioma immunotherapy	
	RP160257pe IIRA-PreE	Chang, Jenny The Methodist Hospital Research Institute Quantification of tumor-infiltrating lymphocytes to predict outcomes in breast cancer	
	RP160280pe IIRA-PreE	Curran, Michael The University of Texas M. D. Anderson Cancer Center Rotten to the core : Tumor immune suppression and immunotherapy resistance critically requires hypoxia	
	RP160289pe IIRA-PreE	Hao, Yaowu The University of Texas at Arlington Transarterial infusion of radioactive nanoseeds for efficacious treatment of hepatocellular carcinomas – Toward translational therapy via rat and swine models	
	RP160290pe IIRA-PreE	Leen, Ann Baylor College of Medicine AML-targeted T-cell Therapy	

2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review

Panel: Clinical / Translational Cancer Research - Preliminary Evalu

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160296pe IIRA-PreE	Chen, Chuo The University of Texas Southwestern Medical Center A Small-Molecule Approach to Elicit Anticancer Immunity	
	RP160302pe IIRA-PreE	Chen, Zhilei Texas A&M University System Health Science Center Plug and Play lentiviral vector for cancer immunotherapy	
	RP160305pe IIRA-PreE	Eckhardt, Bedrich The University of Texas M. D. Anderson Cancer Center Developing a novel cytokine-based strategy for metastatic breast cancer	
	RP160316pe IIRA-PreE	Wargo, Jennifer The University of Texas M. D. Anderson Cancer Center Identifying Immune And Molecular Determinants Of Response And Resistance To Immune Checkpoint Blockade In High-Risk Resectable Metastatic Melanoma	
	RP160336pe IIRA-PreE	Diab, Adi The University of Texas M. D. Anderson Cancer Center Phase I/II Dose Escalation and Cohort Expansion Study of Intratumoral CD40 agonist (APX005M) in Combination with Pembrolizumab in Metastatic Melanoma Patients	V. Engelhard
	RP160339pe IIRA-PreE	Liao, Zhongxing The University of Texas M. D. Anderson Cancer Center Dependence of cardiac troponin expression on the magnitude and distribution of heart radiation dose in NSCLC patients after chemoradiation	
	RP160345pe IIRA-PreE	Arber, Caroline Baylor College of Medicine Engineering T cells to ensure specificity for tumor cells and their environment	
	RP160348pe IIRA-PreE	Tucker, Haley The University of Texas at Austin A unique human subgroup E endogenous retrovirus in the pathology and early detection of Activated B Cell-Diffuse Large B Cell Lymphoma	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Clinical / Translational Cancer Research - Preliminary Evalu

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160368pe IIRA-PreE	Gao, Jinming The University of Texas Southwestern Medical Center cGAMP Nanovaccine for Cancer Immunotherapy	
	RP160370pe IIRA-PreE	Decker, William Baylor College of Medicine Adjuvant Immunotherapy for Pancreatic Ductal Adenocarcinoma	
	RP160384pe IIRA-PreE	Wang, Jin Baylor College of Medicine Promoting The Functions of Memory T cells for Adoptive T cell Therapy	
	RP160391pe IIRA-PreE	Vera, Juan Baylor College of Medicine Engineering a SmarT-cell Design	
	RP160417pe IIRA-PreE	Rao, Manjeet The University of Texas Health Science Center at San Antonio Impramine Blue as a Therapeutic Lead Compound with Negligible Toxicity for Treating Breast Cancers	
	RP160420pe IIRA-PreE	Rezvani, Katy The University of Texas M. D. Anderson Cancer Center Cytomegalovirus as a Novel Immunotherapeutic Target for the treatment of Glioblastoma Multiforme	
	RP160425pe IIRA-PreE	Hong, David The University of Texas M. D. Anderson Cancer Center Interrogating the Molecular and Immune Mechanisms of Response/Resistance to Combined KIT Inhibition and CTLA4 Blockade in Melanoma	
	RP160443pe IIRA-PreE	Ma, Qing The University of Texas M. D. Anderson Cancer Center Targeting of pathogenic properties of Tfh cells in acute and chronic GVHD	

2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review

Panel: Clinical / Translational Cancer Research - Preliminary Evalu

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160449pe IIRA-PreE	Priebe, Waldemar The University of Texas M. D. Anderson Cancer Center IL-13RA2 targeted diagnostic and therapeutic agents for pancreatic ductal adenocarcinoma	
	RP160464pe IIRA-PreE	Aldrich, Melissa The University of Texas Health Science Center at Houston Lymphatic and systemic immunity changes in post-radiation lymphedema development	
	RP160473pe IIRA-PreE	Sarosiek, Irene Texas Tech University Health Sciences Center at El Paso Transcutaneous Needleless Electroacupuncture as an alternative to pharmacologic antiemetic therapies for chemotherapy-induced nausea in breast cancer patients	
	RP160480pe IIRA-PreE	Rodriguez, Ronald The University of Texas Health Science Center at San Antonio A Novel Combination Therapy for Aggressive Prostate Cancer	
	RP160482pe IIRA-PreE	Heimberger, Amy The University of Texas M. D. Anderson Cancer Center Nanoparticle Targeted STAT3 Immune Expression	V. Engelhard
	RP160500pe IIRA-PreE	Clarke, William The University of Texas Health Science Center at San Antonio Evaluation of P7C3-A20 to prevent development of chemotherapy-induced peripheral neuropathy (CIPN)	
	RP160507pe IIRA-PreE	King, Katherine Baylor College of Medicine Immune Defense Against Preleukemic Hematopoietic Stem Cells	
	RP160512pe IIRA-PreE	Dube, Peter The University of Texas Health Science Center at San Antonio Integrin-mediated IL-18 signaling in the prevention and treatment of inflammation-associated colorectal cancer	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Clinical / Translational Cancer Research - Preliminary Evalu

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160517pe IIRA-PreE	Maitra, Anirban The University of Texas M. D. Anderson Cancer Center Exosomal DNA as a surrogate biomarker for early diagnosis and therapeutic stratification in pancreatic cancer	
	RP160532pe IIRA-PreE	Curiel, Tyler The University of Texas Health Science Center at San Antonio mTOR inhibition to improve gamma delta T cell function as novel and effective cancer immunotherapy	
	RP160538pe IIRA-PreE	Moussa, Hanna Texas Tech University Modeling of Mammography Radiation Exposure on Human Adipose:Breast Cancer Cell Interactions	
	RP160558pe IIRA-PreE	Rasband, Matthew Baylor College of Medicine Axon-glia interactions in chemotherapy-induced peripheral neuropathy	
	RP160564pe IIRA-PreE	Shen, Haifa The Methodist Hospital Research Institute Nano-DC Vaccine for Metastatic HER2-Positive Breast Cancer	
	RP160565pe IIRA-PreE	Zhang, Xiaoliu University of Houston Development of a novel viro-immunotherapeutic approach for pancreatic cancer	
	RP160577pe IIRA-PreE	Poojary, Venuprasad Baylor Research Institute A novel function of Itch in controlling IL-17-induced inflammation in colon cancer	K. Cooney
	RP160619pe IIRA-PreE	Serda, Rita Baylor College of Medicine RADIOFREQUENCY STIMULATED GEMCITABINE AND NANO TLR CANCER IMMUNITY	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Clinical / Translational Cancer Research - Preliminary Evalu

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160638pe	WANG, YU-CHIEH	
	IIRA-PreE	University of North Texas Health Science Center at Fort Worth	
		Dissecting the abnormal interactions between autologous immune cells and human melanocytic cells with hyperactive MAPK	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Imaging Technology and Informatics - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160020pe IIRA-PreE	Takahashi, Masaya The University of Texas Southwestern Medical Center Response assessment of concurrent temozolomide chemoradiotherapy in glioblastoma patients by amide proton transfer imaging	
	RP160051pe IIRA-PreE	Ward, Elizabeth Texas A&M University System Health Science Center Improving contrast for antibody-based tumor detection using PET	
	RP160093pe IIRA-PreE	Li, Changzhi Texas Tech University Microwave Tumor Tracking and Imaging using Flexible Antenna for Cancer Radiotherapy	
	RP160122pe IIRA-PreE	ALBUQUERQUE, KEVIN The University of Texas Southwestern Medical Center Truly adaptive Image-guided high-dose-rate brachytherapy for locally advanced cervical cancer	
	RP160149pe IIRA-PreE	Lippert, Alexander Southern Methodist University Chemiluminescent Molecular Imaging Probes for the Detection and Management of Prostate Cancer	
	RP160150pe IIRA-PreE	Colen, Rivka The University of Texas M. D. Anderson Cancer Center Radiogenomic Screen to Identify Novel Proliferation-associated Glioblastoma Genomic Therapeutic Targets: Discovery and Mechanistic Validation Study	
	RP160227pe IIRA-PreE	Wang, Jihong The University of Texas M. D. Anderson Cancer Center Developing, Optimizing, and Implementing a Magnetic Resonance-Based Metabolic Imaging Tool for Diagnosis of Head and Neck and Prostate Cancers and Early Assessm	
	RP160229pe IIRA-PreE	Avritscher, Rony The University of Texas M. D. Anderson Cancer Center Imaging-based quantitative analysis of vascular perfusion and tissue oxygenation to improve therapy of hepatocellular carcinoma	

2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review

Panel: Imaging Technology and Informatics - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160294pe IIRA-PreE	Hao, Guiyang The University of Texas Southwestern Medical Center Theranostic Small-molecule Drug Conjugates for Personalized Prostate Cancer Therapy	
	RP160300pe IIRA-PreE	Lapotko, Dmitri Rice University Rapid non-invasive diagnostics of microtumors in head and neck	
	RP160330pe IIRA-PreE	Li, Chun The University of Texas M. D. Anderson Cancer Center PET-Guided Photothermal-Radiotherapy with Renal Clearable [64Cu]CuS Nanodots in Hepatocellular Carcinoma	
	RP160332pe IIRA-PreE	Kim, Jung-whan The University of Texas at Dallas GLUT1, a novel biomarker for lung squamous cell carcinoma	
	RP160343pe IIRA-PreE	Court, Laurence The University of Texas M. D. Anderson Cancer Center Taking radiomics from the bench to the bedside	
	RP160359pe IIRA-PreE	Bhattacharya, Pratip The University of Texas M. D. Anderson Cancer Center Hyperpolarized Metabolic Imaging of Prostate Cancer for Risk Stratification and Surveillance	D. Haas-Kogan
	RP160387pe IIRA-PreE	Lai, Stephen The University of Texas M. D. Anderson Cancer Center Monitoring Mandibular Osteoradionecrosis and Response to Treatment With Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI)	
	RP160393pe IIRA-PreE	Fuller, Clifton The University of Texas M. D. Anderson Cancer Center Magnetic resonance imaging biomarker assessment of real-time radiotherapy-induced normal tissue injury	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Imaging Technology and Informatics - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160397pe IIRA-PreE	Folkert, Michael The University of Texas Southwestern Medical Center A Phase 1 Therapeutic Dose Escalation Study using Percutaneous Image-Guided Navigation for High Dose Rate Brachyablation of Primary Liver Lesions	
	RP160414pe IIRA-PreE	Wosik, Jarek University of Houston Time Reversal Based Radio-Frequency Antenna System for Non-Invasive Thermal Cancer Therapy	
	RP160429pe IIRA-PreE	Pearce, John The University of Texas at Austin Accurate Prediction and Assessment of Cell Death in Hyperthermia Cancer Therapy	
	RP160456pe IIRA-PreE	Schellingerhout, Dawid The University of Texas M. D. Anderson Cancer Center Preventing Radiation Therapy Damage to the Spinal Cord: Using Molecular Imaging as a Biomarker to Individualize Therapy	
	RP160495pe IIRA-PreE	Stefan, Mihaela The University of Texas at Dallas Responsive Functional Amphiphilic Block Copolymers for Tumor-Specific Drug Delivery and Imaging	
	RP160496pe IIRA-PreE	Simanek, Eric Texas Christian University Dual SPECT Probes for Monitoring the Treatment of Castration Resistant Prostate Cancer that has Metastasized to Bone	
	RP160497pe IIRA-PreE	Krishnan, Sunil The University of Texas M. D. Anderson Cancer Center Amplified gold nanoparticle-mediated radiosensitization of tumors	R. Berbeco
	RP160510pe IIRA-PreE	Frank, Steven The University of Texas M. D. Anderson Cancer Center Enhancing the relative biological effectiveness of proton radiation therapy for head and neck cancer	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Imaging Technology and Informatics - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160521pe IIRA-PreE	Hussain, Fazle Texas Tech University Development of microfluidic devices for high throughput cancer staging using nuclear deformability and lamins-A/B ratio	
	RP160533pe IIRA-PreE	Gu, Xuejun The University of Texas Southwestern Medical Center A real-time surface image-guided soft robotic patient positioning and monitoring system for maskless head-and-neck cancer radiotherapy	
	RP160541pe IIRA-PreE	Zheng, Jie The University of Texas at Dallas Renal Clearable Nanocarriers for Combination Cancer Therapy	
	RP160550pe IIRA-PreE	Yeh, Hsin-Chih The University of Texas at Austin Dissecting anti-cancer drug response in cancers by novel 3D single-particle tracking system	
	RP160561pe IIRA-PreE	Di Pasqua, Anthony University of North Texas Health Science Center at Fort Worth Magnetic nanoparticles for targeted chemoradiotherapy of lung cancer	
	RP160573pe IIRA-PreE	Gnade, Bruce The University of Texas at Dallas Real time beam profile monitor for proton therapy	
	RP160580pe IIRA-PreE	Biros, George The University of Texas at Austin Integration of advanced imaging and biophysical modeling through computational analysis to differentiate treatment effects from tumor progression	D. Mitchell
	RP160582pe IIRA-PreE	Corbin, Ian The University of Texas Southwestern Medical Center Selective Killing of Glioblastoma Cells using Focused Ultrasound Mediated Delivery of Lipoprotein-Docosahexaenoic Acid Nanoparticles	

**2016 Cancer Prevention and Research Institute of Texas Research Programs
Order of Review**

Panel: Imaging Technology and Informatics - Preliminary Evaluation

Aug 30 2015 - Aug 30 2015

Order#	Log No.	PI / Institution / Title	Conflict
	RP160591pe IIRA-PreE	Zhang, Kai The Methodist Hospital Research Institute High-throughput Microfluidic Single-Cell Analysis for Studies of Genotype-Phenotype Correlations	
	RP160607pe IIRA-PreE	Ghosh, Debadyuti The University of Texas at Austin Early Detection of Low-Volume Ovarian Cancer Using Short-Wavelength Infrared Fluorescence Imaging	
	RP160617pe IIRA-PreE	Zhang, Li The University of Texas at Dallas Optimizing therapeutic strategies against lung cancer using Multi-Modality Imaging	
	RP160620pe IIRA-PreE	Akabani, Gamal Texas A&M Engineering Experiment Station Enhancing Alpha Particle Targeted Radionuclide Therapy Using Nuclear Nanotechnologies For The Treatment of Cancer Metastases	
	RP160623pe IIRA-PreE	Tunnell, James The University of Texas at Austin Intraoperative Margin Assessment during Breast Cancer Lumpectomy	
	RP160645pe IIRA-PreE	Jo, Javier Texas Engineering Experiment Station Multimodal Optical Endoscope for Early Detection of Oral Cancer	J Liu J. Sutcliffe
	RP160648pe IIRA-PreE	Chen, Wei The University of Texas at Arlington Microwave induced photodynamic therapy for prostate cancer treatment	K. Zinn

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.1 Basic Cancer Research-2

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
10/5/2015	RP160222	Rao, Hai	The University of Texas Health Science Center at San Antonio	Carol Prives	<i>Carol Prives</i>	Brahm Gicheru/BG

SRA Approval:

Name (PRINT):	Brahm Gicheru
Signature:	<i>Brahm Gicheru</i>
Date:	10/5/2015

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.




Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs


Panel: 16.1 Cancer Biology

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
10/7/15	RP160373	Naora, Honami	The University of Texas M. D. Anderson Cancer Center	Greene, Geoffrey		Brahms Gicheru/BG
10/7/15	RP160395	Lee, Min Gyu	The University of Texas M. D. Anderson Cancer Center	Belinsky, Steven	Not Discussed	Brahms Gicheru/BG
10/7/15	RP160471	Draetta, Giulio	The University of Texas M. D. Anderson Cancer Center	Courtneidge, Sara		Brahms Gicheru/BG
10/7/15	RP160535	Kang, Min	Texas Tech University Health Sciences Center	DeClerck, Yves		Brahms Gicheru/BG
10/7/15	RP160567	Zhang, Michael	The University of Texas at Dallas	Lawlor, Elizabeth	Not Discussed	Brahms Gicheru/BG

SRA Approval:

Name (PRINT):	Brahms Gicheru
Signature:	
Date:	10/7/2015

Comments:

Steven Belinsky and Elizabeth Lawlor applications not discussed.
--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application

Procurement Sensitive Document



Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.1 Cancer Biology

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
10/7/15	RP160589	Chapkin, Robert	Texas AgriLife Research	Fearon, Eric		Brahm Gicheru/BG
10/7/15	RP160589	Chapkin, Robert	Texas AgriLife Research	Greene, Geoffrey		Brahm Gicheru/BG

SRA Approval:

Name (PRINT):	Brahm Gicheru
Signature:	
Date:	10/7/2015

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.






Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs


Panel: 16.1 Cancer Prevention Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
9/30	RP160015	Ness, Roberta	The University of Texas Health Science Center at Houston	Haiman, Christopher		Brendan Morales BRM
9/30	RP160015	Ness, Roberta	The University of Texas Health Science Center at Houston	Kushi, Lawrence		Brendan Morales BRM
9/30	RP160030	Gerber, David	The University of Texas Southwestern Medical Center	Barlow, William		Brendan Morales BRM
9/30	RP160097	Spitz, Margaret	Baylor College of Medicine	Martinez, Maria		Brendan Morales BRM
9/30	RP160145	Bast, Robert	The University of Texas M. D. Anderson Cancer Center	Kushi, Lawrence		Brendan Morales BRM

SRA Approval:

Name (PRINT):	BRENDAN MORALES
Signature:	
Date:	10/7/15

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs


Panel: 16.1 Cancer Prevention Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
9/30	RP160145	Bast, Robert	The University of Texas M. D. Anderson Cancer Center	Li, Christopher	VERIFIED TELEPHONICALLY BY SRA	BRENDAN MORALES BRM
9/30	RP160168	Felini, Martha	University of North Texas Health Science Center at Fort Worth	Olshan, Andrew		Brendan Morales BRM
9/30	RP160224	Schick, Vanessa	The University of Texas Health Science Center at Houston	Brandon, Thomas	23/2/2016	Brendan Morales BRM
9/30	RP160354	Singo, Francesco	The University of Texas M. D. Anderson Cancer Center	Barlow, William	NOT DISCUSSED	Brendan Morales BRM
9/30	RP160354	Singo, Francesco	The University of Texas M. D. Anderson Cancer Center	Li, Christopher	NOT DISCUSSED	Brendan Morales BRM

SRA Approval:

Name (PRINT):	BRENDAN MORALES
Signature:	
Date:	10/7/15

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.1 Cancer Prevention Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
9/30	RP160354	Stingo, Francesco	The University of Texas M. D. Anderson Cancer Center	Petersen, Gloria	NOT DISCUSSED	BRENDAN MORALES BRM
9/30	RP160408	Shen, Qiang	The University of Texas M. D. Anderson Cancer Center	Kumar, Nagi	NOT DISCUSSED	Brendan Morales BRM
9/30	RP160470	Valerio, Melissa	The University of Texas Health Science Center at Houston	Kushi, Lawrence	<i>Lawrence Kushi</i>	Brendan Morales BRM
9/30	RP160499	Minnix, Jennifer	The University of Texas M. D. Anderson Cancer Center	Brandon, Thomas	NOT DISCUSSED	Brendan Morales BRM
9/30	RP160499	Minnix, Jennifer	The University of Texas M. D. Anderson Cancer Center	Schnoll, Robert	NOT DISCUSSED	Brendan Morales BRM

SRA Approval:

Name (PRINT):	BRENDAN MORALES
Signature:	<i>Brendan Morales</i>
Date:	10/7/15

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application

Procurement Sensitive Document


Do not copy or circulate without written permission.

2016 Cancer Prevention and Research Institute of Texas Research Programs

Meeting Type: Onsite Review

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
9/30	RP160527	Hanash, Samir	The University of Texas M. D. Anderson Cancer Center	Barlow, William	William Barlow	Brendan Morales BRM
9/30	RP160527	Hanash, Samir	The University of Texas M. D. Anderson Cancer Center	Li, Christopher	VERIFIED TELEPHONE CALL BY SRA	Brendan Morales BRM
9/30	RP160527	Hanash, Samir	The University of Texas M. D. Anderson Cancer Center	Mucci, Lorelei	[Signature]	Brendan Morales BRM
9/30	RP160554	Bondy, Melissa	Baylor College of Medicine	Haiman, Christopher	[Signature]	Brendan Morales BRM
9/30	RP160554	Bondy, Melissa	Baylor College of Medicine	Martinez, Maria	[Signature]	Brendan Morales BRM

Comments:

Name (PRINT):	BRENDAN MORALES
Signature:	
Date:	10/7/15

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application

Do not copy or circulate without written permission.


2016 Cancer Prevention and Research Institute of Texas Research Programs

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
9/30	RP160587	Wetter, David	Rice University	Brandon, Thomas	<i>[Signature]</i>	Brendan Morales BDM

Comments:

Name (PRINT):	BRENDAN MORALES
Signature:	
Date:	10/7/15

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application

Procurement Sensitive Document

Do not copy or circulate without written permission.






Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs


Panel: 16.1 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
9/29	RP160013	Kundra, Vikas	The University of Texas M. D. Anderson Cancer Center	Engelhard, Victor		Brendan Morales BRM
9/29	RP160013	Kundra, Vikas	The University of Texas M. D. Anderson Cancer Center	Riddell, Stanley		Brendan Morales BRM
9/29	RP160143	Nurieva, Roza	The University of Texas M. D. Anderson Cancer Center	Engelhard, Victor		BRENDAN MORALES 
9/29	RP160143	Nurieva, Roza	The University of Texas M. D. Anderson Cancer Center	Stadler, Walter		BRENDAN MORALES BRM
9/29	RP160176	Sharma, Padmanee	The University of Texas M. D. Anderson Cancer Center	Riddell, Stanley	NOT DISCUSSED	Brendan Morales BRM

SRA Approval:

Name (PRINT):	BRENDAN MORALES
Signature:	
Date:	10/7/15

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.1 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
9/29	RP160188	Schlans, Kimberly	The University of Texas M. D. Anderson Cancer Center	Engelhard, Victor	V. W. Engelhard	Brendan Morales BRM
9/29	RP160336	Diab, Adi	The University of Texas M. D. Anderson Cancer Center	Engelhard, Victor	NOT DISCUSSED	Brendan Morales BRM
10/7	RP160482	Heimberger, Amy	The University of Texas M. D. Anderson Cancer Center	Engelhard, Victor	V. W. Engelhard	Brendan Morales BRM
9/29	RP160525	Jiang, Ning	The University of Texas at Austin	Press, Oliver	NOT DISCUSSED	Brendan Morales BRM
9/29	RP160525	Jiang, Ning	The University of Texas at Austin	Riddeil, Stanley	NOT DISCUSSED	Brendan Morales BRM

SRA Approval:

Name (PRINT):	BRENDAN MORALES
Signature:	
Date:	10/7/15

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application

Procurement Sensitive Document

Do not copy or circulate without written permission.

9/22/2015 11:55:06AM


Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.1 Imaging Technology and Informatics

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
10/1/15	RP160497	Krishnan, Sunil	The University of Texas M. D. Anderson Cancer Center	Berbeco, Ross		BRENDAN MORALES BRM
10/1/15	RP160645	Jo, Javier	Texas Engineering Experiment Station	Liu, Jonathan	NOT DISCUSSED	BRENDAN MORALES BRM
10/1/15	RP160645	Jo, Javier	Texas Engineering Experiment Station	Sutcliffe, Julie	NOT DISCUSSED	BRENDAN MORALES BRM
10/1/15	RP160648	Chen, Wei	The University of Texas at Arlington	Zinn, Kurt	NOT DISCUSSED	BRENDAN MORALES BRM

SRA Approval:

Name (PRINT):	BRENDAN MORALES
Signature:	
Date:	10/17/15

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.1 Imaging Technology and Informatics

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
10/1/15	RP160466	Yuan, Baocheng	UT Arlington	Kurt Zim	[Signature]	BRENDAN MORALES BRM

SRA Approval:

Name (PRINT):	BRENDAN MORALES
Signature:	[Signature]
Date:	10/7/15

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Research Programs
Panel: 16.1 Scientific Review Council Meeting
Meeting Type: Teleconference Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*

SRA Approval:

Name (PRINT):	
Signature:	
Date:	

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

**Conflicts of Interest for Academic Research Recruitment Cycle 16.2 and 16.3 Applications
(Academic Research Recruitment Cycle 16.2 and 16.3 Awards Announced at
November 19, 2015, Oversight Committee Meeting)**

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Recruitment Cycle 16.2 and 16.3 include *Recruitment of Established Investigators*, *Recruitment of Rising Stars*, and *Recruitment of First-Time Tenure-Track Faculty Members*. All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC. COI information used for this table was collected by SRA International, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant	Institution	Conflict Noted
Applications considered by the PIC and Oversight Committee			
RR160019	Hancock, John	The University of Texas Health Science Center at Houston	Prives, Carol
Applications Not Recommended for PIC or Oversight Committee Consideration			
None Reported			

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Recruitment Programs


Panel: Recruitment FY16 Cycle 2 and 3

Meeting Type: Teleconference Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
10/19	RR160019	Hancock, John	The University of Texas Health Science Center at Houston	Prives, Carol	Verified Telephonically by SRA	Brendan Morales BQM

SRA Approval:

Name (PRINT):	BRENDAN MORALES
Signature:	
Date:	10/20/15

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Conflicts of Interest for Academic Research Recruitment Cycle 16.4, 16.5, 16.6, Applications

Academic Research Recruitment Cycle 16.4, 16.5, 16.6, Applications

Awards Announced at February 17, 2016, Oversight Committee Meeting

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in 16.4, 16.5, 16.6, *Recruitment of Rising Stars*, *Recruitment of Established Investigators*, and *Recruitment of First-Time, Tenure-Track Faculty Members*. All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC. COI information used for this table was collected by SRA International, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant	Institution	Conflict Noted
Applications considered by the PIC and Oversight Committee			
RR160023	Appling, Dean	The University of Texas at Austin	Angelou, Angelos
RR160029	Dmitrovsky, Ethan	The University of Texas M.D. Anderson Cancer Center	Jones, Peter
RR160030	Johnston, Sterling	The University of Texas at Austin	Angelou, Angelos
RR160031	Dmitrovsky, Ethan	The University of Texas M.D. Anderson Cancer Center	O'Reilly, Richard
Applications Not Recommended for PIC or Oversight Committee Consideration			
RR160039	Fitz, John	The University of Texas Southwestern Medical Center	Gambhir, Sanjiv Sam

* = Not discussed

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Recruitment Programs

Panel: Recruitment FY16 Cycle 4

Meeting Type: Teleconference Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
11/13/15	RR160029	Dmitrovsky, Ethan	The University of Texas M. D. Anderson Cancer Center	Jones, Peter	VERIFIED TELEPHONICALLY BY SRA	BRENDAN MORALES <i>Buh R M</i>

SRA Approval:

Name (PRINT):	BRENDAN MORALES
Signature:	<i>Buh R M</i>
Date:	11/13/15

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Recruitment Programs

Panel: Recruitment FY16 Cycle 5 and 6

Meeting Type: Teleconference Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
1/14/16	RR160031	Dmitrovsky, Ethan	The University of Texas M. D. Anderson Cancer Center	O'Reilly, Richard	VERIFIED TELEPHONICALLY BY SRA	BRENDAN MORALES BKM
1/14/16	RR160039	Fitz, John	The University of Texas Southwestern Medical Center	Gambhir, Sanjiv Sam	VERIFIED TELEPHONICALLY BY SRA	BRENDAN MORALES BKM

SRA Approval:

Name (PRINT):	BRENDAN MORALES
Signature:	
Date:	1/14/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

**Conflicts of Interest for Academic Research Recruitment Cycle 16.8 and 16.9 Applications
(Academic Research Recruitment Cycle 16.8 and 16.9 Awards Announced at May 18, 2016,
Oversight Committee Meeting)**

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Cycle 16.2 include *Recruitment of First-Time, Tenure-Track Faculty Members*; *Recruitment of Rising Stars*; *Recruitment of Established Investigators*. All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC. COI information used for this table was collected by SRA International, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant	Institution	Conflict Noted
Applications considered by the PIC and Oversight Committee			
RR160053	Weidanz, Jon	The University of Texas at Arlington	O'Reilly, Richard
Applications not considered by the PIC or Oversight Committee			
No conflicts noted			

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Recruitment Programs


Panel: Recruitment FY16 Cycle 7

Meeting Type: Teleconference Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*

SRA Approval:

Name (PRINT):	Thomas Dodelin
Signature:	
Date:	2/11/16

Comments:

No COI's

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.


Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Recruitment Programs

Panel: Recruitment FY16 Cycle 8

Meeting Type: Teleconference Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/24/16	RR160053	Weidanz, Jon	The University of Texas at Arlington	O'Reilly, Richard	VERIFIED TELEPHONICALLY BY SRA	BRENDAN MORALES BRM

SRA Approval:

Name (PRINT):	BRENDAN MORALES
Signature:	
Date:	3/24/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Recruitment Programs


Panel: Recruitment FY16 Cycle 8

Meeting Type: Teleconference Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*

SRA Approval:

Name (PRINT):	BRENDAN MORALES
Signature:	
Date:	3/24/16

Comments:

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.


Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Recruitment Programs

Panel: Recruitment FY16 Cycle 9

Meeting Type: Teleconference Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*

SRA Approval:

Name (PRINT):	THOMAS R. DODELIN
Signature:	
Date:	4/14/16

Comments:

There were no COI's for this panel

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Conflicts of Interest Disclosure
Academic Research Cycle 16.2 Applications
(Academic Research Cycle 16.2 Awards Announced at May 18, 2016, and August 17, 2016,
Oversight Committee Meetings)

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Cycle 16.2 include *High Impact/High Risk Research Awards*, *Core Facilities Support Awards*, and *Multi-Investigator Research Awards*. All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC. COI information used for this table was collected by SRA International, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant	Institution	Conflict Noted
Applications considered by the PIC and Oversight Committee			
RP160657	Dalby, Kevin N	University of Texas at Austin	Angelou, Angelos
RP160704	Tucker, Haley O	University of Texas at Austin	Angelou, Angelos
RP160776	Schiavinato Eberlin, Livia	University of Texas at Austin	Angelou, Angelos
Applications not considered by the PIC or Oversight Committee			
RP160703*	Brekken, Rolf	The University of Texas Southwestern Medical Center	Prendergast, George
RP160703-AC*	Brekken, Rolf	The University of Texas Southwestern Medical Center	Prendergast, George
RP160703-C1*	Hwang, Tae Hyun	The University of Texas Southwestern Medical Center	Prendergast, George
RP160703-P1*	MacDonald, Raymond	The University of Texas Southwestern Medical Center	Prendergast, George
RP160703-P2*	Wilkie, Thomas	The University of Texas Southwestern Medical Center	Prendergast, George

* = Not discussed

Application ID	Applicant	Institution	Conflict Noted
RP160703-P3*	Brekken, Rolf	The University of Texas Southwestern Medical Center	Prendergast, George
RP160703-P4*	Boothman, David	The University of Texas Southwestern Medical Center	Prendergast, George
RP160767*	Ghosh, Rita	The University of Texas Health Science Center at San Antonio	Houchens, David
RP160768*	Srivenugopal, Kalkunte	Texas Tech University Health Sciences Center	Wang, Xiao-Fan
RP160774*	Li, Bing	The University of Texas Southwestern Medical Center	Petrini, John
RP160782*	Suh, Junghae	Rice University	Weitzman, Matthew
RP160835	Rosenberg, Susan	Baylor College of Medicine	Petrini, John
RP160835-AC	Rosenberg, Susan	Baylor College of Medicine	Petrini, John
RP160835-C1	Zong, Chenghang	Baylor College of Medicine	Petrini, John
RP160835-P1	Rosenberg, Susan	Baylor College of Medicine	Petrini, John
RP160835-P2	Miller, Kyle	The University of Texas at Austin	Petrini, John
RP160835-P3	Scott, Kenneth	Baylor College of Medicine	Petrini, John
RP160655*	Roth, Jack	The University of Texas M.D. Anderson Cancer Center	Bernstein, Bradley
RP160655-AC*	Roth, Jack	The University of Texas M.D. Anderson Cancer Center	Bernstein, Bradley
RP160655-C1*	Wang, Jing	The University of Texas M.D. Anderson Cancer Center	Bernstein, Bradley
RP160655-P1*	Wu, Xifeng	The University of Texas M.D. Anderson Cancer Center	Bernstein, Bradley
RP160655-P2*	Ji, Lin	The University of Texas M.D. Anderson Cancer Center	Bernstein, Bradley
RP160655-P3*	Calin, George	The University of Texas M.D. Anderson Cancer Center	Bernstein, Bradley

* = Not discussed

Application ID	Applicant	Institution	Conflict Noted
RP160705*	Orlowski, Robert	The University of Texas M.D. Anderson Cancer Center	Bernstein, Bradley
RP160739	Shi, Xiaobing	The University of Texas M.D. Anderson Cancer Center	Bernstein, Bradley
RP160760*	Sikora, Andrew	Baylor College of Medicine	Costello, Joseph; Wahl, Geoffrey
RP160765	Gregory, Carl	Texas A&M University Health Science Center	Fearon, Eric; Lawlor, Elizabeth
RP160769	Zhang, Xiang	Baylor College of Medicine	Greene, Geoffrey
RP160840	Rowley, David	Baylor College of Medicine	Greene, Geoffrey
RP160840-AC	Rowley, David	Baylor College of Medicine	Greene, Geoffrey
RP160840-C1	Mancini, Michael	Baylor College of Medicine	Greene, Geoffrey
RP160840-C2	Farach-Carson, Mary	Rice University	Greene, Geoffrey
RP160840-P1	Zhang, Xiang	Baylor College of Medicine	Greene, Geoffrey
RP160840-P2	Rowley, David	Baylor College of Medicine	Greene, Geoffrey
RP160840-P3	Weigel, Nancy	Baylor College of Medicine	Greene, Geoffrey
RP160856	Kim, Jung-whan	The University of Texas at Dallas	Werb, Zena
RP160661	Jiang, Steve	The University of Texas Southwestern Medical Center	Koong, Albert
RP160661-AC	Jiang, Steve	The University of Texas Southwestern Medical Center	Koong, Albert
RP160661-C1	Jiang, Steve	The University of Texas Southwestern Medical Center	Koong, Albert
RP160661-P1	Yang, Ming	The University of Texas Southwestern Medical Center	Koong, Albert
RP160661-P2	Jia, Xun	The University of Texas Southwestern Medical Center	Koong, Albert
RP160661-P3	Shao, Yiping	The University of Texas Southwestern Medical Center	Koong, Albert

* = Not discussed

Application ID	Applicant	Institution	Conflict Noted
RP160661-P4	Lu, Weigno	The University of Texas Southwestern Medical Center	Koong, Albert
RP160661-P5	Wang, Jing	The University of Texas Southwestern Medical Center	Koong, Albert
RP160663*	Li, Chun	The University of Texas M.D. Anderson Cancer Center	Engelhard, Victor
RP160663-AC*	Li, Chun	The University of Texas M.D. Anderson Cancer Center	Engelhard, Victor
RP160663-C1*	Overwijk, Willem	The University of Texas M.D. Anderson Cancer Center	Engelhard, Victor
RP160663-C2*	Piwnica-Worms, David	The University of Texas M.D. Anderson Cancer Center	Engelhard, Victor
RP160663-P1*	Liu, Jinsong	The University of Texas M.D. Anderson Cancer Center	Engelhard, Victor
RP160663-P2*	Sood, Anil	The University of Texas M.D. Anderson Cancer Center	Engelhard, Victor
RP160663-P3*	Li, Chun	The University of Texas M.D. Anderson Cancer Center	Engelhard, Victor
RP160672	Woodman, Scott	The University of Texas M.D. Anderson Cancer Center	Engelhard, Victor
RP160679*	Brugarolas, James	The University of Texas Southwestern Medical Center	Koong, Albert
RP160679-AC*	Brugarolas, James	The University of Texas Southwestern Medical Center	Koong, Albert
RP160679-C1*	Kapur, Payal	The University of Texas Southwestern Medical Center	Koong, Albert
RP160679-C2*	Xie, Xian-Jin	The University of Texas Southwestern Medical Center	Koong, Albert
RP160679-C3*	Pedrosa, Ivan	The University of Texas Southwestern Medical Center	Koong, Albert

* = Not discussed

Application ID	Applicant	Institution	Conflict Noted
RP160679-P1*	Brugarolas, James	The University of Texas Southwestern Medical Center	Koong, Albert
RP160679-P2*	Timmerman, Robert	The University of Texas Southwestern Medical Center	Koong, Albert
RP160679-P3*	Mani, Ram	The University of Texas Southwestern Medical Center	Koong, Albert
RP160693	Andreeff, Michael	The University of Texas M.D. Anderson Cancer Center	DePersio, John
RP160693-AC	Andreeff, Michael	The University of Texas M.D. Anderson Cancer Center	DePersio, John
RP160693-C1	Kornblau, Stephen	The University of Texas M.D. Anderson Cancer Center	DePersio, John
RP160693-C2	Andreeff, Michael	The University of Texas M.D. Anderson Cancer Center	DePersio, John
RP160693-C3	Do, Kim-Anh	The University of Texas M.D. Anderson Cancer Center	DePersio, John
RP160693-P1	Andreeff, Michael	The University of Texas M.D. Anderson Cancer Center	DePersio, John
RP160693-P2	Rezvani, Katy	The University of Texas M.D. Anderson Cancer Center	DePersio, John
RP160693-P3	Gottschalk, Stephen	Baylor College of Medicine	DePersio, John
RP160710	Symmans, William	The University of Texas M.D. Anderson Cancer Center	Grandis, Jennifer; Kast, W. Martin; Niedzwiecki, Donna
RP160710-AC	Symmans, William	The University of Texas M.D. Anderson Cancer Center	Grandis, Jennifer; Kast, W. Martin; Niedzwiecki, Donna
RP160710-C1	Moulder, Stacy	The University of Texas M.D. Anderson Cancer Center	Grandis, Jennifer; Kast, W. Martin; Niedzwiecki, Donna
RP160710-C2	Davies, Peter	Texas A&M University Health Science Center Institute of Biosciences and Technolofy	Grandis, Jennifer; Kast, W. Martin; Niedzwiecki, Donna

* = Not discussed

Application ID	Applicant	Institution	Conflict Noted
RP160710-C3	Symmans, William	The University of Texas M.D. Anderson Cancer Center	Grandis, Jennifer; Kast, W. Martin; Niedzwiecki, Donna
RP160710-P1	Thompson, Alastarr	The University of Texas M.D. Anderson Cancer Center	Grandis, Jennifer; Kast, W. Martin; Niedzwiecki, Donna
RP160710-P2	Hong, Mien-Chie	The University of Texas M.D. Anderson Cancer Center	Grandis, Jennifer; Kast, W. Martin; Niedzwiecki, Donna
RP160710-P3	Mani, Sendurai	The University of Texas M.D. Anderson Cancer Center	Grandis, Jennifer; Kast, W. Martin; Niedzwiecki, Donna
RP160724*	Story, Michael	The University of Texas Southwestern Medical Center	Koong, Albert
RP160724-AC*	Story, Michael	The University of Texas Southwestern Medical Center	Koong, Albert
RP160724-C1*	Saha, Debabrata	The University of Texas Southwestern Medical Center	Koong, Albert
RP160724-P1*	Story, Michael	The University of Texas Southwestern Medical Center	Koong, Albert
RP160724-P2*	Aroumougame, Asaithamby	The University of Texas Southwestern Medical Center	Koong, Albert
RP160724-P3*	Chen, Ping-Chi	The University of Texas Southwestern Medical Center	Koong, Albert
RP160724-P4*	Hannan, Raquibul	The University of Texas Southwestern Medical Center	Koong, Albert
RP160745	Reynolds, Charles	Texas Tech University Health Sciences Center	Kast, W. Martin
RP160745-AC	Reynolds, Charles	Texas Tech University Health Sciences Center	Kast, W. Martin
RP160745-C1	Rosen, Daniel	Baylor Research Institute	Kast, W. Martin
RP160745-C2	Becnel, Lauren	Baylor Research Institute	Kast, W. Martin
RP160745-P1	Reynolds, Charles	Texas Tech University Health Sciences Center	Kast, W. Martin
RP160745-P2	Wheeler, David	Baylor Research Institute	Kast, W. Martin

* = Not discussed

Application ID	Applicant	Institution	Conflict Noted
RP160745-P3	Kang, Min	Texas Tech University Health Sciences Center	Kast, W. Martin
RP160826	Fleming, Jason	The University of Texas M.D. Anderson Cancer Center	Prados, Michael
RP160843*	Chang, Jenny	The Methodist Hospital Research Institute	Curran, Walter
RP160864*	Wang, Rongfu	The Methodist Hospital Research Institute	Riddell, Stanley
RP160864-AC*	Wang, Rongfu	The Methodist Hospital Research Institute	Riddell, Stanley
RP160864-C1*	Liu, Xuewu	Houston Methodist	Riddell, Stanley
RP160864-C2*	Gee, Adrian	Baylor College of Medicine	Riddell, Stanley
RP160864-P1*	Shen, Haifa	Houston Methodist	Riddell, Stanley
RP160864-P2*	Wang, Rongfu	The Methodist Hospital Research Institute	Riddell, Stanley
RP160864-P3*	Rooney, Cliona	Baylor College of Medicine	Riddell, Stanley
RP160697*	Kundra, Vikas	The University of Texas M.D. Anderson Cancer Center	Johnson, G. Allan
RP160702	Mancini, Michael	Texas A&M University System Health Science Center	Basillion, James
RP160718	Betancourt, Tania	Texas State University-San Marcos	Berbeen, Ross
RP16074	Goodwin, James	The University of Texas Medical Branch at Galveston	Barlow, William
RP16074-AC	Goodwin, James	The University of Texas Medical Branch at Galveston	Barlow, William
RP16074-C1	Elting, Linda	The University of Texas M.D. Anderson Cancer Center	Barlow, William
RP16074-C2	Peterson, Susan	The University of Texas M.D. Anderson Cancer Center	Barlow, William
RP16074-C3	Kuo, Yong-Fang	The University of Texas Medical Branch at Galveston	Barlow, William
RP16074-P1	Goodwin, James	The University of Texas Medical Branch at Galveston	Barlow, William

* = Not discussed

Application ID	Applicant	Institution	Conflict Noted
RP16074-P2	Glordano, Sharon	The University of Texas M.D. Anderson Cancer Center	Barlow, William
RP16074-P3	Smith, Benjamin	The University of Texas M.D. Anderson Cancer Center	Barlow, William
RP16074-P4	Guadagnolo, Beverly	The University of Texas M.D. Anderson Cancer Center	Barlow, William
RP160735	DiGiovanni, John	The University of Texas at Austin	Barlow, William
RP160735-AC	DiGiovanni, John	The University of Texas at Austin	Barlow, William
RP160735-C1	Glickman, Randolph	The University of Texas Health Science Center at San Antonio	Barlow, William
RP160735-C2	Tiziani, Stefano	The University of Texas at Austin	Barlow, William
RP160735-C3	Gelfond, Jonathan	The University of Texas Health Science Center at San Antonio	Barlow, William
RP160735-P1	DiGiovanni, John	The University of Texas at Austin	Barlow, William
RP160735-P2	Slaga, Thomas	The University of Texas Health Science Center at San Antonio	Barlow, William
RP160735-P3	Kumar, Pratap	The University of Texas Health Science Center at San Antonio	Barlow, William
RP160735-P4	Thompson, Ian	The University of Texas Health Science Center at San Antonio	Barlow, William
RP160674	Goodwin, James	The University of Texas Medical Branch at Galveston	Barlow, William
RP160674-AC	Goodwin, James	The University of Texas Medical Branch at Galveston	Barlow, William
RP160674-C1	Elting, Linda	The University of Texas M.D. Anderson Cancer Center	Barlow, William
RP160674-C2	Peterson, Susan	The University of Texas M.D. Anderson Cancer Center	Barlow, William

Application ID	Applicant	Institution	Conflict Noted
RP160674-C3	Kuo, Yong-Fang	The University of Texas Medical Branch at Galveston	Barlow, William
RP160674-P1	Goodwin, James	The University of Texas Medical Branch at Galveston	Barlow, William
RP160674-P2	Giordano, Sharon	The University of Texas M.D. Anderson Cancer Center	Barlow, William
RP160674-P3	Smith, Benjamin	The University of Texas M.D. Anderson Cancer Center	Barlow, William
RP160674-P4	Guadagnolo, Beverly	The University of Texas M.D. Anderson Cancer Center	Barlow, William

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Basic Cancer Research-1

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PI/PI Name	Applicant/PI/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/14	RP160703	Brecken, Rolf	The University of Texas Southwestern Medical Center	Prendergast, George	Not Discussed	Thomas Doderin
3/14	RP160703-AC	Brecken, Rolf	The University of Texas Southwestern Medical Center	Prendergast, George	Not Discussed	Thomas Doderin
3/14	RP160703-C1	Hwang, Tae Hyun	The University of Texas Southwestern Medical Center	Prendergast, George	Not Discussed	Thomas Doderin
3/14	RP160703-P1	MacDonald, Raymond	The University of Texas Southwestern Medical Center	Prendergast, George	Not Discussed	Thomas Doderin
3/14	RP160703-P2	Wilkie, Thomas	The University of Texas Southwestern Medical Center	Prendergast, George	Not Discussed	Thomas Doderin

SRA Approval:

Name (PRINT):	THOMAS R. DODERIN
Signature:	
Date:	3/14/16

Comments:

--

* All SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Basic Cancer Research-1

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/14	RP160703-P3	Brekken, Rolf	The University of Texas Southwestern Medical Center	Prendergast, George	Not Discussed	JD
3/14	RP160703-P4	Bouthman, David	The University of Texas Southwestern Medical Center	Prendergast, George	Not Discussed	JD
3/14	RP160767	Ghosh, Rita	The University of Texas Health Science Center at San Antonio	Houchens, David	Not Discussed	JD
3/14	RP160768	Srivengopal, Kalkunte	Texas Tech University Health Sciences Center	Wang, Xiao-Fan	Not Discussed	

SRA Approval:

Name (PRINT):	THOMAS R. DOBETIN
Signature:	
Date:	3/14/16

Comments:

--

* An SRA Representative will add their name and initials to this form to acknowledge that the reviewer identified as a conflict of interest has signed this form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission





Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Basic Cancer Research-2

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PI/PI Name	Applicant/PI/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/16	RP160774	Li, Bing	The University of Texas Southwestern Medical Center	Perrin, John		JP
3/16	RP160782	Suh, Junghae	Rice University	Weizman, Matthew		MD
3/16	RP160835	Rosenberg, Susan	Baylor College of Medicine	Perrin, John		JP
3/16	RP160835-AC	Rosenberg, Susan	Baylor College of Medicine	Perrin, John		JP
3/16	RP160835-C1	Zang, Chenfeng	Taylor College of Medicine	Perrin, John		JP

SRA Approval:

Comments:

Name (PRINT):	THOMAS R. DOVELIN
Signature:	
Date:	3/16/16

Comments:

* As SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified no conflict of interest has signed the form and left the panel room during the discussion of the application.




Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Basic Cancer Research-2
Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PI/PI Name	Applicant/PI/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/16	RP160835-P1	Rosenberg, Susan	Baylor College of Medicine	Petrini, John		JP
3/16	RP160835-P2	Muller, Kyle	The University of Texas at Austin	Petrini, John		JP
3/16	RP160835-P3	Scott, Kenneth	Baylor College of Medicine	Petrini, John		JP

SRA Approvals:

Name (PRINT):	THOMAS R. DODDIN
Signature:	
Date:	3/16/16

Comments:

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Cancer Biology

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials ^a
3/15	RP160655	Roth, Jack	The University of Texas M. D. Anderson Cancer Center	Bernstein, Bradley	Not Discussed NB	JD
3/15	RP160655-AC	Roth, Jack	The University of Texas M. D. Anderson Cancer Center	Bernstein, Bradley	Not Discussed NB	JD
3/15	RP160655-C1	Wang, Jing	The University of Texas M. D. Anderson Cancer Center	Bernstein, Bradley	Not Discussed NB	JD
3/15	RP160655-P1	Wu, Xifeng	The University of Texas M. D. Anderson Cancer Center	Bernstein, Bradley	Not Discussed NB	JD
3/15	RP160655-P2	Ji, Lin	The University of Texas M. D. Anderson Cancer Center	Bernstein, Bradley	Not Discussed NB	JD

SRA Approval:

Name (PRINT)	THOMAS R. DOVECLIN
Signature	
Date	3/15/16

Comments:

--

^a As SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Cancer Biology

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PO/PI Name	Applicant/PO/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/15	RP160655-P3	Calin, George	The University of Texas M. D. Anderson Cancer Center	Bernstein, Bradley	<i>Not Discussed</i>	<i>JD</i>
3/15	RP160705	Orlowski, Robert	The University of Texas M. D. Anderson Cancer Center	Bernstein, Bradley	<i>Not Discussed</i>	<i>JD</i>
3/15	RP160739	Shi, Xiaobing	The University of Texas M. D. Anderson Cancer Center	Bernstein, Bradley	<i>Not Discussed</i> <i>Not Discussed</i>	<i>JD</i>
3/15	RP160760	Sikora, Andrew	Baylor College of Medicine	Costello, Joseph	<i>Not Discussed</i>	<i>JD</i>
3/15	RP160760	Sikora, Andrew	Baylor College of Medicine	Wahl, Geoffrey	<i>Not Discussed</i>	<i>JD</i>

SRA Approval:

Name (PRINT):	THOMAS R. DOELIN
Signature:	<i>[Signature]</i>
Date:	3/15/16

Comments:

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.





Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Cancer Biology

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/15	RP160765	Gregory, Carl	Texas A&M University System Health Science Center	Fearon, Eric		EF
3/15	RP160765	Gregory, Carl	Texas A&M University System Health Science Center	Lawlor, Elizabeth		EL
3/15	RP160769	Zhang, Xiang	Baylor College of Medicine	Groene, Geoffrey		GG
3/15	RP160840	Rowley, David	Baylor College of Medicine	Groene, Geoffrey		GG
3/15	RP160840-AC	Rowley, David	Baylor College of Medicine	Groene, Geoffrey		GG

SRA Approval:

Name (PRINT):	THOMAS R. DODELIN
Signature:	
Date:	3/15/16

Comments:

--

* As SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.





Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Cancer Biology

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PI/PI Name	Applicant/PI/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/15	RP160840-C1	Mancho, Michael	Baylor College of Medicine	Greene, Geoffrey		GD
3/15	RP160840-C2	Farach-Carson, Mury	Rice University	Greene, Geoffrey		GD
3/15	RP160840-P1	Zhang, Xiang	Baylor College of Medicine	Greene, Geoffrey		GD
3/15	RP160840-P2	Rowley, David	Baylor College of Medicine	Greene, Geoffrey		GD
3/15	RP160840-P3	Weigel, Nancy	Baylor College of Medicine	Greene, Geoffrey		GD

SRA Approval:

Name (PRINT):	THOMAS R. DODELIN
Signature:	
Date:	3/15/16

Comments:

--

* As SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Cancer Biology

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PI Name	Applicant/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/15	RPI60856	Kim, Jung-whan	The University of Texas at Dallas	Werb, Zena	<i>Not Discussed</i>	<i>JD</i>

SRA Approval:

Name (PRINT)	THOMAS R. DODELIN	
Signature	<i>Thomas R. Dodelin</i>	
Date	5/15/16	

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document






Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10/16	RP160661	Jiang, Steve	The University of Texas Southwestern Medical Center	Koong, Albert		BM Brendan Morales
3/10/16	RP160661-A1	Jiang, Steve	The University of Texas Southwestern Medical Center	Koong, Albert		BM Brendan Morales
3/10/16	RP160661-C1	Jiang, Steve	The University of Texas Southwestern Medical Center	Koong, Albert		BM Brendan Morales
3/10/16	RP160661-P1	Yang, Ming	The University of Texas Southwestern Medical Center	Koong, Albert		BM Brendan Morales
3/10/16	RP160661-P2	Jia, Xun	The University of Texas Southwestern Medical Center	Koong, Albert		BM Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature	
Date	3/10/16

Comments:

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document




Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PI/PI Name	Applicant/PI/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10/16	RP160661-P3	Shao, Yiping	The University of Texas Southwestern Medical Center	Koong, Albert		BM Brendan Morales
3/10/16	RP160661-P4	Lu, Weiguo	The University of Texas Southwestern Medical Center	Koong, Albert		BM Brendan Morales
3/10/16	RP160661-P5	Wang, Jing	The University of Texas Southwestern Medical Center	Koong, Albert		BM Brendan Morales
3/10/16	RP160663	Li, Chun	The University of Texas M. D. Anderson Cancer Center	Engelhard, Victor	NOT DISCUSSED	BM Brendan Morales
3/10/16	RP160663-AC	Li, Chun	The University of Texas M. D. Anderson Cancer Center	Engelhard, Victor	NOT DISCUSSED	BM Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature	
Date	3/14/16

Comments:

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs


Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications.

Date	Application Number	Applicant/PI/PI Name	Applicant/PI/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10	RP160663-C1	Overwijk, Willem	The University of Texas M. D. Anderson Cancer Center	Engelhard, Victor	NOT DISCUSSED	BM Brendan Morales
3/10	RP160663-C2	Piwnicka-Worms, David	The University of Texas M. D. Anderson Cancer Center	Engelhard, Victor	NOT DISCUSSED	BM Brendan Morales
3/10	RP160663-P1	Liu, Jinsong	The University of Texas M. D. Anderson Cancer Center	Engelhard, Victor	NOT DISCUSSED	BM Brendan Morales
3/10	RP160663-P2	Sund, Aril	The University of Texas M. D. Anderson Cancer Center	Engelhard, Victor	NOT DISCUSSED	BM Brendan Morales
3/10	RP160663-P3	Li, Chun	The University of Texas M. D. Anderson Cancer Center	Engelhard, Victor	NOT DISCUSSED	BM Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature	
Date	3/14/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the applications.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10	RP160672	Woodman, Scott	The University of Texas M. D. Anderson Cancer Center	Engelhard, Victor	<i>[Signature]</i>	BM Brendan Morales
3/10	RP160679	Brugarolas, James	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales
3/10	RP160679-AC	Brugarolas, James	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales
3/10	RP160679-C1	Kapur, Payal	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales
3/10	RP160679-C2	Xie, Xian-Jun	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature	<i>[Signature]</i>
Date	3/14/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document


Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following application:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10	RP160679-C3	Pedrosa, Ivan	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales
3/10	RP160679-P1	Brugarolas, James	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales
3/10	RP160679-P2	Timmerman, Robert	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales
3/10	RP160679-P3	Mani, Ram	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales
3/10	RP160693	Andreeff, Michael	The University of Texas M. D. Anderson Cancer Center	DiPersio, John		BM Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature	
Date	3/14/16

Comments:

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document






Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10	RP160693-AC	Andreeff, Michael	The University of Texas M. D. Anderson Cancer Center	DiPersio, John		BM Brendan Morales
3/10	RP160693-C1	Kornblau, Stephen	The University of Texas M. D. Anderson Cancer Center	DiPersio, John		BM Brendan Morales
3/10	RP160693-C2	Andreeff, Michael	The University of Texas M. D. Anderson Cancer Center	DiPersio, John		BM Brendan Morales
3/10	RP160693-C3	Do, Kim-Anh	The University of Texas M. D. Anderson Cancer Center	DiPersio, John		BM Brendan Morales
3/10	RP160693-P1	Andreeff, Michael	The University of Texas M. D. Anderson Cancer Center	DiPersio, John		BM Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature	
Date	3/14/16

Comments:

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document






Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10	RP160693-P2	Rezvani, Katy	The University of Texas M. D. Anderson Cancer Center	DiPersio, John		BM Brendan Morales
3/10	RP160693-P3	Gottschalk, Stephen	Baylor College of Medicine	DiPersio, John		BM Brendan Morales
3/10	RP160710	Symmans, William	The University of Texas M. D. Anderson Cancer Center	Grandis, Jennifer		VERIFIED TELEPHONICALLY
3/10	RP160710	Symmans, William	The University of Texas M. D. Anderson Cancer Center	Kast, W. Martin		BM Brendan Morales
3/10	RP160710	Symmans, William	The University of Texas M. D. Anderson Cancer Center	Niedzwiecki, Donna		BM Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature	
Date	3/14/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10	RP160710-A1	Symmans, William	The University of Texas M. D. Anderson Cancer Center	Grandis, Jennifer	<i>Donna Niedzwiecki</i>	BM Brendan Morales
3/10	RP160710-A1	Symmans, William	The University of Texas M. D. Anderson Cancer Center	Kast, W. Martin	<i>W. Martin Kast</i>	BM Brendan Morales
3/10	RP160710-A1	Symmans, William	The University of Texas M. D. Anderson Cancer Center	Niedzwiecki, Donna	<i>Donna Niedzwiecki</i>	BM Brendan Morales
3/10	RP160710-C1	Moulder, Stacy	The University of Texas M. D. Anderson Cancer Center	Kast, W. Martin	<i>W. Martin Kast</i>	BM Brendan Morales
3/10	RP160710-C1	Moulder, Stacy	The University of Texas M. D. Anderson Cancer Center	Niedzwiecki, Donna	<i>Donna Niedzwiecki</i>	BM Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature	<i>B. Morales</i>
Date	3/14/16

Comments:

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document





Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10	RP160710-C2	Davies, Peter	Texas A&M University Health Science Center Institute of Biosciences and Technology	Karl W. Martin		BH Brendan Morales
3/10	RP160710-C2	Davies, Peter	Texas A&M University Health Science Center Institute of Biosciences and Technology	Niedzwiecki, Donna		BH Brendan Morales
3/10	RP160710-C3	Symmans, William	The University of Texas M. D. Anderson Cancer Center	Karl W. Martin		BH Brendan Morales
3/10	RP160710-C3	Symmans, William	The University of Texas M. D. Anderson Cancer Center	Niedzwiecki, Donna		BH Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature	
Date	3/14/16

Comments:

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document






Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10	RP160710-P1	Thompson, Alastair	The University of Texas M. D. Anderson Cancer Center	Kast, W. Martin		BN Brendan Morales
3/10	RP160710-P1	Thompson, Alastair	The University of Texas M. D. Anderson Cancer Center	Niedzwiecki, Donna		BN Brendan Morales
3/10	RP160710-P2	Hung, Mien-Chie	The University of Texas M. D. Anderson Cancer Center	Kast, W. Martin		BN Brendan Morales
3/10	RP160710-P2	Hung, Mien-Chie	The University of Texas M. D. Anderson Cancer Center	Niedzwiecki, Donna		BN Brendan Morales
3/10	RP160710-P3	Mani, Sendurai	The University of Texas M. D. Anderson Cancer Center	Kast, W. Martin		BN Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature	
Date	3/14/16

Comments:

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10	RP160710-P3	Mani, Sundurai	The University of Texas M. D. Anderson Cancer Center	Niedzwiecki, Donna	<i>Donna Niedzwiecki</i>	BM Brendan Morales
3/10	RP160724	Story, Michael	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales
3/10	RP160724-AC	Story, Michael	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales
3/10	RP160724-C1	Saha, Debabrata	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales
3/10	RP160724-P1	Story, Michael	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature:	<i>Brendan Morales</i>
Date	3/14/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document



Do not copy or circulate without written permission

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10	RP160724-P2	Aroumougaie, Asathambhy	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales
3/10	RP160724-P3	Chen, Ping-Chi	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales
3/10	RP160724-P4	Hannan, Raquibul	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales
3/10	RP160745	Reynolds, Charles	Texas Tech University Health Sciences Center	Kast, W. Martin		BM Brendan Morales
3/10	RP160745-AC	Reynolds, Charles	Texas Tech University Health Sciences Center	Kast, W. Martin		BM Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature	
Date	3/14/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document






Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10	RP160745-C1	Rosen, Daniel	Baylor Research Institute	Kast, W. Martin		BM Brendan Morales
3/10	RP160745-C2	Beckel, Lauren	Baylor Research Institute	Kast, W. Martin		BM Brendan Morales
3/10	RP160745-P1	Reynolds, Charles	Texas Tech University Health Sciences Center	Kast, W. Martin		BM Brendan Morales
3/10	RP160745-P2	Wheeler, David	Baylor Research Institute	Kast, W. Martin		BM Brendan Morales
3/10	RP160745-P3	Kang, Min	Texas Tech University Health Sciences Center	Kast, W. Martin		BM Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature	
Date	3/14/16

Comments:

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10	RP160826	Fleming, Jason	The University of Texas M. D. Anderson Cancer Center	Prados, Michael	<i>Michael Prados</i>	BRM Brendan Morales
3/10	RP160843	Chang, Jenny	The Methodist Hospital Research Institute	Curran, Walter	NOT DISCUSSED	BM Brendan Morales
3/10	RP160864	Wang, Rongfu	The Methodist Hospital Research Institute	Riddell, Stanley	NOT DISCUSSED	BM Brendan Morales
3/10	RP160864-A1	Wang, Rongfu	The Methodist Hospital Research Institute	Riddell, Stanley	NOT DISCUSSED	BM Brendan Morales
3/10	RP160864-C1	Liu, Xuewu	Houston Methodist	Riddell, Stanley	NOT DISCUSSED	BM Brendan Morales

SRA Approval:

Name (PRINT):	Brendan Morales
Signature	<i>Brendan Morales</i>
Date	3/14/16

Comments:

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PI/PI Name	Applicant/PI/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10	RP160864-C2	Gee, Adrian	Baylor College of Medicine	Riddell, Stanley	NOT DISCUSSED	BM Brendan Morales
3/10	RP160864-P1	Shen, Haifa	Houston Methodist	Riddell, Stanley	NOT DISCUSSED	BM Brendan Morales
3/10	RP160864-P2	Wang, Rongli	The Methodist Hospital Research Institute	Riddell, Stanley	NOT DISCUSSED	BM Brendan Morales
3/10	RP160864-P3	Rooney, Cherie	Baylor College of Medicine	Riddell, Stanley	NOT DISCUSSED	BM Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature	
Date	3/14/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*

SRA Approval:

Name (PRINT):	Brenda Morales
Signature	
Date:	3/14/16

Comments:

--

* An SRA Representative will add their name and initials to this form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document



Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Imaging Technology and Informatics

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PO/PI Name	Applicant/PO/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/11/16	RP160697	Kundra, Vikas	The University of Texas M. D. Anderson Cancer Center	Johnson, G. Allan	NOT DISCUSSED	BM Brendan Morales
3/11/16	RP160702	Mancini, Michael	Texas A&M University System Health Science Center	Basilion, James		BM Brendan Morales
3/11/16	RP160718	Betancourt, Tania	Texas State University - San Marcos	Berbeco, Russ		BM Brendan Morales

SRA Approval:

Name (PRINT):	Brendan Morales
Signature:	
Date:	3/11/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Imaging Technology and Informatics

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*

SRA Approval:

Name (PRINT)	Brendan Mocalles
Signature	
Date	3/14/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Scientific Review Council Meeting

Meeting Type: Teleconference Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*

SRA Approval:

Name (PRINT):	Katia E. Garcia Crespo
Signature:	Katia E. Garcia Crespo
Date:	03-29-16

Comments:

NO COIs

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Cancer Prevention Research


Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/Pb/PI Name	Applicant/Pb/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/9/16	RP160674	Goodwin, James	The University of Texas Medical Branch at Galveston	Barlow, William	Verified Telephonically by SRA	Liz Spinks [Signature]
3/9/16	RP160674-AC	Goodwin, James	The University of Texas Medical Branch at Galveston	Barlow, William	Verified Telephonically by SRA	Liz Spinks [Signature]
3/9/16	RP160674-C1	Eiting, Linda	The University of Texas M. D. Anderson Cancer Center	Barlow, William	Verified Telephonically by SRA	Liz Spinks [Signature]
3/9/16	RP160674-C2	Peterson, Susan	The University of Texas M. D. Anderson Cancer Center	Barlow, William	Verified Telephonically by SRA	Liz Spinks [Signature]
3/9/16	RP160674-C3	Kuo, Yong-Fang	The University of Texas Medical Branch at Galveston	Barlow, William	Verified Telephonically by SRA	Liz Spinks [Signature]

SKA Approved:

Comments:

Name (PRINT):	LIZ SPINKS
Signature:	
Date:	3/9/16

* An SPA Remittance will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and led the panel from during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.


Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Research Programs
Panel: 16.2 Cancer Prevention Research
Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/9/16	RP160674-P1	Goodwin, James	The University of Texas Medical Branch at Galveston	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS
3/9/16	RP160674-P2	Chiodaro, Sharon	The University of Texas M. D. Anderson Cancer Center	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS
3/9/16	RP160674-P3	Smith, Benjamin	The University of Texas M. D. Anderson Cancer Center	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS
3/9/16	RP160674-P4	Guadagnolo, Beverly	The University of Texas M. D. Anderson Cancer Center	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS
3/9/16	RP160735	Djiliovanni, John	The University of Texas at Austin	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS

SRA Approval:

Comments:

Name (PRINT)	LIZ SPINKS	
Signature		
Date	3/9/16	

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Cancer Prevention Research


Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/9/16	RP160735-AC	DIGIOVANNI, John	The University of Texas at Austin	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS SS
3/9/16	RP160735-C1	Clickman, Randolph	The University of Texas Health Science Center at San Antonio	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS SS
3/9/16	RP160735-C2	Fizient, Stefano	The University of Texas at Austin	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS SS
3/9/16	RP160735-C3	Gellford, Jonathan	The University of Texas Health Science Center at San Antonio	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS SS
3/9/16	RP160735-P1	Digiovanni, John	The University of Texas at Austin	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS SS

SRA Approval:

Comments:

Name (PRINT):	LIZ SPINKS
Signature:	
Date:	3/9/16

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Cancer Prevention Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/9/16	RP160735-P2	Shiga, Thomas	The University of Texas Health Science Center at San Antonio	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS <i>[Signature]</i>
3/9/16	RP160735-P3	Kumar, Pratap	The University of Texas Health Science Center at San Antonio	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS <i>[Signature]</i>
3/9/16	RP160735-P4	Thompson, Ian	The University of Texas Health Science Center at San Antonio	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS <i>[Signature]</i>

SRA Approval:

Name (PRINT)	LIZ SPINCKS
Signature:	
Date:	3/9/16

Comments



* An IFA Representative will hold their name and initials in the form in acknowledgment that the reviewer identified as a conflict of interest has signed the form and left the post room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Cancer Prevention Research


Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PI/PI Name	Applicant/PI/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*

SRA Approval:

Comments:

Name (PRINT):	LIZ SPINKS	
Signature:		
Date:	3/9/14	

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Conflict of Interest Disclosure
Academic Research Recruitment Cycle 16.10
(Academic Research Recruitment Cycle 16.10
Awards Announced at August 17, 2016, Oversight Committee Meeting)

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Recruitment Cycle 16.10 include *Recruitment of Established Investigators*; *Recruitment of Rising Stars*; and *Recruitment of First-Time, Tenure-Track Faculty Members*. All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC. COI information used for this table was collected by SRA International, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant	Institution	Conflict Noted
Applications considered by the PIC and Oversight Committee			
No conflicts reported.			
Applications not considered by the PIC or Oversight Committee			
RR160074	Fitz, John	The University of Texas Southwestern Medical Center	Sellers, Thomas

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Recruitment Programs


Panel: Recruitment FY16 Cycle 10

Meeting Type: Teleconference Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
5/26	RR160074	Fitz, John	The University of Texas Southwestern Medical Center	Sellers, Thomas	VERIFIED TELEPHONICALLY BY SRA	Brendan Morales BRM

SRA Approval:

Name (PRINT):	BRENDAN MORALES
Signature:	
Date:	5/26/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Recruitment Programs


Panel: Recruitment FY16 Cycle 10

Meeting Type: Teleconference Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*

SRA Approval:

Name (PRINT):	BRENDAN MORALES
Signature:	
Date:	5/26/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Conflicts of Interest Disclosure
Academic Research Cycle 16.2 Applications
(Academic Research Cycle 16.2 Awards Announced at May 18, 2016, and August 17, 2016,
Oversight Committee Meetings)

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Academic Research Cycle 16.2 include *High Impact/High Risk Research Awards*, *Core Facilities Support Awards*, and *Multi-Investigator Research Awards*. All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC. COI information used for this table was collected by SRA International, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant	Institution	Conflict Noted
Applications considered by the PIC and Oversight Committee			
RP160657	Dalby, Kevin N	University of Texas at Austin	Angelou, Angelos
RP160704	Tucker, Haley O	University of Texas at Austin	Angelou, Angelos
RP160776	Schiavinato Eberlin, Livia	University of Texas at Austin	Angelou, Angelos
Applications not considered by the PIC or Oversight Committee			
RP160703*	Brekken, Rolf	The University of Texas Southwestern Medical Center	Prendergast, George
RP160703-AC*	Brekken, Rolf	The University of Texas Southwestern Medical Center	Prendergast, George
RP160703-C1*	Hwang, Tae Hyun	The University of Texas Southwestern Medical Center	Prendergast, George
RP160703-P1*	MacDonald, Raymond	The University of Texas Southwestern Medical Center	Prendergast, George
RP160703-P2*	Wilkie, Thomas	The University of Texas Southwestern Medical Center	Prendergast, George

* = Not discussed

Application ID	Applicant	Institution	Conflict Noted
RP160703-P3*	Brekken, Rolf	The University of Texas Southwestern Medical Center	Prendergast, George
RP160703-P4*	Boothman, David	The University of Texas Southwestern Medical Center	Prendergast, George
RP160767*	Ghosh, Rita	The University of Texas Health Science Center at San Antonio	Houchens, David
RP160768*	Srivenugopal, Kalkunte	Texas Tech University Health Sciences Center	Wang, Xiao-Fan
RP160774*	Li, Bing	The University of Texas Southwestern Medical Center	Petrini, John
RP160782*	Suh, Junghae	Rice University	Weitzman, Matthew
RP160835	Rosenberg, Susan	Baylor College of Medicine	Petrini, John
RP160835-AC	Rosenberg, Susan	Baylor College of Medicine	Petrini, John
RP160835-C1	Zong, Chenghang	Baylor College of Medicine	Petrini, John
RP160835-P1	Rosenberg, Susan	Baylor College of Medicine	Petrini, John
RP160835-P2	Miller, Kyle	The University of Texas at Austin	Petrini, John
RP160835-P3	Scott, Kenneth	Baylor College of Medicine	Petrini, John
RP160655*	Roth, Jack	The University of Texas M.D. Anderson Cancer Center	Bernstein, Bradley
RP160655-AC*	Roth, Jack	The University of Texas M.D. Anderson Cancer Center	Bernstein, Bradley
RP160655-C1*	Wang, Jing	The University of Texas M.D. Anderson Cancer Center	Bernstein, Bradley
RP160655-P1*	Wu, Xifeng	The University of Texas M.D. Anderson Cancer Center	Bernstein, Bradley
RP160655-P2*	Ji, Lin	The University of Texas M.D. Anderson Cancer Center	Bernstein, Bradley
RP160655-P3*	Calin, George	The University of Texas M.D. Anderson Cancer Center	Bernstein, Bradley

* = Not discussed

Application ID	Applicant	Institution	Conflict Noted
RP160705*	Orlowski, Robert	The University of Texas M.D. Anderson Cancer Center	Bernstein, Bradley
RP160739	Shi, Xiaobing	The University of Texas M.D. Anderson Cancer Center	Bernstein, Bradley
RP160760*	Sikora, Andrew	Baylor College of Medicine	Costello, Joseph; Wahl, Geoffrey
RP160765	Gregory, Carl	Texas A&M University Health Science Center	Fearon, Eric; Lawlor, Elizabeth
RP160769	Zhang, Xiang	Baylor College of Medicine	Greene, Geoffrey
RP160840	Rowley, David	Baylor College of Medicine	Greene, Geoffrey
RP160840-AC	Rowley, David	Baylor College of Medicine	Greene, Geoffrey
RP160840-C1	Mancini, Michael	Baylor College of Medicine	Greene, Geoffrey
RP160840-C2	Farach-Carson, Mary	Rice University	Greene, Geoffrey
RP160840-P1	Zhang, Xiang	Baylor College of Medicine	Greene, Geoffrey
RP160840-P2	Rowley, David	Baylor College of Medicine	Greene, Geoffrey
RP160840-P3	Weigel, Nancy	Baylor College of Medicine	Greene, Geoffrey
RP160856	Kim, Jung-whan	The University of Texas at Dallas	Werb, Zena
RP160661	Jiang, Steve	The University of Texas Southwestern Medical Center	Koong, Albert
RP160661-AC	Jiang, Steve	The University of Texas Southwestern Medical Center	Koong, Albert
RP160661-C1	Jiang, Steve	The University of Texas Southwestern Medical Center	Koong, Albert
RP160661-P1	Yang, Ming	The University of Texas Southwestern Medical Center	Koong, Albert
RP160661-P2	Jia, Xun	The University of Texas Southwestern Medical Center	Koong, Albert
RP160661-P3	Shao, Yiping	The University of Texas Southwestern Medical Center	Koong, Albert

* = Not discussed

Application ID	Applicant	Institution	Conflict Noted
RP160661-P4	Lu, Weigno	The University of Texas Southwestern Medical Center	Koong, Albert
RP160661-P5	Wang, Jing	The University of Texas Southwestern Medical Center	Koong, Albert
RP160663*	Li, Chun	The University of Texas M.D. Anderson Cancer Center	Engelhard, Victor
RP160663-AC*	Li, Chun	The University of Texas M.D. Anderson Cancer Center	Engelhard, Victor
RP160663-C1*	Overwijk, Willem	The University of Texas M.D. Anderson Cancer Center	Engelhard, Victor
RP160663-C2*	Piwnica-Worms, David	The University of Texas M.D. Anderson Cancer Center	Engelhard, Victor
RP160663-P1*	Liu, Jinsong	The University of Texas M.D. Anderson Cancer Center	Engelhard, Victor
RP160663-P2*	Sood, Anil	The University of Texas M.D. Anderson Cancer Center	Engelhard, Victor
RP160663-P3*	Li, Chun	The University of Texas M.D. Anderson Cancer Center	Engelhard, Victor
RP160672	Woodman, Scott	The University of Texas M.D. Anderson Cancer Center	Engelhard, Victor
RP160679*	Brugarolas, James	The University of Texas Southwestern Medical Center	Koong, Albert
RP160679-AC*	Brugarolas, James	The University of Texas Southwestern Medical Center	Koong, Albert
RP160679-C1*	Kapur, Payal	The University of Texas Southwestern Medical Center	Koong, Albert
RP160679-C2*	Xie, Xian-Jin	The University of Texas Southwestern Medical Center	Koong, Albert
RP160679-C3*	Pedrosa, Ivan	The University of Texas Southwestern Medical Center	Koong, Albert

* = Not discussed

Application ID	Applicant	Institution	Conflict Noted
RP160679-P1*	Brugarolas, James	The University of Texas Southwestern Medical Center	Koong, Albert
RP160679-P2*	Timmerman, Robert	The University of Texas Southwestern Medical Center	Koong, Albert
RP160679-P3*	Mani, Ram	The University of Texas Southwestern Medical Center	Koong, Albert
RP160693	Andreeff, Michael	The University of Texas M.D. Anderson Cancer Center	DePersio, John
RP160693-AC	Andreeff, Michael	The University of Texas M.D. Anderson Cancer Center	DePersio, John
RP160693-C1	Kornblau, Stephen	The University of Texas M.D. Anderson Cancer Center	DePersio, John
RP160693-C2	Andreeff, Michael	The University of Texas M.D. Anderson Cancer Center	DePersio, John
RP160693-C3	Do, Kim-Anh	The University of Texas M.D. Anderson Cancer Center	DePersio, John
RP160693-P1	Andreeff, Michael	The University of Texas M.D. Anderson Cancer Center	DePersio, John
RP160693-P2	Rezvani, Katy	The University of Texas M.D. Anderson Cancer Center	DePersio, John
RP160693-P3	Gottschalk, Stephen	Baylor College of Medicine	DePersio, John
RP160710	Symmans, William	The University of Texas M.D. Anderson Cancer Center	Grandis, Jennifer; Kast, W. Martin; Niedzwiecki, Donna
RP160710-AC	Symmans, William	The University of Texas M.D. Anderson Cancer Center	Grandis, Jennifer; Kast, W. Martin; Niedzwiecki, Donna
RP160710-C1	Moulder, Stacy	The University of Texas M.D. Anderson Cancer Center	Grandis, Jennifer; Kast, W. Martin; Niedzwiecki, Donna
RP160710-C2	Davies, Peter	Texas A&M University Health Science Center Institute of Biosciences and Technolofy	Grandis, Jennifer; Kast, W. Martin; Niedzwiecki, Donna

* = Not discussed

Application ID	Applicant	Institution	Conflict Noted
RP160710-C3	Symmans, William	The University of Texas M.D. Anderson Cancer Center	Grandis, Jennifer; Kast, W. Martin; Niedzwiecki, Donna
RP160710-P1	Thompson, Alastarr	The University of Texas M.D. Anderson Cancer Center	Grandis, Jennifer; Kast, W. Martin; Niedzwiecki, Donna
RP160710-P2	Hong, Mien-Chie	The University of Texas M.D. Anderson Cancer Center	Grandis, Jennifer; Kast, W. Martin; Niedzwiecki, Donna
RP160710-P3	Mani, Sendurai	The University of Texas M.D. Anderson Cancer Center	Grandis, Jennifer; Kast, W. Martin; Niedzwiecki, Donna
RP160724*	Story, Michael	The University of Texas Southwestern Medical Center	Koong, Albert
RP160724-AC*	Story, Michael	The University of Texas Southwestern Medical Center	Koong, Albert
RP160724-C1*	Saha, Debabrata	The University of Texas Southwestern Medical Center	Koong, Albert
RP160724-P1*	Story, Michael	The University of Texas Southwestern Medical Center	Koong, Albert
RP160724-P2*	Aroumougame, Asaithamby	The University of Texas Southwestern Medical Center	Koong, Albert
RP160724-P3*	Chen, Ping-Chi	The University of Texas Southwestern Medical Center	Koong, Albert
RP160724-P4*	Hannan, Raquibul	The University of Texas Southwestern Medical Center	Koong, Albert
RP160745	Reynolds, Charles	Texas Tech University Health Sciences Center	Kast, W. Martin
RP160745-AC	Reynolds, Charles	Texas Tech University Health Sciences Center	Kast, W. Martin
RP160745-C1	Rosen, Daniel	Baylor Research Institute	Kast, W. Martin
RP160745-C2	Becnel, Lauren	Baylor Research Institute	Kast, W. Martin
RP160745-P1	Reynolds, Charles	Texas Tech University Health Sciences Center	Kast, W. Martin
RP160745-P2	Wheeler, David	Baylor Research Institute	Kast, W. Martin

* = Not discussed

Application ID	Applicant	Institution	Conflict Noted
RP160745-P3	Kang, Min	Texas Tech University Health Sciences Center	Kast, W. Martin
RP160826	Fleming, Jason	The University of Texas M.D. Anderson Cancer Center	Prados, Michael
RP160843*	Chang, Jenny	The Methodist Hospital Research Institute	Curran, Walter
RP160864*	Wang, Rongfu	The Methodist Hospital Research Institute	Riddell, Stanley
RP160864-AC*	Wang, Rongfu	The Methodist Hospital Research Institute	Riddell, Stanley
RP160864-C1*	Liu, Xuewu	Houston Methodist	Riddell, Stanley
RP160864-C2*	Gee, Adrian	Baylor College of Medicine	Riddell, Stanley
RP160864-P1*	Shen, Haifa	Houston Methodist	Riddell, Stanley
RP160864-P2*	Wang, Rongfu	The Methodist Hospital Research Institute	Riddell, Stanley
RP160864-P3*	Rooney, Cliona	Baylor College of Medicine	Riddell, Stanley
RP160697*	Kundra, Vikas	The University of Texas M.D. Anderson Cancer Center	Johnson, G. Allan
RP160702	Mancini, Michael	Texas A&M University System Health Science Center	Basillion, James
RP160718	Betancourt, Tania	Texas State University-San Marcos	Berbeen, Ross
RP16074	Goodwin, James	The University of Texas Medical Branch at Galveston	Barlow, William
RP16074-AC	Goodwin, James	The University of Texas Medical Branch at Galveston	Barlow, William
RP16074-C1	Elting, Linda	The University of Texas M.D. Anderson Cancer Center	Barlow, William
RP16074-C2	Peterson, Susan	The University of Texas M.D. Anderson Cancer Center	Barlow, William
RP16074-C3	Kuo, Yong-Fang	The University of Texas Medical Branch at Galveston	Barlow, William
RP16074-P1	Goodwin, James	The University of Texas Medical Branch at Galveston	Barlow, William

* = Not discussed

Application ID	Applicant	Institution	Conflict Noted
RP16074-P2	Glordano, Sharon	The University of Texas M.D. Anderson Cancer Center	Barlow, William
RP16074-P3	Smith, Benjamin	The University of Texas M.D. Anderson Cancer Center	Barlow, William
RP16074-P4	Guadagnolo, Beverly	The University of Texas M.D. Anderson Cancer Center	Barlow, William
RP160735	DiGiovanni, John	The University of Texas at Austin	Barlow, William
RP160735-AC	DiGiovanni, John	The University of Texas at Austin	Barlow, William
RP160735-C1	Glickman, Randolph	The University of Texas Health Science Center at San Antonio	Barlow, William
RP160735-C2	Tiziani, Stefano	The University of Texas at Austin	Barlow, William
RP160735-C3	Gelfond, Jonathan	The University of Texas Health Science Center at San Antonio	Barlow, William
RP160735-P1	DiGiovanni, John	The University of Texas at Austin	Barlow, William
RP160735-P2	Slaga, Thomas	The University of Texas Health Science Center at San Antonio	Barlow, William
RP160735-P3	Kumar, Pratap	The University of Texas Health Science Center at San Antonio	Barlow, William
RP160735-P4	Thompson, Ian	The University of Texas Health Science Center at San Antonio	Barlow, William
RP160674	Goodwin, James	The University of Texas Medical Branch at Galveston	Barlow, William
RP160674-AC	Goodwin, James	The University of Texas Medical Branch at Galveston	Barlow, William
RP160674-C1	Elting, Linda	The University of Texas M.D. Anderson Cancer Center	Barlow, William
RP160674-C2	Peterson, Susan	The University of Texas M.D. Anderson Cancer Center	Barlow, William

Application ID	Applicant	Institution	Conflict Noted
RP160674-C3	Kuo, Yong-Fang	The University of Texas Medical Branch at Galveston	Barlow, William
RP160674-P1	Goodwin, James	The University of Texas Medical Branch at Galveston	Barlow, William
RP160674-P2	Giordano, Sharon	The University of Texas M.D. Anderson Cancer Center	Barlow, William
RP160674-P3	Smith, Benjamin	The University of Texas M.D. Anderson Cancer Center	Barlow, William
RP160674-P4	Guadagnolo, Beverly	The University of Texas M.D. Anderson Cancer Center	Barlow, William

2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Basic Cancer Research-1

Meeting Type: Onsite Review

Date	Application Number	Applicant/PO/PI Name	Applicant/PO/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/14	RP160703	Brekken, Rolf	The University of Texas Southwestern Medical Center	Prendergast, George	Not Discussed	JD Thomas Doherty
3/14	RP160703-AC	Brekken, Rolf	The University of Texas Southwestern Medical Center	Prendergast, George	Not Discussed	JD Thomas Doherty
3/14	RP160703-C1	Hwang, Tae Hyun	The University of Texas Southwestern Medical Center	Prendergast, George	Not Discussed	JD Thomas Doherty
3/14	RP160703-P1	MacDonald, Raymond	The University of Texas Southwestern Medical Center	Prendergast, George	Not Discussed	JD
3/14	RP160703-P2	Wilke, Thomas	The University of Texas Southwestern Medical Center	Prendergast, George	Not Discussed	JD

SRA Approval:

Name (PRINT):	THOMAS R. DODERIN
Signature:	
Date:	3/14/16

Signature: _____

Date:

Comments:

The reviewer acknowledges that the reviewer identified as a Conflict of Interest has signed the form and left the journal room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Basic Cancer Research-1

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/14	RP160703-P3	Brekken, Rolf	The University of Texas Southwestern Medical Center	Prendergast, George	Not Discussed	JD
3/14	RP160703-P4	Bouthman, David	The University of Texas Southwestern Medical Center	Prendergast, George	Not Discussed	JD
3/14	RP160767	Ghosh, Rita	The University of Texas Health Science Center at San Antonio	Houchens, David	Not Discussed	JD
3/14	RP160768	Srivengopal, Kallumle	Texas Tech University Health Sciences Center	Wang, Xiao-Fan	Not Discussed	

SRA Approval:

Name (PRINT):	THOMAS R. DOBETIN
Signature:	
Date:	3/14/16

Comments:

--

* An SRA Representative will add their name and initials to this form to acknowledge that the reviewer identified as a conflict of interest has signed this form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission






Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Basic Cancer Research-2

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PI/PI Name	Applicant/PI/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/16	RP160774	Li, Bing	The University of Texas Southwestern Medical Center	Perrin, John		JP
3/16	RP160782	Suh, Junghae	Rice University	Weizman, Matthew		MD
3/16	RP160835	Rosenberg, Susan	Baylor College of Medicine	Perrin, John		JP
3/16	RP160835-AC	Rosenberg, Susan	Baylor College of Medicine	Perrin, John		JP
3/16	RP160835-C1	Zang, Xuejun	Baylor College of Medicine	Perrin, John		JP

SRA Approval:

Comments:

Name (PRINT):	THOMAS R. DOVELIN
Signature:	
Date:	3/16/16

Comments:

* As SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified no conflict of interest has signed the form and left the panel room during the discussion of the application.


Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Basic Cancer Research-2
Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PI/PI Name	Applicant/PI/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/16	RP160835-P1	Rosenberg, Susan	Baylor College of Medicine	Petrini, John		JP
3/16	RP160835-P2	Muller, Kyle	The University of Texas at Austin	Petrini, John		JP
3/16	RP160835-P3	Scott, Kenneth	Baylor College of Medicine	Petrini, John		JP

SRA Approvals:

Name (PRINT):	THOMAS R. DODDIN
Signature:	
Date:	3/16/16

Comments:

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Cancer Biology

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials ^a
3/15	RP160655	Roth, Jack	The University of Texas M. D. Anderson Cancer Center	Bernstein, Bradley	Not Discussed NB	JD
3/15	RP160655-AC	Roth, Jack	The University of Texas M. D. Anderson Cancer Center	Bernstein, Bradley	Not Discussed NB	JD
3/15	RP160655-C1	Wang, Jing	The University of Texas M. D. Anderson Cancer Center	Bernstein, Bradley	Not Discussed NB	JD
3/15	RP160655-P1	Wu, Xifeng	The University of Texas M. D. Anderson Cancer Center	Bernstein, Bradley	Not Discussed NB	JD
3/15	RP160655-P2	Ji, Lin	The University of Texas M. D. Anderson Cancer Center	Bernstein, Bradley	Not Discussed NB	JD

SRA Approval:

Name (PRINT)	THOMAS R. DOVECLIN
Signature	
Date	3/15/16

Comments:

--

^a As SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed this form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Cancer Biology

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PO/PI Name	Applicant/PO/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/15	RP160655-P3	Calin, George	The University of Texas M. D. Anderson Cancer Center	Bernstein, Bradley	<i>Not Discussed</i>	<i>JD</i>
3/15	RP160705	Orlowski, Robert	The University of Texas M. D. Anderson Cancer Center	Bernstein, Bradley	<i>Not Discussed</i>	<i>JD</i>
3/15	RP160739	Shi, Xiaobing	The University of Texas M. D. Anderson Cancer Center	Bernstein, Bradley	<i>Not Discussed</i> <i>Not Discussed</i>	<i>JD</i>
3/15	RP160760	Sikora, Andrew	Baylor College of Medicine	Costello, Joseph	<i>Not Discussed</i>	<i>JD</i>
3/15	RP160760	Sikora, Andrew	Baylor College of Medicine	Wahl, Geoffrey	<i>Not Discussed</i>	<i>JD</i>

SRA Approval:

Name (PRINT):	THOMAS R. DOELIN
Signature:	<i>[Signature]</i>
Date:	3/15/16

Comments:

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.






Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Cancer Biology

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/15	RP160765	Gregory, Carl	Texas A&M University System Health Science Center	Fearon, Eric		EF
3/15	RP160765	Gregory, Carl	Texas A&M University System Health Science Center	Lawlor, Elizabeth		EL
3/15	RP160769	Zhang, Xiang	Baylor College of Medicine	Groene, Geoffrey		GG
3/15	RP160840	Rowley, David	Baylor College of Medicine	Groene, Geoffrey		GG
3/15	RP160840-AC	Rowley, David	Baylor College of Medicine	Groene, Geoffrey		GG

SRA Approval:

Name (PRINT):	THOMAS R. DODELIN
Signature:	
Date:	3/15/16

Comments:

--

* As SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.






Procurement Sensitive Document

Do not copy or circulate without written permission.


Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Cancer Biology

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PI/PI Name	Applicant/PI/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/15	RP160840-C1	Mancho, Michael	Baylor College of Medicine	Greene, Geoffrey		GD
3/15	RP160840-C2	Farach-Carson, Mury	Rice University	Greene, Geoffrey		GD
3/15	RP160840-P1	Zhang, Xiang	Baylor College of Medicine	Greene, Geoffrey		GD
3/15	RP160840-P2	Rowley, David	Baylor College of Medicine	Greene, Geoffrey		GD
3/15	RP160840-P3	Weigel, Nancy	Baylor College of Medicine	Greene, Geoffrey		GD

SRA Approval:

Name (PRINT):	THOMAS R. DODELIN
Signature:	
Date:	3/15/16

Comments:

--

* As SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Cancer Biology

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PI Name	Applicant/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/15	RPI60856	Kim, Jung-whan	The University of Texas at Dallas	Werb, Zena	<i>Not Discussed</i>	<i>JD</i>

SRA Approval:

Name (PRINT)	THOMAS R. DODELIN	
Signature	<i>[Signature]</i>	
Date	5/15/16	

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document






Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10/16	RP160661	Jiang, Steve	The University of Texas Southwestern Medical Center	Koong, Albert		BM Brendan Morales
3/10/16	RP160661-A1	Jiang, Steve	The University of Texas Southwestern Medical Center	Koong, Albert		BM Brendan Morales
3/10/16	RP160661-C1	Jiang, Steve	The University of Texas Southwestern Medical Center	Koong, Albert		BM Brendan Morales
3/10/16	RP160661-P1	Yang, Ming	The University of Texas Southwestern Medical Center	Koong, Albert		BM Brendan Morales
3/10/16	RP160661-P2	Jia, Xun	The University of Texas Southwestern Medical Center	Koong, Albert		BM Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature	
Date	3/10/16

Comments:

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document




Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PI/PI Name	Applicant/PI/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10/16	RP160661-P3	Shao, Yiping	The University of Texas Southwestern Medical Center	Koong, Albert		BM Brendan Morales
3/10/16	RP160661-P4	Lu, Weiguo	The University of Texas Southwestern Medical Center	Koong, Albert		BM Brendan Morales
3/10/16	RP160661-P5	Wang, Jing	The University of Texas Southwestern Medical Center	Koong, Albert		BM Brendan Morales
3/10/16	RP160663	Li, Chun	The University of Texas M. D. Anderson Cancer Center	Engelhard, Victor	NOT DISCUSSED	BM Brendan Morales
3/10/16	RP160663-AC	Li, Chun	The University of Texas M. D. Anderson Cancer Center	Engelhard, Victor	NOT DISCUSSED	BM Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature	
Date	3/14/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs


Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications.

Date	Application Number	Applicant/PI/PI Name	Applicant/PI/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10	RP160663-C1	Overwijk, Willem	The University of Texas M. D. Anderson Cancer Center	Engelhard, Victor	NOT DISCUSSED	BM Brendan Morales
3/10	RP160663-C2	Piwnicka-Worms, David	The University of Texas M. D. Anderson Cancer Center	Engelhard, Victor	NOT DISCUSSED	BM Brendan Morales
3/10	RP160663-P1	Liu, Jinsong	The University of Texas M. D. Anderson Cancer Center	Engelhard, Victor	NOT DISCUSSED	BM Brendan Morales
3/10	RP160663-P2	Sund, Aril	The University of Texas M. D. Anderson Cancer Center	Engelhard, Victor	NOT DISCUSSED	BM Brendan Morales
3/10	RP160663-P3	Li, Chun	The University of Texas M. D. Anderson Cancer Center	Engelhard, Victor	NOT DISCUSSED	BM Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature	
Date	3/14/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the applications.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10	RP160672	Woodman, Scott	The University of Texas M. D. Anderson Cancer Center	Engelhard, Victor	<i>[Signature]</i>	BM Brendan Morales
3/10	RP160679	Brugarolas, James	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales
3/10	RP160679-AC	Brugarolas, James	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales
3/10	RP160679-C1	Kapur, Payal	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales
3/10	RP160679-C2	Xie, Xian-Jun	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature	<i>[Signature]</i>
Date	3/14/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document


Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following application(s):						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10	RP160679-C3	Pedrosa, Ivan	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales
3/10	RP160679-P1	Brugarolas, James	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales
3/10	RP160679-P2	Timmerman, Robert	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales
3/10	RP160679-P3	Mani, Ram	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales
3/10	RP160693	Andreeff, Michael	The University of Texas M. D. Anderson Cancer Center	DiPersio, John		BM Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature	
Date	3/14/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document






Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10	RP160693-AC	Andreeff, Michael	The University of Texas M. D. Anderson Cancer Center	DiPersio, John		B.M Brendan Morales
3/10	RP160693-C1	Kornblau, Stephen	The University of Texas M. D. Anderson Cancer Center	DiPersio, John		BM Brendan Morales
3/10	RP160693-C2	Andreeff, Michael	The University of Texas M. D. Anderson Cancer Center	DiPersio, John		B.M Brendan Morales
3/10	RP160693-C3	Do, Kim-Anh	The University of Texas M. D. Anderson Cancer Center	DiPersio, John		B.M Brendan Morales
3/10	RP160693-P1	Andreeff, Michael	The University of Texas M. D. Anderson Cancer Center	DiPersio, John		BM Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature	
Date	3/14/16

Comments:

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document






Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10	RP160693-P2	Rezvani, Katy	The University of Texas M. D. Anderson Cancer Center	DiPersio, John		BM Brendan Morales
3/10	RP160693-P3	Gottschalk, Stephen	Baylor College of Medicine	DiPersio, John		BM Brendan Morales
3/10	RP160710	Symmans, William	The University of Texas M. D. Anderson Cancer Center	Grandis, Jennifer		VERIFIED TELEPHONICALLY
3/10	RP160710	Symmans, William	The University of Texas M. D. Anderson Cancer Center	Kast, W. Martin		BM Brendan Morales
3/10	RP160710	Symmans, William	The University of Texas M. D. Anderson Cancer Center	Niedzwiecki, Donna		BM Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature	
Date	3/14/16

Comments:

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10	RP160710-A1	Symmans, William	The University of Texas M. D. Anderson Cancer Center	Grandis, Jennifer	<i>Donna Niedzwiecki</i>	BM Brendan Morales
3/10	RP160710-A1	Symmans, William	The University of Texas M. D. Anderson Cancer Center	Kast, W. Martin	<i>Wm Kast</i>	BM Brendan Morales
3/10	RP160710-A1	Symmans, William	The University of Texas M. D. Anderson Cancer Center	Niedzwiecki, Donna	<i>Donna Niedzwiecki</i>	BM Brendan Morales
3/10	RP160710-C1	Moulder, Stacy	The University of Texas M. D. Anderson Cancer Center	Kast, W. Martin	<i>Wm Kast</i>	BM Brendan Morales
3/10	RP160710-C1	Moulder, Stacy	The University of Texas M. D. Anderson Cancer Center	Niedzwiecki, Donna	<i>Donna Niedzwiecki</i>	BM Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature	<i>B. Morales</i>
Date	3/14/16

Comments:

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document





Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10	RP160710-C2	Davies, Peter	Texas A&M University Health Science Center Institute of Biosciences and Technology	Karl W. Martin		BH Brendan Morales
3/10	RP160710-C2	Davies, Peter	Texas A&M University Health Science Center Institute of Biosciences and Technology	Niedzwiecki, Donna		BH Brendan Morales
3/10	RP160710-C3	Symmans, William	The University of Texas M. D. Anderson Cancer Center	Karl W. Martin		BH Brendan Morales
3/10	RP160710-C3	Symmans, William	The University of Texas M. D. Anderson Cancer Center	Niedzwiecki, Donna		BH Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature	
Date	3/14/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document






Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10	RP160710-P1	Thompson, Alastair	The University of Texas M. D. Anderson Cancer Center	Kast, W. Martin		BN Brendan Morales
3/10	RP160710-P1	Thompson, Alastair	The University of Texas M. D. Anderson Cancer Center	Niedzwiecki, Donna		BN Brendan Morales
3/10	RP160710-P2	Hung, Mien-Chie	The University of Texas M. D. Anderson Cancer Center	Kast, W. Martin		BN Brendan Morales
3/10	RP160710-P2	Hung, Mien-Chie	The University of Texas M. D. Anderson Cancer Center	Niedzwiecki, Donna		BN Brendan Morales
3/10	RP160710-P3	Mani, Sendurai	The University of Texas M. D. Anderson Cancer Center	Kast, W. Martin		BN Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature	
Date	3/14/16

Comments:

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10	RP160710-P3	Mani, Sundurai	The University of Texas M. D. Anderson Cancer Center	Niedzwiecki, Donna	<i>Donna Niedzwiecki</i>	BM Brendan Morales
3/10	RP160724	Story, Michael	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales
3/10	RP160724-AC	Story, Michael	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales
3/10	RP160724-C1	Saha, Debabrata	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales
3/10	RP160724-P1	Story, Michael	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature:	<i>Brendan Morales</i>
Date	3/14/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document



Do not copy or circulate without written permission

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10	RP160724-P2	Aroumougaie, Asathambhy	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales
3/10	RP160724-P3	Chen, Ping-Chi	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales
3/10	RP160724-P4	Hannan, Raquibul	The University of Texas Southwestern Medical Center	Koong, Albert	NOT DISCUSSED	BM Brendan Morales
3/10	RP160745	Reynolds, Charles	Texas Tech University Health Sciences Center	Kast, W. Martin		BM Brendan Morales
3/10	RP160745-AC	Reynolds, Charles	Texas Tech University Health Sciences Center	Kast, W. Martin		BM Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature	
Date	3/14/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document






Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PI Name	Applicant/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10	RP160745-C1	Rosen, Daniel	Baylor Research Institute	Kast, W. Martin		BM Brendan Morales
3/10	RP160745-C2	Beckel, Lauren	Baylor Research Institute	Kast, W. Martin		BM Brendan Morales
3/10	RP160745-P1	Reynolds, Charles	Texas Tech University Health Sciences Center	Kast, W. Martin		BM Brendan Morales
3/10	RP160745-P2	Wheeler, David	Baylor Research Institute	Kast, W. Martin		BM Brendan Morales
3/10	RP160745-P3	Kang, Min	Texas Tech University Health Sciences Center	Kast, W. Martin		BM Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature	
Date	3/14/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10	RP160826	Fleming, Jason	The University of Texas M. D. Anderson Cancer Center	Prados, Michael	<i>Michael Prados</i>	BRM Brendan Morales
3/10	RP160843	Chang, Jenny	The Methodist Hospital Research Institute	Curran, Walter	NOT DISCUSSED	BM Brendan Morales
3/10	RP160864	Wang, Rongfu	The Methodist Hospital Research Institute	Riddell, Stanley	NOT DISCUSSED	BM Brendan Morales
3/10	RP160864-A1	Wang, Rongfu	The Methodist Hospital Research Institute	Riddell, Stanley	NOT DISCUSSED	BM Brendan Morales
3/10	RP160864-C1	Liu, Xuewu	Houston Methodist	Riddell, Stanley	NOT DISCUSSED	BM Brendan Morales

SRA Approval:

Name (PRINT):	Brendan Morales
Signature	<i>Brendan Morales</i>
Date	3/14/16

Comments:

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PI/PI Name	Applicant/PI/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/10	RP160864-C2	Gee, Adrian	Baylor College of Medicine	Riddell, Stanley	NOT DISCUSSED	BM Brendan Morales
3/10	RP160864-P1	Shen, Haifa	Houston Methodist	Riddell, Stanley	NOT DISCUSSED	BM Brendan Morales
3/10	RP160864-P2	Wang, Rongli	The Methodist Hospital Research Institute	Riddell, Stanley	NOT DISCUSSED	BM Brendan Morales
3/10	RP160864-P3	Rooney, Cherie	Baylor College of Medicine	Riddell, Stanley	NOT DISCUSSED	BM Brendan Morales

SRA Approval:

Name (PRINT)	Brendan Morales
Signature	
Date	3/14/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Clinical / Translational Cancer Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*

SRA Approval:

Name (PRINT):	Brenda Morales
Signature	
Date:	3/14/16

Comments:

--

* An SRA Representative will add their name and initials to this form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document



Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Imaging Technology and Informatics

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PO/PI Name	Applicant/PO/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/11/16	RP160697	Kundra, Vikas	The University of Texas M. D. Anderson Cancer Center	Johnson, G. Allan	NOT DISCUSSED	BM Brendan Morales
3/11/16	RP160702	Mancini, Michael	Texas A&M University System Health Science Center	Basilion, James		BM Brendan Morales
3/11/16	RP160718	Betancourt, Tania	Texas State University - San Marcos	Berbeco, Russ		BM Brendan Morales

SRA Approval:

Name (PRINT):	Brendan Morales
Signature:	
Date:	3/11/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Imaging Technology and Informatics

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*

SRA Approval:

Name (PRINT)	Brendan Mocalles
Signature	
Date	3/14/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Scientific Review Council Meeting

Meeting Type: Teleconference Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*

SRA Approval:

Name (PRINT):	Katia E. Garcia Crespo
Signature:	Katia E. Garcia Crespo
Date:	03-29-16

Comments:

NO COIs

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.






Procurement Sensitive Document

Do not copy or circulate without written permission.


Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Cancer Prevention Research
Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following application(s):

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/9/16	RP160674	Goodwin, James	The University of Texas Medical Branch at Galveston	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS 
3/9/16	RP160674-AC	Goodwin, James	The University of Texas Medical Branch at Galveston	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS 
3/9/16	RP160674-CT	Elting, Linda	The University of Texas M. D. Anderson Cancer Center	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS 
3/9/16	RP160674-C2	Peterson, Susan	The University of Texas M. D. Anderson Cancer Center	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS 
3/9/16	RP160674-C3	Kuo, Yong-Fang	The University of Texas Medical Branch at Galveston	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS 

SRA Approval:

Name (PRINT):	LIZ SPINKS
Signature:	
Date:	3/9/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.


Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Research Programs
Panel: 16.2 Cancer Prevention Research
Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/9/16	RP160674-P1	Goodwin, James	The University of Texas Medical Branch at Galveston	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS
3/9/16	RP160674-P2	Cherlano, Sharon	The University of Texas M. D. Anderson Cancer Center	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS
3/9/16	RP160674-P3	Smith, Benjamin	The University of Texas M. D. Anderson Cancer Center	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS
3/9/16	RP160674-P4	Guadagnolo, Beverly	The University of Texas M. D. Anderson Cancer Center	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS
3/9/16	RP160735	Djilchouran, John	The University of Texas at Austin	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS

SRA Approval:

Comments:

Name (PRINT)	LIZ SPINKS	
Signature		
Date	3/9/16	

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Cancer Prevention Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/9/16	RP160735-AC	DIGIOVANNI, John	The University of Texas at Austin	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS SSA
3/9/16	RP160735-C1	Clickman, Randolph	The University of Texas Health Science Center at San Antonio	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS SSA
3/9/16	RP160735-C2	Fizient, Stefano	The University of Texas at Austin	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS SSA
3/9/16	RP160735-C3	Gellford, Jonathan	The University of Texas Health Science Center at San Antonio	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS SSA
3/9/16	RP160735-P1	Digiovanni, John	The University of Texas at Austin	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS SSA

SRA Approval:

Name (PRINT):	LIZ SPINKS
Signature:	
Date:	3/9/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs

Panel: 16.2 Cancer Prevention Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/9/16	RP160735-P2	Shiga, Thomas	The University of Texas Health Science Center at San Antonio	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS LIZ SPINKS
3/9/16	RP160735-P3	Kannan, Prasad	The University of Texas Health Science Center at San Antonio	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS LIZ SPINKS
3/9/16	RP160735-P4	Thompson, Ian	The University of Texas Health Science Center at San Antonio	Barlow, William	Verified Telephonically by SRA	LIZ SPINKS LIZ SPINKS

SRA Approval:

Name (PRINT)	LIZ SPINKS
Signature:	
Date:	3/9/16

Comments:

--

* As SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Research Programs


Panel: 16.2 Cancer Prevention Research

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PI/PI Name	Applicant/PI/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*

SRA Approval:

Name (PRINT):	LIZ SPINKS
Signature:	
Date:	3/9/14

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

APPENDIX:
CONFLICT OF INTEREST DOCUMENTATION

PRODUCT DEVELOPMENT RESEARCH



Conflicts of Interest for Product Development Cycle 15.4 Applications
(Product Development Cycle 15.4 Awards Announced at November 19, 2015, Oversight Committee Meeting)

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Product Development Cycle 15.4 *New Company Product Development Awards*, *Company Relocation Product Development Awards*, and *Established Company Product Development Awards*. All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC. COI information used for this table was collected by SRA International, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant	Institution	Conflict Noted
Applications considered by the PIC and Oversight Committee			
DP150127	Giaccia, Amato	Ruga Corporation	Pegram, Mark; Sarisky, Robert; Saxberg, Bo;
Applications Not Recommended for PIC or Oversight Committee Consideration			
DP150125	Adams, Christopher P.	Andarix Pharmaceuticals, Inc.	Dhingra, Kapil; Saxberg, Bo
DP150118	Xu, Jeff	Digital Biopsy, Inc.	Dhingra, Kapil; Saxberg, Bo;
DP150119	Prasad, Sridhar	CalaAsia Pharmaceuticals, Inc.	Geltosky, Jack; Saxberg, Bo
DP150120	Gunaratne, Preethi	University of Houston	Saxberg, Bo
DP150126	Holland, George	Aviara Pharmaceuticals, Inc.	Saxberg, Bo
DP150128	Carney, Darrell	Chrysalis BioTherapeutics, Inco.	Saxberg, Bo
DP150129	Dada, Aspha	Biopep Solutions, Inc.	Saxberg, Bo
DP150130	Vankayalapati, Hariprasad	Oncolexis Therapeutics, Inc.	Geltosky, Jack; Saxberg, Bo
DP150132	Chiesi, Antonio	EXOSOMICS SIENA SPA	Dhingra, Kapil; Saxberg, Bo
DP150133	Perrine, Michael	Agilvax, Inc.	Saxberg, Bo
DP150134	Prendergast, John	Antyra, Inc.	Geltosky, Jack; Saxberg, Bo

Application ID	Applicant	Institution	Conflict Noted
DP150137	Bainbridge, Matthew	Codified Genomics, LLC	Pegram, Mark; Saxberg, Bo
DP150138	Foster, David	Tuevol Therapeutics, Inc.	Saxberg, Bo

**Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2015 Cancer Prevention and Research Institute of Texas Product Development**

Panel: Due Diligence Meeting 1

Meeting Type: Teleconference Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
10/12/15	DP150125	Adams, Christopher P	Andarix Pharmaceuticals, Inc.	Dhingra, Kapil	Verified telephonically by SRA	KR

SRA Approval:

Name (PRINT):	Katie Reece
Signature:	Katie Reece
Date:	10/12/15

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.


Procurement Sensitive Document

Do not copy or circulate without written permission.


Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2015 Cancer Prevention and Research Institute of Texas Product Development

Panel: 15.4 Product Development Panel - 1

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
4/27	DP150118	Xu, Jeff	Digital Biopsy, Inc.	Dhingra, Kapil		Paul Brohawn / pcb
4/27	DP150118	Xu, Jeff	Digital Biopsy, Inc.	Saxberg, Bo	not present	Paul Brohawn / pcb
	DP150119	Prasad, Sridhar	CalaAsia Pharmaceuticals, Inc.	Geltosky, Jack	not DISCUSSED	Paul Brohawn / pcb
	DP150119	Prasad, Sridhar	CalaAsia Pharmaceuticals, Inc.	Saxberg, Bo	NOT DISCUSSED	Paul Brohawn / pcb
4/28	DP150120	Gunaratne, Preethi	University of Houston	Saxberg, Bo	not present	Paul Brohawn / pcb

SRA Approval:

Name (PRINT):	Paul Brohawn
Signature:	
Date:	4/28/15

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document




Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2015 Cancer Prevention and Research Institute of Texas Product Development

Panel: 15.4 Product Development Panel - 1

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
4/28	DP150125	Adams, Christopher	Andarix Pharmaceuticals, Inc.	Dhingra, Kapil		Paul Brohawn / pcb
4/28	DP150125	Adams, Christopher	Andarix Pharmaceuticals, Inc.	Saxberg, Bo	not present	Paul Brohawn / pcb
4/27	DP150126	Holland, George	Aviara Pharmaceuticals, Inc.	Saxberg, Bo	not present	Paul Brohawn / pcb
4/28	DP150127	Giaccia, Amato	Ruga Corporation	Pegram, Mark		Paul Brohawn / pcb
4/28	DP150127	Giaccia, Amato	Ruga Corporation	Sarisky, Robert		Paul Brohawn / pcb

SRA Approval:

Name (PRINT):	Paul Brohawn
Signature:	
Date:	4/28/15

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2015 Cancer Prevention and Research Institute of Texas Product Development

Panel: 15.4 Product Development Panel - 1

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
4/28	DP150127	Giaccia, Amato	Ruga Corporation	Saxberg, Bo	Not present	Paul Brohawn / pcb
4/28	DP150128	Carney, Darrell	Chrysalis BioTherapeutics, Inc.	Saxberg, Bo	Not present	Paul Brohawn / pcb
4/28	DP150129	Dada, Aspha	Biopep Solutions, Inc.	Saxberg, Bo	Not present	Paul Brohawn / pcb
4/27	DP150130	Vankayalapati, Hariprasad	Oncolexis Therapeutics Inc.	Geltosky, Jack	J. Geltosky	Paul Brohawn / pcb
4/27	DP150130	Vankayalapati, Hariprasad	Oncolexis Therapeutics Inc.	Saxberg, Bo	not present	Paul Brohawn / pcb

SRA Approval:

Name (PRINT):	Paul Brohawn
Signature:	
Date:	4/28/15

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2015 Cancer Prevention and Research Institute of Texas Product Development

Panel: 15.4 Product Development Panel - 1

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
	DP150132	Chiesi, Antonio	EXOSOMICS SIENA SPA	Dhingra, Kapil	NOT DISCUSSED	Paul Brohawn / pcb
	DP150132	Chiesi, Antonio	EXOSOMICS SIENA SPA	Saxberg, Bo	NOT DISCUSSED	Paul Brohawn / pcb
	DP150133	Perrine, Michael	Agilvax, Inc.	Saxberg, Bo	NOT DISCUSSED	Paul Brohawn / pcb
	DP150134	Prendergast, John	Antyra, Inc.	Geltosky, Jack	NOT DISCUSSED	Paul Brohawn / pcb
	DP150134	Prendergast, John	Antyra, Inc.	Saxberg, Bo	NOT DISCUSSED	Paul Brohawn / pcb

SRA Approval:

Name (PRINT):	Paul Brohawn
Signature:	
Date:	4/28/15

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document


Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2015 Cancer Prevention and Research Institute of Texas Product Development

Panel: 15.4 Product Development Panel - 1

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
4/27	DP150137	bainbridge, matthew	Codified Genomics, LLC	Pegram, Mark		Paul Brohawn / pcb
4/27	DP150137	bainbridge, matthew	Codified Genomics, LLC	Saxberg, Bo	not present	Paul Brohawn / pcb
4/28	DP150138	Foster, David	Tuevol Therapeutics, Inc.	Saxberg, Bo	not present	Paul Brohawn / pcb

SRA Approval:

Name (PRINT):	Paul Brohawn
Signature:	
Date:	4/28/15

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document



Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest


2015 Cancer Prevention and Research Institute of Texas Product Development

Panel: 15.4 Product Development Panel - 1

Meeting Type: Onsite Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
4/27	DP150135	Dehant	Northshoe Bio	Saffe, Chuck		Paul Brohawn/pcb
4/28	DP150125	Adams	ADARIX Pharmaceuticals	Serrero, Ginette		Paul Brohawn/pcb

SRA Approval:

Name (PRINT):	Paul Brohawn
Signature:	
Date:	4/28/15

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2015 Cancer Prevention and Research Institute of Texas Product Development

Panel: 15.4 Product Development Panel - 1

Meeting Type: Screening Teleconference

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/26/15	DP150118	Xu, Jeff	Digital Biopsy, Inc.	Dhingra, Kapil	Verified Telephonically by SRA	KR
3/26/15	DP150118	Xu, Jeff	Digital Biopsy, Inc.	Saxberg, Bo	not present	KR
3/26/15	DP150119	Prasad, Sridhar	CalaAsia Pharmaceuticals, Inc.	Geltosky, Jack	Verified Telephonically by SRA	KR
3/26/15	DP150119	Prasad, Sridhar	CalaAsia Pharmaceuticals, Inc.	Saxberg, Bo	not present	KR
3/26/15	DP150120	Gunaratne, Preethi	University of Houston	Saxberg, Bo	not present	KR

SRA Approval:

Name (PRINT):	Kelie Reece
Signature:	Kelie Reece
Date:	3/26/15

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2015 Cancer Prevention and Research Institute of Texas Product Development

Panel: 15.4 Product Development Panel - 1

Meeting Type: Screening Teleconference

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/26/15	DP150125	Adams, Christopher	Andarix Pharmaceuticals, Inc.	Dhingra, Kapil	Verified Telephonically by SRA	KR
3/26/15	DP150125	Adams, Christopher	Andarix Pharmaceuticals, Inc.	Saxberg, Bo	not present	KR
3/26/15	DP150126	Holland, George	Aviara Pharmaceuticals, Inc.	Saxberg, Bo	not present	KR
3/26/15	DP150127	Giaccia, Amato	Ruga Corporation	Sarisky, Robert	Verified Telephonically by SRA	KR
3/26/15	DP150127	Giaccia, Amato	Ruga Corporation	Saxberg, Bo	not present	KR

SRA Approval:

Name (PRINT):	Kelie Reece
Signature:	Kelie Reece
Date:	3/26/15

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2015 Cancer Prevention and Research Institute of Texas Product Development

Panel: 15.4 Product Development Panel - 1

Meeting Type: Screening Teleconference

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/26/15	DP150128	Carney, Darrell	Chrysalis BioTherapeutics, Inc.	Saxberg, Bo	not present	KR
3/26/15	DP150129	Dada, Aspha	Biopep Solutions, Inc.	Saxberg, Bo	not present	KR
3/26/15	DP150130	Vankayalapati, Hariprasad	Oncolexis Therapeutics Inc.	Geltosky, Jack	Verified Telephonically by SRA	KR
3/26/15	DP150130	Vankayalapati, Hariprasad	Oncolexis Therapeutics Inc.	Saxberg, Bo	not present	KR
3/26/15	DP150132	Chiesi, Antonio	EXOSOMICS SIENA SPA	Dhingra, Kapil	Verified Telephonically by SRA	KR

SRA Approval:

Name (PRINT):	Kelie Reece
Signature:	Kelie Reece
Date:	3/26/15

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.


Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2015 Cancer Prevention and Research Institute of Texas Product Development

Panel: 15.4 Product Development Panel - 1

Meeting Type: Screening Teleconference

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/26/15	DP150132	Chiesi, Antonio	EXOSOMICS SIENA SPA	Saxberg, Bo	not present	KR
3/26/15	DP150133	Perrine, Michael	Agilvax, Inc.	Saxberg, Bo	not present	KR
3/26/15	DP150134	Prendergast, John	Antyra, Inc.	Geltosky, Jack	Verified Telephonically by SRA	KR
3/26/15	DP150134	Prendergast, John	Antyra, Inc.	Saxberg, Bo	not present	KR
3/26/15	DP150137	bainbridge, matthew	Codified Genomics, LLC	Pegram, Mark	Verified Telephonically by SRA	KR

SRA Approval:

Name (PRINT):	Kelie Reece
Signature:	
Date:	3/26/15

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application

Procurement Sensitive Document

Do not copy or circulate without written permission.

**Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2015 Cancer Prevention and Research Institute of Texas Product Development**


Panel: 15.4 Product Development Panel - 1

Meeting Type: Screening Teleconference

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/26/15	DP150137	bainbridge, matthew	Codified Genomics, LLC	Saxberg, Bo	not present	KR
3/26/15	DP150138	Foster, David	Tuevol Therapeutics, Inc.	Saxberg, Bo	not present	KR

SRA Approval:

Name (PRINT):	Kelie Reece
Signature:	
Date:	3/26/2015

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

**Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2015 Cancer Prevention and Research Institute of Texas Product Development**

Panel: 15.4 Product Development Panel - 1

Meeting Type: Screening Teleconference

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/26/15	DP150127	GIACCIA, Amato	Ruba Corporation	PEGHAM, MARK	Verified Telephonically by SRA	KR

SRA Approval:

Name (PRINT):	Kelle Reece
Signature:	Kelle Reece
Date:	3/26/2015

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

**Conflicts of Interest for Product Development Research Cycle 16.1 Applications
(Product Development Research Cycle 16.1 Awards Announced at May 18, 2016, Oversight
Committee Meeting)**

The table below lists the conflicts of interest (COIs) identified by peer reviewers, Program Integration Committee (PIC) members, and Oversight Committee members on an application-by-application basis. Applications reviewed in Product Development Research Cycle 16.1 include *New Company Product Development Awards*, *Established Company Product Development Awards*, and *Company Relocation Product Development Awards*. All applications with at least one identified COI are listed below; applications with no COIs are not included. It should be noted that an individual is asked to identify COIs for only those applications that are to be considered by the individual at that particular stage in the review process. For example, Oversight Committee members identify COIs, if any, with only those applications that have been recommended for the grant awards by the PIC. COI information used for this table was collected by SRA International, CPRIT's third party grant administrator, and by CPRIT.

Application ID	Applicant	Organization	Conflict Noted
Applications considered by the PIC and Oversight Committee			
DP160012	Hornblower, Josiah	Pelican Therapeutics	Kramer, Robert; Saxberg, Bo; Pegram, Mark
DP160014	Arthur, David	Salaris Pharmaceuticals LLC	Saxberg, Bo, Spector, Neil; Yamashita, Elizabeth; Gavin, Brenda
Applications not considered by the PIC or Oversight Committee			
DP160015	Liu, Qingyun	Wntrix, Inc.	Kramer, Robert; Saxberg, Bo; Yamashita, Elizabeth
DP160035	Matthews, Bill	Leuchemix, Inc.	Kramer, Robert; Saxberg, Bo
DP160039	Jiang, Steve	Texas Radiotherapy Innovation & Optimization, Inc.	Kramer, Robert; Yamashita, Elizabeth
DP160016*	Aiila, Hector	Experance Pharmaceuticals, Inc.	Weng, David

* = Not discussed

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Product Development

Panel: 16.1 Due Diligence Panel

Meeting Type: Teleconference Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/21/16	DP160012DD	Hornblower, Josiah	Pelican Therapeutics	Geltosky, Jack	Verified as <u>not a COI</u> by SRA	AMC
3/21/16	DP160012DD	Hornblower, Josiah	Pelican Therapeutics	Kramer, Robert	Verified telephonically by SRA	AMC
3/21/16	DP160012DD	Hornblower, Josiah	Pelican Therapeutics	Saxberg, Bo	Verified telephonically by SRA	AMC
3/21/16	DP160014DD	Arthur, David	Salarius Pharmaceuticals LLC	Saxberg, Bo	Verified telephonically by SRA	AMC
3/21/16	DP160014DD	Arthur, David	Salarius Pharmaceuticals LLC	Spector, Neil	Verified telephonically by SRA	AMC

SRA Approval:

Name (PRINT):	Aaron Chumbris
Signature:	<i>Aaron Chumbris</i>
Date:	3/21/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Product Development

Panel: 16.1 Due Diligence Panel

Meeting Type: Teleconference Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/21/16	DP160014DD	Arthur, David	Salarius Pharmaceuticals LLC	Yamashita, Elizabeth	Verified telephonically by SRA	AMC
3/21/16	DP160015DD	Liu, Qingyun	Wntrix, Inc.	Kramer, Robert	Verified telephonically by SRA	AMC
3/21/16	DP160015DD	Liu, Qingyun	Wntrix, Inc.	Saxberg, Bo	Verified by telephonically by SRA	AMC
3/21/16	DP160015DD	Liu, Qingyun	Wntrix, Inc.	Yamashita, Elizabeth	Verified telephonically by SRA	AMC
3/21/16	DP160035DD	Matthews, Bill	Leuchemix, Inc.	Kramer, Robert	Verified telephonically by SRA	AMC

SRA Approval:

Name (PRINT):	Aaron Chumbris
Signature:	<i>Aaron Chumbris</i>
Date:	3/21/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Product Development

Panel: 16.1 Due Diligence Panel

Meeting Type: Teleconference Review

This is to certify that I was not present and did not participate in the review of the following applications:						
Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
3/21/16	DP160035DD	Matthews, Bill	LeuChemix, Inc.	Saxberg, Bo	Verified telephonically by SRA	AMC
3/21/16	DP160039DD	Jiang, Steve	Texas Radiotherapy Innovation & Optimization, Inc.	Kramer, Robert	Verified telephonically by SRA	AMC
3/21/16	DP160039DD	Jiang, Steve	Texas Radiotherapy Innovation & Optimization, Inc.	Yamashita, Elizabeth	Verified telephonically by SRA	AMC

SRA Approval:

Name (PRINT):	Aaron Chumbris
Signature:	<i>Aaron Chumbris</i>
Date:	3/21/16

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Product Development

Panel: 16.1 Product Development Panel - 1

Meeting Type: Online Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
12/3/2015	DP160014	Arthur, David	Salarius Pharmaceuticals LLC	Gavin, Brenda	Brenda J. Gavin	Brahm Gichery/BG
12/3/2015	DP160014	Arthur, David	Salarius Pharmaceuticals LLC	Spector, Neil	Neil Spector	Brahm Gichery/BG

SRA Approval:

Name (PRINT):	Brahm Gichery
Signature:	Brahm Gichery
Date:	12/3/2015

Comments:

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Product Development

Panel: 16.1 Product Development Panel - 2

Meeting Type: Online Review

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
12/2/2015	DP160012	Hornblower, Josiah	Pelican Therapeutics	Pegram, Mark	Telephonically verified by SRA	Brahm Gicherv/BG
12/2/2015	DP160016	Alila, Hector	Esperance Pharmaceuticals, Inc.	Weng, David	Not Discussed Application	Brahm Gicherv/BG

SRA Approval:

Name (PRINT):	Brahm Gicherv
Signature:	Brahm Gicherv
Date:	12/2/2015

Comments:

DP160016 is a not discussed application

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest

2016 Cancer Prevention and Research Institute of Texas Product Development

Panel: 16.1 Product Development Panel - 2

Meeting Type: Screening Teleconference

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
10/24/15	DP160012	Hornblower, Josiah	Pelican Therapeutics	Pegram, Mark	Verified telephonically by SRA	Kelle Reece KR
10/29/15	DP160016	Alila, Hector	Esperance Pharmaceuticals,	Weng, David	Verified telephonically by SRA NOT Discussed	Kelle Reece KR

SRA Approval:

Name (PRINT):	Kelle Reece
Signature:	Kelle Reece
Date:	10/29/15

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

Peer Review Certification of Non-Participant in Evaluation of Individual Applications Because of Real or Apparent Conflict of Interest
2016 Cancer Prevention and Research Institute of Texas Product Development

Panel: 16.1 Product Development Panel - 1

Meeting Type: Screening Teleconference

This is to certify that I was not present and did not participate in the review of the following applications:

Date	Application Number	Applicant/PD/PI Name	Applicant/PD/PI Organization	Reviewer Name	Reviewer Signature	SRA Name/Initials*
10/30/15	DP160014	Arthur, David	Salarius Pharmaceuticals LLC	Gavin, Brenda	Verified telephonically by SRA	Kelie Reece KR
10/30/15	DP160014	Arthur, David	Salarius Pharmaceuticals LLC	Spector, Neil	Verified telephonically by SRA	Kelie Reece KR

SRA Approval:

Name (PRINT):	Kelie Reece
Signature:	Kelie Reece
Date:	10/30/15

Comments:

--

* An SRA Representative will add their name and initials to the form to acknowledge that the reviewer identified as a Conflict of Interest has signed the form and left the panel room during the discussion of the application.

Procurement Sensitive Document

Do not copy or circulate without written permission.

APPENDIX:
CONFLICT OF INTEREST DOCUMENTATION

FISCAL YEAR 2016
CONFLICT OF INTEREST WAIVERS





CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

To: OVERSIGHT COMMITTEE CHAIR DR. WILLIAM RICE
From: WAYNE R. ROBERTS, CHIEF EXECUTIVE OFFICER
Subject: SECTION 102.1062 WAIVER – DR. JOHN HELLERSTEDT
Date: JANUARY 14, 2016

Waiver Request and Recommendation

I request that the Oversight Committee approve a conflict of interest waiver for FY 2016 for Program Integration Committee (PIC) member DSHS Commissioner Dr. John Hellerstedt, pursuant to Health & Safety Code Section 102.1062 “Exceptional Circumstances Requiring Participation.” The waiver is necessary for Commissioner Hellerstedt to participate in CPRIT’s review process as a PIC member. Together with the waiver’s proposed limitations, adequate protections are in place to mitigate the opportunity for the award of grant funds to be driven by anything other than merit and established criteria.

Background

Dr. Hellerstedt was appointed Commissioner of the Department of State Health Services (DSHS) on January 1, 2016. The DSHS Commissioner is a statutorily designated member of the PIC. As a PIC member, Commissioner Hellerstedt is called upon to exercise discretion related to whether applications proposed for grant awards by the peer review committees should be recommended to the Oversight Committee for final approval.

DSHS is a CPRIT grant recipient, which implicates conflict of interest concerns. Health & Safety Code Section 102.106(c)(3) mandates that a professional conflict of interest exists if a PIC member is an employee of an entity applying to receive or receiving CPRIT funds. Furthermore, CPRIT’s administrative rule 702.13(c) categorizes this type of professional conflict of interest as one that raises the presumption that the existence of the conflict may affect the impartial review of all other grant applications submitted pursuant to the same grant mechanism in the grant review cycle. A person involved in the review process that holds one of the conflicts included in the Section 702.13(c) “super conflict” category must be recused from participating in the “review, discussion, scoring, deliberation and vote on all grant applications competing for the same grant mechanism in the entire grant review cycle, unless a waiver has been granted...”

CPRIT’s administrative rule Section 702.17(3) authorizes the Oversight Committee to approve a waiver that applies for all activities affected by the conflict during the fiscal year.

Exceptional Circumstances Requiring Commissioner Hellerstedt's Participation

In order to approve a conflict of interest waiver, the Oversight Committee must find that there are exceptional circumstances justifying the conflicted individual's participation in the review process. Commissioner Hellerstedt's participation in the review process is compelled by the statute. In order to fulfill legislative intent that the DSHS Commissioner serve as a PIC member, the proposed waiver must be granted. The proposed limitations will substantially mitigate any potential for bias.

Proposed Waiver and Limitations

In granting the waiver of the conflict of interest set forth in Section 102.106(c)(3), I recommend that Commissioner Hellerstedt be permitted to continue to perform the following activities and duties associated with CPRIT's review process subject to the stated limitations:

1. Attend and participate fully in the PIC meetings except that Commissioner Hellerstedt shall not participate in the PIC's discussion or vote on grant award recommendations to be made to DSHS;
2. Have access to grant application information developed during the grant review process, except for information related to DSHS applicants, if any; and
3. Provide information to the Oversight Committee or CPRIT personnel about the grant review process and applications recommended by the PIC for grant awards, including answering questions raised by the Oversight Committee or CPRIT personnel. To the extent that information is provided by Commissioner Hellerstedt on his own initiative in a review cycle in which DSHS is a grant applicant, the information provided by Commissioner Hellerstedt should be general information related to the overall grant application process and not advocate specifically for a grant application submitted by DSHS.

CPRIT's Compliance Officer is statutorily required to attend PIC meetings to document compliance with CPRIT's rules and processes, including adherence to this limitation. The Compliance Officer shall report to the Oversight Committee any violation of this waiver prior to the Oversight Committee's action on the PIC recommendations.

Important Information Regarding this Waiver and the Waiver Process

- The Oversight Committee may amend, revoke, or revise this waiver, including but not limited to the list of approved activities and duties and the limitations on duties and activities. Approval for any change to the waiver granted shall be by a vote of the Oversight Committee in an open meeting.
- This waiver is limited to the conflict of interest specified in this request. To the extent that Commissioner Hellerstedt has a conflict of interest with an application that is not the conflict identified in Section 102.106(c)(3), then Commissioner Hellerstedt will follow the required notification and recusal process.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

TO: OVERSIGHT COMMITTEE MEMBERS
FROM: WAYNE R. ROBERTS, CHIEF EXECUTIVE OFFICER
SUBJECT: SECTION 102.1062 WAIVER – DR. BECKY GARCIA
DATE: MAY 11, 2016

Waiver Request and Recommendation

I request that the Oversight Committee approve a conflict of interest waiver for FY 2016 for Program Integration Committee (“PIC”) member Dr. Becky Garcia, pursuant to Health & Safety Code Section 102.1062 “Exceptional Circumstances Requiring Participation.” Dr. Garcia recently accepted an appointment to the advisory committee serving the Texas Health Improvement Network, a statutorily-created program that is administratively attached to The University of Texas System. The waiver is necessary for Dr. Garcia to participate in CPRIT’s review process as a PIC member. Together with the waiver’s proposed limitations, adequate protections are in place to mitigate the opportunity for the award of grant funds to be driven by anything other than merit and established criteria.

Background

In 2015, the Legislature created the Texas Health Improvement Network (“THIN”) with the purpose to “address urgent health care challenges and improve the health care system in this state and the nation and to develop, based on population health research, health care initiatives, policies, and best practices.” Texas Health and Safety Code § 118.051(a). By statute, THIN is administratively attached to the University of Texas System, which coordinates the program and provides administrative support. Texas Health and Safety Code § 118.054. Dr. Garcia, CPRIT Chief Prevention Officer, was appointed to serve on the advisory council that advises THIN on health care needs of Texas.

Texas Health & Safety Code § 102.106(c)(1) holds that a professional conflict of interest exists if a PIC member is a member of any committee affiliated with an entity receiving or applying to receive money from CPRIT during the same grant cycle. The University of Texas System is composed of several institutions, many of which are current CPRIT grantees, including, but not limited to, UT Southwestern Medical Center, M.D. Anderson Cancer Center, and UT Health Science Center at San Antonio. Since Dr. Garcia serves on a committee administered by a university system that includes CPRIT grantees, a professional conflict of interest arises.

CPRIT's administrative rule § 702.17(3) authorizes the Oversight Committee to approve a waiver that applies for all activities affected by the conflict during the fiscal year.

Exceptional Circumstances Requiring Dr. Garcia's Participation

In order to approve a conflict of interest waiver, the Oversight Committee must find that there are exceptional circumstances justifying the conflicted individual's participation in the review process. The statute compels the Chief Prevention Officer's participation in the review process as a PIC member. In order to fulfill legislative intent that the Chief Prevention Officer serve as a PIC member, the proposed waiver should be granted. The proposed limitations will substantially mitigate any potential for bias.

Proposed Waiver and Limitations

In granting the waiver of the conflict of interest set forth in Section 102.106(c)(1), I recommend that Dr. Garcia be permitted to continue to perform the following activities and duties associated with CPRIT's review process subject to the stated limitations:

1. If THIN submits an application for a CPRIT grant award, Dr. Garcia must recuse herself from any discussion, review and vote related to the application.
2. If a principal investigator applying for CPRIT funds has also received funds from THIN for the same project, Dr. Garcia must recuse herself from any discussion, review and vote related to the application.

CPRIT's Chief Compliance Officer is statutorily required to attend PIC meetings to document compliance with CPRIT's rules and processes, including adherence to this limitation. The Compliance Officer shall report to the Oversight Committee any violation of this waiver prior to the Oversight Committee's action on the PIC recommendations.

Important Information Regarding this Waiver and the Waiver Process

- The Oversight Committee may amend, revoke, or revise this waiver, including but not limited to the list of approved activities and duties and the limitations on duties and activities. Approval for any change to the waiver granted shall be by a vote of the Oversight Committee in an open meeting.
- This waiver is limited to the conflict of interest specified in this request. To the extent that Dr. Garcia has a conflict of interest with an application that is not the conflict identified in Section 102.106(c)(1), then Dr. Garcia will follow the required notification and recusal process.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

To: OVERSIGHT COMMITTEE MEMBERS
From: WAYNE R. ROBERTS, CHIEF EXECUTIVE OFFICER
Subject: SECTION 102.1062 WAIVER – MARGARET L. KRIPKE, PH.D.
Date: August 11, 2015

Waiver Request and Recommendation

I request that the Oversight Committee approve a renewal of the conflict of interest waiver for FY 2016 for Dr. Margaret L. Kripke, CPRIT's Chief Scientific Officer, pursuant to Health & Safety Code Section 102.1062 "Exceptional Circumstances Requiring Participation." The Oversight Committee approved the same waiver for Mr. Montgomery that was effective during FY2015. The waiver is necessary for Dr. Kripke to continue to effectively perform her duties as Chief Scientific Officer. Together with the waiver's proposed limitations, adequate protections are in place to mitigate the opportunity for the award of grant funds to be driven by anything other than merit and established criteria.

Background

Dr. Kripke's husband, Dr. Isaiah J. Fidler, is employed by The University of Texas M. D. Anderson Cancer as a professor in the Department of Cancer Biology and holds an endowed chair.¹ Therefore, Dr. Kripke continues to have the same conflict of interest and requires a renewal of the conflict of interest waiver for the 2016 fiscal year. The recommendations and limitations in the waiver renewal remain the same as previously approved by the Oversight Committee for the 2014 and 2015 fiscal years.

Health & Safety Code Section 102.106(c)(3) mandates that a professional conflict of interest exists if a CPRIT employee's spouse is an employee of an entity applying to receive or receiving CPRIT funds. Furthermore, CPRIT's administrative rule 702.13(c) categorizes this type of professional conflict of interest as one that raises the presumption that the existence of the conflict may affect the impartial review of all other grant applications submitted pursuant to the same grant mechanism in the grant review cycle. A person involved in the review process that holds one of conflicts included in the Section 702.13(c) "super conflict" category must be recused from participating in the "review, discussion, scoring, deliberation and vote on all grant

¹ Dr. Fidler does not have a recognized administrative or leadership position at M.D. Anderson, nor has he ever applied for or received CPRIT funding.

applications competing for the same grant mechanism in the entire grant review cycle, unless a waiver has been granted...”

Due to M.D. Anderson’s wide-ranging involvement in cancer prevention and cancer research activities in Texas it is reasonable to expect that the same conflict will affect Dr. Kripke’s participation in more than one grant review cycle in this fiscal year as well as other grant monitoring activities she will undertake. CPRIT’s administrative rule Section 702.17(3) authorizes the Oversight Committee to approve a waiver that applies for all activities affected by the conflict during the fiscal year.

Exceptional Circumstances Requiring Dr. Kripke’s Participation

In order to approve a waiver, the Oversight Committee must find that there are exceptional circumstances justifying the conflicted individual’s participation in the review process. As explained below, there are compelling reasons warranting Dr. Kripke’s continued participation in the review process when she would otherwise be excluded because of the conflict. The proposed limitations and CPRIT’s existing process and procedures will substantially mitigate any potential for bias.

One of the principal duties for a CPRIT program officer is serving as the Oversight Committee’s expert-in-residence for his or her particular grant program. Dr. Kripke is a respected scientist and administrator who has been recognized both nationally and internationally for her work as a cancer researcher. Her nine-year tenure on the President’s Cancer Panel has given her a comprehensive overview of the cancer problem and exceptional insight into the needs and future directions of cancer research. She was recruited to CPRIT as its Chief Scientific Officer following an extensive national search and was deemed to be an ideal candidate for the position.

Dr. Kripke’s expertise and experience is important not only to address scientific and technical questions but also when she act as the Oversight Committee’s “eyes and ears” into the peer review process. Peer review committees are primarily responsible for the work necessary to evaluate grant applications and recommend awards. CPRIT employees may attend peer review meetings but are expressly prohibited from actively participating in the peer review panel’s discussion or scoring of grant applications. By attending the peer review committee meetings, Dr. Kripke will continue to credibly relay the peer reviewers’ impression of the grant applications and to effectively address questions the Oversight Committee may have related to a grant recommendation. Without the waiver Dr. Kripke will be unable to attend peer review committee meetings and effectively perform her job.

Dr. Kripke’s attendance at peer review meetings is valuable even for those applications that are not recommended for a grant award. Grant applicants often contact the program officer after receiving the peer reviewers’ written comments and overall score for their applications. Because Dr. Kripke was able to attend the peer review committee meeting when the application was

discussed, she will be able to provide meaningful guidance and feedback to the applicant on the proposal's strengths and weaknesses.

Another important role for the program officer is to recruit and retain members of the program's review council. These review council members serve as strategic advisors for CPRIT's grant programs as well as being responsible for recruiting high-quality reviewers to the peer review committees chaired by each council member. Texas has established a gold-standard peer review process directly dependent on CPRIT's scientific leader, the Chief Scientific Officer. Dr. Kripke's stature in the cancer research arena provides Texas access to the premier cancer researchers in the world—since these are Dr. Kripke's peers. The Chairs of CPRIT review panels are all highly distinguished in their respective fields and bring enormous stature to the peer review process. Having panel chairs of this caliber distinguishes CPRIT's peer review process from all others.

The review council members and peer reviewers that serve on the CPRIT peer review panels are ineligible to receive CPRIT awards; a main attraction to serving as CPRIT peer reviewers is the opportunity for intellectual interactions with their scientific colleagues. These interactions do not occur without the leadership of the Chief Scientific Officer, Dr. Kripke.

Proposed Waiver and Limitations

In granting the waiver of the conflict of interest set forth in Section 102.106(c)(3), I recommend that Dr. Kripke be permitted to continue to perform the following activities and duties of the Chief Scientific Officer:

1. Assign grant applications, including M.D. Anderson grant applications, to various peer review committees for peer review evaluation;
2. Attend scientific research peer review committee meetings as an observer, including meetings where M.D. Anderson application are discussed;
3. Attend and participate fully in the Program Integration Committee (PIC) meetings, subject to the limitation set forth under "Limitations."
4. Have access to grant application information developed during the grant review process, including information related to M.D. Anderson applications;
5. Provide information about grant applications recommended for grant awards to the Oversight Committee or CPRIT personnel, including answering questions raised by the Oversight Committee or CPRIT personnel about M.D. Anderson grant applications. To the extent that information is provided by Dr. Kripke on her own initiative (e.g. the Chief Scientific Officer's summary of the recommended awards) and not in response to a specific question or request, it should be general information related to the overall grant application process and not advocate specifically for grant application submitted by M.D. Anderson.

6. Following the Oversight Committee's approval of a grant award to M.D. Anderson by the Oversight Committee, Dr. Kripke may review and approve programmatic requests associated with M.D. Anderson grant contracts and grant monitoring activities.

With regard to item number 2, Dr. Kripke will be required to follow CPRIT's established policy that CPRIT employees are prohibited from actively participating in peer review committee meetings. This means that Dr. Kripke may attend the peer review committee meetings as an observer, but may not participate in the substantive discussion of any grant application, may not score any application, and may not vote on any application. CPRIT contracts with an independent third-party observer to document that CPRIT's observer policy is followed. The independent third-party observer report will be made available to the Oversight Committee prior to any action taken related to the grant award recommendations. Following Oversight Committee action, the independent third-party observer report will be publicly available.

LIMITATION ON DUTIES AND ACTIVITIES

Dr. Kripke is a member of the PIC. As a PIC member, Dr. Kripke is called upon to exercise discretion related to whether applications proposed for grant awards by the peer review committees should be recommended to the Oversight Committee for final approval. Dr. Kripke shall not vote on any award recommendations related to M.D. Anderson.

CPRIT's Compliance Officer is statutorily required to attend PIC meetings to document compliance with CPRIT's rules and processes, including adherence to this limitation.

Important Information Regarding this Waiver and the Waiver Process

- The Oversight Committee may amend, revoke, or revise this waiver, including but not limited to the list of approved activities and duties and the limitations on duties and activities. Approval for any change to the waiver granted shall be by a vote of the Oversight Committee in an open meeting.
- This waiver is limited to the conflict of interest specified in this request. To the extent that Dr. Kripke has a conflict of interest with an application that is not the conflict identified in Section 102.106(c)(3), then Dr. Kripke will follow the required notification and recusal process.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

To: OVERSIGHT COMMITTEE CHAIR DR. WILLIAM RICE
From: WAYNE R. ROBERTS, CHIEF EXECUTIVE OFFICER
Subject: SECTION 102.1062 WAIVER – KIRK COLE
Date: AUGUST 11, 2015

Waiver Request and Recommendation

I request that the Oversight Committee approve a conflict of interest waiver for FY 2016 for Program Integration Committee (PIC) member DSHS Interim Commissioner Kirk Cole, pursuant to Health & Safety Code Section 102.1062 “Exceptional Circumstances Requiring Participation.” The Oversight Committee approved the same waiver for Commissioner Cole that was effective during FY2015. The waiver is necessary for Commissioner Cole to participate in CPRIT’s review process as a PIC member. Together with the waiver’s proposed limitations, adequate protections are in place to mitigate the opportunity for the award of grant funds to be driven by anything other than merit and established criteria.

Background

Mr. Cole was appointed Interim Commissioner of the Department of State Health Services (DSHS) in January, 2015. The DSHS Commissioner is a statutorily designated member of the PIC. As a PIC member, Commissioner Cole is called upon to exercise discretion related to whether applications proposed for grant awards by the peer review committees should be recommended to the Oversight Committee for final approval.

DSHS is a CPRIT grant recipient, which implicates conflict of interest concerns. Health & Safety Code Section 102.106(c)(3) mandates that a professional conflict of interest exists if a PIC member is an employee of an entity applying to receive or receiving CPRIT funds. Furthermore, CPRIT’s administrative rule 702.13(c) categorizes this type of professional conflict of interest as one that raises the presumption that the existence of the conflict may affect the impartial review of all other grant applications submitted pursuant to the same grant mechanism in the grant review cycle. A person involved in the review process that holds one of the conflicts included in the Section 702.13(c) “super conflict” category must be recused from participating in the “review, discussion, scoring, deliberation and vote on all grant applications competing for the same grant mechanism in the entire grant review cycle, unless a waiver has been granted...”

CPRIT’s administrative rule Section 702.17(3) authorizes the Oversight Committee to approve a waiver that applies for all activities affected by the conflict during the fiscal year. The

recommendations and limitations in Commissioner Cole's waiver remain the same as previously approved by the Oversight Committee for FY 2015.

Exceptional Circumstances Requiring Commissioner Cole's Participation

In order to approve a conflict of interest waiver, the Oversight Committee must find that there are exceptional circumstances justifying the conflicted individual's participation in the review process. Commissioner Cole's participation in the review process is compelled by the statute. In order to fulfill legislative intent that the DSHS Commissioner serve as a PIC member, the proposed waiver must be granted. The proposed limitations will substantially mitigate any potential for bias.

Proposed Waiver and Limitations

In granting the waiver of the conflict of interest set forth in Section 102.106(c)(3), I recommend that Commissioner Cole be permitted to continue to perform the following activities and duties associated with CPRIT's review process subject to the stated limitations:

1. Attend and participate fully in the PIC meetings except that Commissioner Cole shall not participate in the PIC's discussion or vote on grant award recommendations to be made to DSHS;
2. Have access to grant application information developed during the grant review process, except for information related to DSHS applicants, if any; and
3. Provide information to the Oversight Committee or CPRIT personnel about the grant review process and applications recommended by the PIC for grant awards, including answering questions raised by the Oversight Committee or CPRIT personnel. To the extent that information is provided by Commissioner Cole on his own initiative in a review cycle in which DSHS is a grant applicant, the information provided by Commissioner Cole should be general information related to the overall grant application process and not advocate specifically for a grant application submitted by DSHS.

CPRIT's Compliance Officer is statutorily required to attend PIC meetings to document compliance with CPRIT's rules and processes, including adherence to this limitation. The Compliance Officer shall report to the Oversight Committee any violation of this waiver prior to the Oversight Committee's action on the PIC recommendations.

Important Information Regarding this Waiver and the Waiver Process

- The Oversight Committee may amend, revoke, or revise this waiver, including but not limited to the list of approved activities and duties and the limitations on duties

and activities. Approval for any change to the waiver granted shall be by a vote of the Oversight Committee in an open meeting.

- This waiver is limited to the conflict of interest specified in this request. To the extent that Commissioner Cole has a conflict of interest with an application that is not the conflict identified in Section 102.106(c)(3), then Commissioner Cole will follow the required notification and recusal process.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

To: OVERSIGHT COMMITTEE CHAIR DR. WILLIAM RICE
From: WAYNE R. ROBERTS, CHIEF EXECUTIVE OFFICER
Subject: SECTION 102.1062 WAIVER – WILL MONTGOMERY
Date: AUGUST 11, 2015

Waiver Request and Recommendation

I request that the Oversight Committee approve a conflict of interest waiver for FY 2016 for Mr. Will Montgomery, CPRIT Oversight Committee member, pursuant to Health & Safety Code Section 102.1062 “Exceptional Circumstances Requiring Participation.” The only changes to the waiver previously approved by the Oversight Committee is the addition of six entities to the list of grant applicants and grant recipients that employ Mr. Montgomery’s law firm. The waiver is necessary for Mr. Montgomery to fully participate in the grant award approval process. Together with the waiver’s proposed limitations, adequate protections are in place to mitigate the opportunity for the award of grant funds to be driven by anything other than merit and established criteria.

Background

Mr. Montgomery is a partner at Jackson Walker L.L.P., a long-time, Texas-based law firm that employs more than 350 attorneys. Mr. Montgomery’s legal practice focuses on disputes related to the financial services industry, including regulatory investigations, enforcement proceedings, and internal investigations relating to securities, options, derivatives, commodities and futures. Mr. Montgomery does not personally represent CPRIT grant recipients; however, some lawyers employed by Jackson Walker provide legal services to the following grant applicants and grant recipients:

- Rice University
- Texas A & M University System
- Texas A & M System Technology Commercialization
- Texas A & M Institute for Biosciences & Technology
- Methodist Hospital System (Houston)
- UT Southwestern
- UT School of Public Health
- UT Medical Branch, Galveston
- Children's Medical Center Research Institute
- UT San Antonio

- UT Austin
- UT Health Science Center at Houston
- Texas Association of Nurse Anesthetists
- University General Health system
- MHMR Tarrant County
- Texas Tech University
- UNT Health Science Center
- Baylor University

Health & Safety Code Section 102.106(c)(4) mandates that a professional conflict of interest exists if an Oversight Committee member represents an entity applying to receive or receiving CPRIT funds. Similarly, Texas Administrative Code Section 702.11(d) finds that there is a professional conflict of interest if an Oversight Committee member “represents in business or law an entity receiving or applying to receive money from the Institute...”

The entities listed above were clients of the law firm prior to Mr. Montgomery’s appointment to the Oversight Committee. Although Mr. Montgomery does not perform legal work for these entities or supervise anyone who does so, he has previously recused himself from participating in the grant award process related to these entities out of an abundance of caution. He does not have an economic interest in the revenues associated with these entities paid to Jackson Walker, aside from his position as a partner of the firm. However, Mr. Montgomery’s percentage of ownership interest in the law firm is not impacted whether or not these entities are clients of the firm.

It is reasonable to expect that the same conflict will affect Mr. Montgomery’s participation in more than one grant review cycle in the 2016 fiscal year as well. CPRIT’s administrative rule Section 702.17(3) authorizes the Oversight Committee to approve a waiver that applies for all activities affected by the conflict during the fiscal year.

Exceptional Circumstances Requiring Mr. Montgomery’s Participation

In order to approve a waiver, the Oversight Committee must find that there are exceptional circumstances justifying the conflicted individual’s participation in the review process. There are compelling reasons warranting Mr. Montgomery’s participation in the review process when he would otherwise be excluded because of the conflict. One of the principal duties for an Oversight Committee member is to approve grant award recommendations submitted by the Program Integration Committee. The statute requires a two-thirds vote of the Oversight Committee to approve a grant award. The vast majority of CPRIT’s grant applicants and grant recipients are academic institutions, including many of the entities listed above. Excluding Mr. Montgomery from participation in the decision-making process related to grant awards reduces the number of Oversight Committee members that are able to perform the critical task of reviewing information about potential grantees and the review process associated with the grant recommendations.

The proposed limitations and CPRIT's existing process and procedures will substantially mitigate any potential for bias.

Proposed Waiver and Limitations

In granting the waiver of the conflict of interest set forth in Health & Safety Code Section 102.106(c)(4), I recommend that Mr. Montgomery be permitted to participate in the review process for applications submitted by the following entities, subject to the limitations stated below:

- Rice University
- Texas A & M University System
- Texas A & M System Technology Commercialization
- Texas A & M Institute for Biosciences & Technology
- Methodist Hospital System (Houston)
- UT Southwestern
- UT School of Public Health
- UT Medical Branch, Galveston
- Children's Medical Center Research Institute
- UT San Antonio
- UT Austin
- UT Health Science Center at Houston
- Texas Association of Nurse Anesthetists
- University General Health system
- MHMR Tarrant County
- Texas Tech University
- UNT Health Science Center
- Baylor University

Important Information Regarding this Waiver and the Waiver Process

- The Oversight Committee may amend, revoke, or revise this waiver. Approval for any change to the waiver granted shall be by a vote of the Oversight Committee in an open meeting.
- This waiver is limited to the conflict of interest specified in this request, Health & Safety Code Section 102.106(c)(4). To the extent that Mr. Montgomery has a conflict of interest with an application submitted by an entity listed herein that is not the conflict identified in Section 102.106(c)(4), then Mr. Montgomery will follow the required notification and recusal process.
- The waiver is limited to the entities specified in the request and based upon the circumstances stated herein. If circumstances change such that Mr. Montgomery is

required to personally represent one of the entities listed herein or to supervise the work of someone representing the entity, he will notify the Chief Executive Officer and the presiding officer of the Oversight Committee.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

To: OVERSIGHT COMMITTEE MEMBERS
From: WAYNE R. ROBERTS, CHIEF EXECUTIVE OFFICER
Subject: SECTION 102.1062 WAIVER – AMY MITCHELL
Date: AUGUST 11, 2015

Waiver Request and Recommendation

I request that the Oversight Committee approve a conflict of interest waiver for FY 2016 for Ms. Amy Mitchell, CPRIT Oversight Committee member, pursuant to Health & Safety Code Section 102.1062 “Exceptional Circumstances Requiring Participation.” The waiver is necessary for Ms. Mitchell to fully participate in the grant award approval process. Together with the waiver’s proposed limitations, adequate protections are in place to mitigate the opportunity for the award of grant funds to be driven by anything other than merit and established criteria.

Background

Ms. Mitchell is Senior Counsel at Norton Rose Fulbright, an international law firm with 3800 attorneys. Her practice focuses on matters related to improved and unimproved real property including sales and acquisitions, leases, ground leases, subleases, real estate financing, real estate development, environmental issues affecting real property, construction matters for owners, general contractors and subcontractors, and the formation of entities to acquire, develop, finance and operate real property. Ms. Mitchell does not personally represent CPRIT grant recipients; however, some lawyers employed by Norton Rose Fulbright provide legal services to the following grant applicants and grant recipients:

- University Health System
- University of Texas at Austin, Arlington, Brownsville, Dallas, and El Paso
- University of Texas-Pan American
- University of Texas of the Permian Basin
- University of Texas Medical Branch at Galveston
- University of Texas Health Science Center at San Antonio
- University of Texas M.D. Anderson Cancer Center
- University of Texas Southwestern Medical Center
- University of Texas Health Science Center at Houston, and Tyler
- Angelo State University
- University of Houston

- University Houston-Clear Lake, Downtown, and Victoria,
- Baylor University
- Baylor College of Medicine
- Baylor Research Institute
- Methodist Hospital Research Institute
- Rice University
- Texas Tech University
- Texas Tech University Health Science Center
- Texas A&M University
- Prairie View A&M University
- Texas A&M University Commerce, Kingsville, Corpus Christi, Texarkana, Central Texas, and San Antonio
- Tarleton State University
- West Texas A&M University
- Texas A&M International University
- Texas A&M University Health Science Center
- Texas A&M University System
- Texas A&M Health Science Center
- Texas A&M Engineering Experiment Station
- Texas A&M Agrilife Extension Services
- Texas A&M Agrilife Research

Health & Safety Code Section 102.106(c)(4) mandates that a professional conflict of interest exists if an Oversight Committee member represents an entity applying to receive or receiving CPRIT funds. Similarly, Texas Administrative Code Section 702.11(d) finds that there is a professional conflict of interest if an Oversight Committee member “represents in business or law an entity receiving or applying to receive money from the Institute...”

The entities listed above were clients of the law firm prior to Ms. Mitchell’s appointment to the Oversight Committee. Although Ms. Mitchell does not perform legal work for these entities or supervise anyone who does so, she has previously recused herself from participating in the grant award process related to these entities out of an abundance of caution. She does not have an economic interest in the revenues associated with these entities paid to Norton Rose Fulbright, aside from her position as Senior Counsel at the firm.

It is reasonable to expect that the same conflict will affect Ms. Mitchell’s participation in more than one grant review cycle in this fiscal year as well. CPRIT’s administrative rule Section 702.17(3) authorizes the Oversight Committee to approve a waiver that applies for all activities affected by the conflict during the fiscal year.

Exceptional Circumstances Requiring Ms. Mitchell's Participation

In order to approve a waiver, the Oversight Committee must find that there are exceptional circumstances justifying the conflicted individual's participation in the review process. There are compelling reasons warranting Ms. Mitchell's participation in the review process when she would otherwise be excluded because of the conflict. One of the principal duties for an Oversight Committee member is to approve grant award recommendations submitted by the Program Integration Committee. The statute requires a two-thirds vote of the Oversight Committee to approve a grant award. The vast majority of CPRIT's grant applicants and grant recipients are academic institutions, including many of the entities listed above. Excluding Ms. Mitchell from participation in the decision-making process related to grant awards reduces the number of Oversight Committee members that are able to perform the critical task of reviewing information about potential grantees and the review process associated with the grant recommendations.

The proposed limitations and CPRIT's existing process and procedures will substantially mitigate any potential for bias.

Proposed Waiver and Limitations

In granting the waiver of the conflict of interest set forth in Health & Safety Code Section 102.106(c)(4), I recommend that Ms. Mitchell be permitted to participate in the review process for applications submitted by the following entities, subject to the limitations stated below:

- University Health System
- University of Texas at Austin, Arlington, Brownsville, Dallas, and El Paso
- University of Texas-Pan American
- University of Texas of the Permian Basin
- University of Texas Medical Branch at Galveston
- University of Texas Health Science Center at San Antonio
- University of Texas M.D. Anderson Cancer Center
- University of Texas Southwestern Medical Center
- University of Texas Health Science Center at Houston, and Tyler
- Angelo State University
- University of Houston
- University Houston-Clear Lake, Downtown, and Victoria,
- Baylor University
- Baylor College of Medicine
- Baylor Research Institute
- Methodist Hospital Research Institute
- Rice University
- Texas Tech University

- Texas Tech University Health Science Center
- Texas A&M University
- Prairie View A&M University
- Texas A&M University Commerce, Kingsville, Corpus Christi, Texarkana, Central Texas, and San Antonio
- Tarleton State University
- West Texas A&M University
- Texas A&M International University
- Texas A&M University Health Science Center
- Texas A&M University System
- Texas A&M Health Science Center
- Texas A&M Engineering Experiment Station
- Texas A&M Agrilife Extension Services
- Texas A&M Agrilife Research

Important Information Regarding this Waiver and the Waiver Process

- The Oversight Committee may amend, revoke, or revise this waiver. Approval for any change to the waiver granted shall be by a vote of the Oversight Committee in an open meeting.
- This waiver is limited to the conflict of interest specified in this request, Health & Safety Code Section 102.106(c)(4). To the extent that Ms. Mitchell has a conflict of interest with an application submitted by an entity listed herein that is not the conflict identified in Section 102.106(c)(4), then Ms. Mitchell will follow the required notification and recusal process.
- The waiver is limited to the entities specified in the request and based upon the circumstances stated herein. If circumstances change such that Ms. Mitchell is required to personally represent one of the entities listed herein or to supervise the work of someone representing the entity, she will notify the Chief Executive Officer and the presiding officer of the Oversight Committee.



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

MEMORANDUM

To: OVERSIGHT COMMITTEE MEMBERS
From: WAYNE ROBERTS, CHIEF EXECUTIVE OFFICER
Subject: SECTION 102.1062 WAIVER—DONALD BRANDY
Date: AUGUST 11, 2015

Waiver Request and Recommendation

I request that the Oversight Committee approve a conflict of interest waiver for FY 2016 for Mr. Donald Brandy, CPRIT's Purchaser and HUB Coordinator, pursuant to Health & Safety Code Section 102.1062 "Exceptional Circumstances Requiring Participation." The Oversight Committee approved the same waiver for Mr. Brandy that was effective during FY2015.

Mr. Brandy is not involved in the grant application or reporting process in his official capacity as purchaser of goods and services for the agency. However, the waiver ensures transparency regarding Mr. Brandy's relationship with some universities that receive CPRIT grants. Furthermore, CPRIT's Code of Conduct makes it clear that the agency's conflict of interest provisions apply to any expenditure of CPRIT funds. Although it is unlikely that CPRIT will procure goods and services from a university receiving grant funds from CPRIT, having the conflict of interest waiver in place ensures that Mr. Brandy can perform his duties. Together with the waiver's proposed limitations, adequate protections are in place to mitigate the opportunity for a conflict of interest to unduly influencing agency purchases.

Background

Mr. Brandy serves as the agency purchaser, responsible for planning, organizing, coordinating, and preparing bid specifications and procurement documents to acquire goods and services from vendors and outside contractors used by the agency. The agency purchaser role requires little, if any, involvement with CPRIT's grant award process because CPRIT's grant award contracts are not considered vendor or outside service contracts.

At the time that he was hired, Mr. Brandy requested approval to continue his outside employment as a referee for tennis tournaments held in and around Austin. In addition to refereeing for adult and junior-level tournaments, he serves occasionally as a referee for NCAA tennis matches held at area universities, including The University of Texas at Austin. Mr. Brandy is paid for his services as an independent contractor by the university athletic department when he referees collegiate matches.

CPRIT employees may engage in outside employment so long as the employment does not detract from the employee's ability to reasonably fulfill his or her responsibilities to CPRIT. Employees must receive written approval from the CEO to engage in outside employment and I am required to notify the Audit Subcommittee regarding any approvals and to annually report all approved outside employment. I notified the Audit Subcommittee regarding my approval for Mr. Brandy's outside employment and it was discussed at the December 18, 2014, subcommittee meeting.

Exceptional Circumstances Requiring Mr. Brandy's Participation

In order to approve a conflict of interest waiver, the Oversight Committee must find that there are exceptional circumstances justifying the conflicted individual's participation in the review process or other expenditure of CPRIT funds.¹

This conflict of interest waiver is different than other waivers I have requested in that it is not seeking a waiver for actions related to CPRIT's grant review or grant monitoring process. As CPRIT's purchaser, I do not anticipate that Mr. Brandy will play any role in the review process for grant applications or grant reports. The purchaser deals only with agency procurement matters and has no influence over the grant award processes of the agency. To the extent that his outside employment necessitates involvement with university personnel, it is with collegiate athletic department staff that have no interaction with researchers working on or applying for grants. Nevertheless, if Mr. Brandy must be part of the review process or grant monitoring activities in the future, he will comply with CPRIT's conflict of interest notification and recusal requirements.

However, during the course of his official duties there may be circumstances requiring Mr. Brandy to procure goods or services on CPRIT's behalf from a university that has also employed him as a tennis referee. This is unlikely to occur; to date, CPRIT has only one services contract with an academic institution, Texas Tech University. However, as CPRIT's lead contact for agency purchases, Mr. Brandy should be allowed to perform his official duties to the fullest extent possible. Any involvement with university athletic department personnel resulting from his outside employment is unlikely to be the same individuals at the university responsible for contracting with CPRIT.

¹ CPRIT's Code of Conduct Section III.B(2) states that, "The conflict of interest statutory and administrative rule provisions **apply to any decision to commit CPRIT funds**, whether or not the commitment is part of the grant award process or to a Grant Applicant." (emphasis added)

Proposed Waiver and Limitations

In granting the waiver of the conflict of interest set forth in Health & Safety Code Section 102.106(c)(3), I recommend that Mr. Brandy be permitted to perform all duties assigned as purchaser, subject to the limitations stated below:

1. Provide the Chief Operating Officer a list of universities that have used his services as referee during the past twelve months;
2. Notify the Chief Operating Officer prior to taking any action on a contract or other procurement document that would result in payment of CPRIT funds to a university on the list referenced above; and
3. The Chief Operating Officer, in conjunction with the CEO, Chief Compliance Officer and General Counsel, can review the circumstances and determine whether Mr. Brandy should be recused from involvement in the procurement.

Important Information Regarding this Waiver and the Waiver Process

- The Oversight Committee may amend, revoke, or review this waiver, including but not limited to the list of approved activities and duties and the limitations on duties and activities. Approval of any change to the waiver granted shall be by a vote of the Oversight Committee in an open meeting.
- This waiver is limited to the conflict of interest specified in this request. To the extent that Mr. Brandy has a conflict of interest not address in this waiver, then Mr. Brandy will follow the required notification and recusal process.